[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 182
1. Chen R, Pan S, Duan X, Nelson BH, Sahota RA, de Rham S, Kozarek RA, McIntosh M, Brentnall TA: Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol Cancer; 2010 Jun 15;9:149
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia.
  • BACKGROUND: Pancreatic intraepithelial neoplasias (PanINs) are precursors of malignant pancreatic cancer, an ideal stage for early cancer detection.
  • An ELISA assay was developed to evaluate AGR2 levels in 51 pancreatic juice samples and 23 serum samples from patients with pancreatic cancer, pre-malignant lesions (including PanIN3, PanIN2, Intraductal Papillary Mucinous Neoplasms (IPMNs)) and benign disease controls (including chronic pancreatitis).
  • AGR2 levels in the pancreatic juice samples were found significantly elevated in patients with pre-malignant conditions (PanINs and IPMNs) as well as pancreatic cancer compared to control samples (p < or = 0.03).
  • By ROC analysis, the AGR2 ELISA achieved 67% sensitivity at 90% specificity in predicting PanIN3 juice samples from the benign disease controls.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Clin Sci (Lond). 2010 Jun;118(12):717-25 [20136634.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Pancreas. 1994 Nov;9(6):741-7 [7846018.001]
  • [Cites] Mech Dev. 1998 Mar;72(1-2):115-30 [9533957.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):247-55 [10454945.001]
  • [Cites] Mol Cell Proteomics. 2004 Dec;3(12):1154-69 [15385600.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):523-33 [15684406.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6626-36 [16103885.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1728-34 [16551856.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2066-9 [16609017.001]
  • [Cites] Histol Histopathol. 2007 Jul;22(7):703-8 [17455144.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(3):293-300 [17457305.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Sep;23(5):508-14 [17762556.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Nov;5(10):1034-41 [18053427.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):492-7 [18199544.001]
  • [Cites] EMBO Rep. 2008 May;9(5):429-34 [18451766.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7811-8 [18829536.001]
  • [Cites] Cancer Detect Prev. 2008;32(3):236-50 [18801625.001]
  • [Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]
  • [Cites] PLoS Med. 2009 Apr 7;6(4):e1000046 [19360088.001]
  • [Cites] Electrophoresis. 2009 Apr;30(7):1132-44 [19373808.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):6950-5 [19359471.001]
  • [Cites] Histol Histopathol. 2009 Sep;24(9):1121-8 [19609859.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]
  • (PMID = 20550709.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01DK081368; United States / NCI NIH HHS / CA / CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296; United States / NCI NIH HHS / CA / R01CA107209; United States / NCI NIH HHS / CA / K07CA116296; United States / NCI NIH HHS / CA / K25CA137222
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteins; EC 5.3.4.1 / AGR2 protein, human
  • [Other-IDs] NLM/ PMC2893103
  •  go-up   go-down


2. Prasad NB, Somervell H, Tufano RP, Dackiw AP, Marohn MR, Califano JA, Wang Y, Westra WH, Clark DP, Umbricht CB, Libutti SK, Zeiger MA: Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res; 2008 Jun 1;14(11):3327-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of genes differentially expressed in benign versus malignant thyroid tumors.
  • PURPOSE: Although fine-needle aspiration biopsy is the most useful diagnostic tool in evaluating a thyroid nodule, preoperative diagnosis of thyroid nodules is frequently imprecise, with up to 30% of fine-needle aspiration biopsy cytology samples reported as "suspicious" or "indeterminate."
  • EXPERIMENTAL DESIGN: In an attempt to identify diagnostic markers for the preoperative distinction of these lesions, we chose to study by microarray analysis the eight different thyroid tumor subtypes that can present a diagnostic challenge to the clinician.
  • RESULTS: Our microarray-based analysis of 94 thyroid tumors identified 75 genes that are differentially expressed between benign and malignant tumor subtypes.
  • Of these, 33 were overexpressed and 42 were underexpressed in malignant compared with benign thyroid tumors.
  • CONCLUSIONS: Our results suggest that these 12 genes could be useful in the development of a panel of markers to differentiate benign from malignant tumors and thus serve as an important first step in solving the clinical problem associated with suspicious thyroid lesions.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thyroid. 1998 May;8(5):377-83 [9623727.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):56-63 [17943974.001]
  • [Cites] Semin Cancer Biol. 1999 Aug;9(4):303-18 [10448117.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7637-44 [15569996.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1587-97 [15735049.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1693-9 [15753364.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Apr;27(2):101-10 [15913203.001]
  • [Cites] Biochem J. 2005 Jul 1;389(Pt 1):91-7 [15713121.001]
  • [Cites] Methods Mol Med. 2005;103:89-101 [15542899.001]
  • [Cites] Expert Opin Biol Ther. 2005 Aug;5(8):1069-83 [16050784.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4652-61 [16651416.001]
  • [Cites] J Pathol. 2006 Jun;209(2):206-12 [16521118.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4773-83 [16899629.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Dec;31(12):1363-6 [10641790.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):595-605 [10666389.001]
  • [Cites] Br J Cancer. 2000 Mar;82(6):1123-30 [10735494.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):521-6 [11179481.001]
  • [Cites] Matrix Biol. 2001 Jan;19(8):816-27 [11223341.001]
  • [Cites] Thyroid. 2001 Mar;11(3):271-7 [11327619.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):151-63 [11896570.001]
  • [Cites] Cell Calcium. 2002 Jul;32(1):1-10 [12127057.001]
  • [Cites] J Comput Biol. 2002;9(3):505-11 [12162889.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5351-7 [12235006.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7077-91 [12370830.001]
  • [Cites] Histopathology. 2002 Oct;41(4):357-62 [12383219.001]
  • [Cites] J Pathol. 2003 Feb;199(2):176-84 [12533830.001]
  • [Cites] Pathol Oncol Res. 2002;8(4):231-40 [12579208.001]
  • [Cites] Clin Biochem. 2003 Mar;36(2):135-43 [12633763.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1710-20 [12738725.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1792-800 [12738736.001]
  • [Cites] Carcinogenesis. 2003 Jul;24(7):1191-8 [12807722.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3638-46 [14512395.001]
  • [Cites] Bioinformatics. 2003 Dec 12;19(18):2448-55 [14668230.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2898-903 [15087409.001]
  • [Cites] J Cell Biochem. 2004 Jul 1;92(4):679-90 [15211566.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):667-74; discussion 675-6 [15383794.001]
  • [Cites] J Clin Lab Anal. 1991;5(5):344-66 [1941355.001]
  • [Cites] Biochem J. 1997 May 15;324 ( Pt 1):311-9 [9164872.001]
  • [Cites] Br J Cancer. 1997;75(9):1279-83 [9155046.001]
  • [Cites] Genomics. 1998 Mar 15;48(3):377-80 [9545645.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):490-8; quiz 528 [16931590.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5043-51 [17075124.001]
  • [Cites] Endokrynol Pol. 2006;57 Suppl A:12-7 [17091451.001]
  • [Cites] Endokrynol Pol. 2006;57 Suppl A:18-25 [17091452.001]
  • [Cites] Int Immunopharmacol. 2006 Dec 20;6(13-14):1935-42 [17161346.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4193-8 [9751634.001]
  • (PMID = 18519760.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107247-01A1; United States / NCI NIH HHS / CA / R01 CA107247-05; United States / NCI NIH HHS / CA / CA107247-01A1; United States / NCI NIH HHS / CA / R01 CA107247; United States / NCI NIH HHS / CA / R01-CA107247-01A1; United States / NCI NIH HHS / CA / CA107247-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS282977; NLM/ PMC3086681
  •  go-up   go-down


3. Wells WA, Wang X, Daghlian CP, Paulsen KD, Pogue BW: Phase contrast microscopy analysis of breast tissue: differences in benign vs. malignant epithelium and stroma. Anal Quant Cytol Histol; 2009 Aug;31(4):197-207
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase contrast microscopy analysis of breast tissue: differences in benign vs. malignant epithelium and stroma.
  • OBJECTIVE: To assess how optical scatter properties in breast tissue, as measured by phase contrast microscopy and interpreted pathophysiologically, might be exploited as a diagnostic tool to differentiate cancer from benign tissue.
  • STUDY DESIGN: We evaluated frozen human breast tissue sections of adipose tissue, normal breast parenchyma, benign fibroadenoma tumors and noninvasive and invasive malignant cancers by phase contrast microscopy through quantification of grayscale values, using multiple regions of interest (ROI).
  • RESULTS: Stroma demonstrated significantly higher scatter intensity than did epithelium, with lower scattering in tumor-associated stroma as compared with normal or benign-associated stroma.
  • Measures were comparable for invasive and noninvasive malignant tumors but were higher than those found in benign tumors and were lowest in adipose tissue.
  • CONCLUSION: Significant differences were found in scatter coefficient properties of epithelium and stroma across diagnostic categories of breast tissue, particularly between benign and malignant-associated stroma.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biomed Opt. 2000 Apr;5(2):221-8 [10938787.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):677-82 [10982761.001]
  • [Cites] Biophys J. 2002 Apr;82(4):2256-64 [11916880.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):53-60 [12672030.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3556-9 [12839941.001]
  • [Cites] Radiology. 2004 May;231(2):571-80 [15128998.001]
  • [Cites] Anal Quant Cytol Histol. 2004 Jun;26(3):166-74 [15218693.001]
  • [Cites] Phys Med Biol. 2004 Aug 21;49(16):3573-83 [15446788.001]
  • [Cites] Pathol Res Pract. 1984 Sep;179(1):61-6 [6504769.001]
  • [Cites] Surg Gynecol Obstet. 1987 Dec;165(6):523-9 [2825366.001]
  • [Cites] J Dermatol Surg Oncol. 1993 Sep;19(9):869-74 [7690052.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2497-503 [10811131.001]
  • [Cites] Radiology. 2000 Mar;214(3):895-901 [10715065.001]
  • [Cites] Am J Surg Pathol. 1995 Nov;19(11):1267-71 [7573688.001]
  • [Cites] Radiology. 2007 May;243(2):350-9 [17400760.001]
  • [Cites] Opt Lett. 2007 Apr 15;32(8):933-5 [17375158.001]
  • [Cites] J Surg Oncol. 1997 Dec;66(4):248-53 [9425328.001]
  • [Cites] Ann Surg Oncol. 1998 Apr-May;5(3):220-6 [9607622.001]
  • [Cites] Phys Med Biol. 1998 Sep;43(9):2555-67 [9755945.001]
  • [Cites] Phys Med Biol. 1998 Oct;43(10):2845-52 [9814522.001]
  • [Cites] J Biomed Opt. 2004 Nov-Dec;9(6):1122-8 [15568931.001]
  • [Cites] Biophys J. 2005 Apr;88(4):2929-38 [15653724.001]
  • [Cites] PLoS Biol. 2005 Jun;3(6):e187 [15869330.001]
  • [Cites] Opt Lett. 2005 Jun 1;30(11):1354-6 [15981531.001]
  • [Cites] J Biomed Opt. 2006 Nov-Dec;11(6):064007 [17212530.001]
  • [Cites] Histopathology. 2007 Feb;50(3):338-47 [17257129.001]
  • (PMID = 19736867.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U54 CA105480-010002; United States / NCI NIH HHS / CA / U54 CA105480; None / None / / U54 CA105480-010002; United States / NCI NIH HHS / CA / CA080139-09; United States / NCI NIH HHS / CA / P01 CA080139; United States / NCI NIH HHS / CA / P01 CA080139-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS183687; NLM/ PMC2857332
  •  go-up   go-down


Advertisement
4. Heyn J, Placzek M, Ozimek A, Baumgaertner AK, Siebeck M, Volkenandt M: Malignant melanoma of the anal region. Clin Exp Dermatol; 2007 Sep;32(5):603-7
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma of the anal region.
  • Malignant melanoma (MM) of the anal region is an uncommon disease.
  • In many cases, the disease is undetected or mistaken for a benign polyp or haemorrhoids until it reaches an advanced state.
  • Owing to delayed diagnosis and early metastases, the prognosis is often poor.
  • Anorectal melanomas (AM) are most common in the rectum, followed by the anal canal and anal verge.
  • The diagnosis of an AM is usually made using a biopsy.
  • We report on a 39-year old man who presented with a 5-week history of recurrent prolapse of an anal tumour.
  • The tumour was histologically confirmed to be malignant melanoma.
  • [MeSH-major] Anus Neoplasms. Melanoma
  • [MeSH-minor] Adult. Angiogenesis Inhibitors / therapeutic use. Cancer Vaccines / therapeutic use. Diagnosis, Differential. Humans. Interferon-alpha / therapeutic use. Male. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17376215.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Cancer Vaccines; 0 / Interferon-alpha
  • [Number-of-references] 25
  •  go-up   go-down


5. Garrison JB, Kyprianou N: Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res; 2006 Jan 1;66(1):464-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway.
  • In this study, the molecular events initiating this apoptotic effect were further investigated in vitro using the human androgen-independent prostate cancer cells PC-3 and the human benign prostate epithelial cells BPH-1.
  • These results show that doxazosin exerts its apoptotic effects against benign and malignant prostate cells via a death receptor-mediated mechanism with a potential integrin contribution towards cell survival outcomes.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Cell Dev Biol. 1999;15:269-90 [10611963.001]
  • [Cites] Cell Death Differ. 2005 Mar;12(3):233-42 [15665818.001]
  • [Cites] Cell Tissue Res. 2000 Jul;301(1):153-62 [10928288.001]
  • [Cites] J Cell Biol. 2001 Feb 5;152(3):633-43 [11157988.001]
  • [Cites] J Urol. 2003 Mar;169(3):1150-6 [12576871.001]
  • [Cites] J Urol. 2003 Apr;169(4):1520-5 [12629407.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):593-600 [12740905.001]
  • [Cites] Oncogene. 2003 May 8;22(18):2795-804 [12743602.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1615-21 [12771931.001]
  • [Cites] J Cell Physiol. 2003 Aug;196(2):386-93 [12811833.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37632-6 [12876280.001]
  • [Cites] J Med Chem. 2004 Aug 26;47(18):4453-62 [15317457.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]
  • [Cites] Cell. 1995 May 19;81(4):505-12 [7538907.001]
  • [Cites] Cell. 1996 Jun 14;85(6):817-27 [8681377.001]
  • [Cites] Nat Med. 1996 Dec;2(12):1361-6 [8946836.001]
  • [Cites] Curr Biol. 1996 Oct 1;6(10):1241-3 [8939562.001]
  • [Cites] J Natl Cancer Inst. 1997 Jun 4;89(11):783-9 [9182976.001]
  • [Cites] Cell Immunol. 1997 Aug 25;180(1):70-83 [9316641.001]
  • [Cites] Br J Urol. 1997 Oct;80(4):521-32 [9352686.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):76-83 [9426061.001]
  • [Cites] Prostate. 1998 Jul 1;36(2):92-101 [9655261.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5870-5 [9865748.001]
  • [Cites] Clin Cancer Res. 1997 Jun;3(6):963-72 [9815772.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):382-90 [9927051.001]
  • [Cites] J Biol Chem. 1999 Mar 19;274(12):7987-92 [10075697.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Mar 24;256(3):603-7 [10080945.001]
  • [Cites] J Immunol. 1999 May 1;162(9):5205-11 [10227994.001]
  • [Cites] Cell Death Differ. 1999 May;6(5):394-401 [10381629.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):371-8 [10408840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8699-704 [10411938.001]
  • [Cites] Curr Biol. 1999 Sep 23;9(18):1043-6 [10508619.001]
  • [Cites] Curr Biol. 1999 Sep 23;9(18):1047-9 [10508612.001]
  • [Cites] Oncogene. 2001 Apr 5;20(15):1852-9 [11313933.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):319-27 [11803475.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):597-602 [11809715.001]
  • [Cites] Prostate. 2002 Apr 1;51(1):42-9 [11920957.001]
  • [Cites] Apoptosis. 2002 Jun;7(3):247-60 [11997669.001]
  • [Cites] Prostate. 2002 Jun 1;51(4):231-40 [11987151.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):296-300 [12124829.001]
  • [Cites] Anal Quant Cytol Histol. 2000 Feb;22(1):45-54 [10696460.001]
  • (PMID = 16397262.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107575; United States / NCI NIH HHS / CA / R01 CA107575-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Adrenergic alpha-Antagonists; 0 / Antigens, CD95; 0 / FADD protein, human; 0 / Fas-Associated Death Domain Protein; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases; NW1291F1W8 / Doxazosin
  • [Other-IDs] NLM/ NIHMS19062; NLM/ PMC1850148
  •  go-up   go-down


6. Zhang S, Gao F, Chen LS, Tang ZJ, Liang JL, Wu Q: [Clinical analysis of anorectal malignant melanoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Jul;8(4):309-11
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of anorectal malignant melanoma].
  • OBJECTIVE: To summarize the clinicopathological characteristics of primary anorectal malignant melanoma (AMM).
  • RESULTS: Anorectal malignant melanoma had a female predominance.
  • The average age was 56 years old and average course of disease was 5.8 months.
  • The onset of symptom was hematochezia, then anus prolapses.
  • 94.7% of patients had AMM within 5 cm from anus margin; the average tumor size was (3.3+/- 2.1) cm.
  • More than a half (54.5%) of the tumor was movable, 19.1% smooth surfaced, 6.6% soft textured.
  • Half of the patients were misdiagnosed,and over 50% of patients were misdiagnosed as benign disease.
  • Mile's operation was performed in most of patients (63%), while anal resection was performed in 30% of the patients.
  • CONCLUSIONS: Anorectal malignant melanoma is often misdiagnosed,surgical procedure is the first choice for patients with AMM.
  • [MeSH-major] Anus Neoplasms / pathology. Melanoma / pathology. Rectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167248.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Tanaka S, Ohta T, Fujimoto T, Makino Y, Murakami I: Endoscopic mucosal resection of primary anorectal malignant melanoma: a case report. Acta Med Okayama; 2008 Dec;62(6):421-4
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic mucosal resection of primary anorectal malignant melanoma: a case report.
  • Anorectal melanoma is a rare malignant tumor with a poor prognosis.
  • An 85-year-old man was referred to our hospital for further examination and treatment of an anal tumor 2 cm in size.
  • Endoscopic ultrasonography revealed that the depth of tumor invasion was confined to the submucosal layer.
  • Endoscopic mucosal resection was performed, and the tumor was diagnosed as a malignant melanoma.
  • The patient was followed without any additional treatment, which was per his wishes.
  • If the depth of tumor invasion is shallow, endoscopic mucosal resection is a useful option among other therapeutic modalities.
  • [MeSH-major] Anal Canal / surgery. Endoscopy / methods. Melanoma / surgery. Rectal Neoplasms / surgery. Rectum / surgery
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Reoperation

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122689.001).
  • [ISSN] 0386-300X
  • [Journal-full-title] Acta medica Okayama
  • [ISO-abbreviation] Acta Med. Okayama
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Herrera Espiñeira C, Fernández Valdivia J, López-Cuervo JE, Martínez Tapias J: Textural analysis in the diagnosis of benign and malignant breast cells. Anal Quant Cytol Histol; 2007 Dec;29(6):365-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Textural analysis in the diagnosis of benign and malignant breast cells.
  • OBJECTIVE: To study the discriminatory capacity of textural variables to classify the nuclei of breast tumor cells as benign or malignant, using a statistical approach.
  • The sample comprised 95 cases of malignant lesions and 47 cases of benign lesions (approximately 25 nuclei per case), and 27 textural variables were measured.
  • RESULTS: The variance in gray levels was the most decisive variable in the CART analysis, correctly classifying 57% and 97% of benign and malignant cases, respectively.
  • Discriminant analysis yielded the best results, correctly classifying 79% and 85% of benign and malignant cases, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18225392.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


9. Krishna CM, Sockalingum GD, Bhat RA, Venteo L, Kushtagi P, Pluot M, Manfait M: FTIR and Raman microspectroscopy of normal, benign, and malignant formalin-fixed ovarian tissues. Anal Bioanal Chem; 2007 Mar;387(5):1649-56
Hazardous Substances Data Bank. FORMALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FTIR and Raman microspectroscopy of normal, benign, and malignant formalin-fixed ovarian tissues.
  • This is attributed to a lack of reliable screening methods and the inadequacy of treatment modalities for the advanced stages of the disease.
  • FTIR and Raman spectroscopic studies of formalin-fixed normal, benign, and malignant ovarian tissues have been undertaken in order to investigate and attempt to understand the underlying biochemical changes associated with the disease, and to explore the feasibility of discriminating between these different tissue types.
  • Raman spectra of normal tissues indicate the dominance of proteins and lower contents of DNA and lipids compared to malignant tissues.
  • Among the pathological tissues studied, spectra from benign tissues seem to contain more proteins and less DNA and lipids compared to malignant tissue spectra.
  • FTIR and Raman spectra of both normal and benign tissues showed more similarities than those of malignant tissues.
  • Cluster analysis of first-derivative Raman spectra in the 700-1700 cm(-1) range gave two clear groups, one corresponding to malignant and the other to normal+benign tissues.
  • At a lower heterogeneity level, the normal+benign cluster gave three nonoverlapping subclusters, one corresponding to normal and two for benign tissues.
  • Cluster analysis of second-derivative FTIR spectra in the combined spectral regions of 1540-1680 and 1720-1780 cm(-1) resulted into two clear clusters corresponding to malignant and normal+benign tissues.
  • The cluster corresponding to normal+benign tissues produced nonoverlapping subclusters for normal and benign tissues at a lower heterogeneity level.
  • The findings of this study demonstrate the feasibility of Raman and FTIR microspectroscopic discrimination of formalin-fixed normal, benign, and malignant ovarian tissues.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / analysis. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Spectroscopy, Fourier Transform Infrared / methods. Spectrum Analysis, Raman / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043798.001).
  • [ISSN] 1618-2642
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fixatives; 0 / Neoplasm Proteins; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


10. Karaitianos IG, Archondakis SK, Korkolis D, Koundouris C, Xenitidis M, Daskalopoulou D, Tsigris C: The role of cytology in the diagnosis of benign and malignant anal lesions. Acta Chir Iugosl; 2006;53(2):39-42
MedlinePlus Health Information. consumer health - Anal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytology in the diagnosis of benign and malignant anal lesions.
  • Squamous cell carcinoma is a rather infrequent neoplasm of the gastrointestinal tract.
  • Squamous cell carcinoma is a slowly and locally growing neoplasm which metastasizes in advanced stages.
  • Its diagnosis must be accomplished by the least traumatic examinations possible.
  • In 89 of them cytological material from ulcerated positions of the anal region was examined.
  • In the rest 27 cytological material was obtained by fine needle aspiration of subcutaneous or submucosal anal lesions.
  • Cytological evaluation revealed 29 cases of normal anal epithelium, 13 granulomas, 12 cases of HPV infection, 28 anal squamous intraepithelial lesions (ASIL), 17 post radiation injuri-es of the anal mucosa and 17 carcinomas.
  • The neoplasms were further subclassified in 12 well differentiated squamous cell carcinomas, 4 cloacogenic carcinomas and 1 leiomyosarcoma.
  • Histological examination followed the initial cytological diagnosis in 75 cases.
  • It is well accepted by the patients and of paramount clinical utility for the initial diagnostic assessment, the long-term follow up after treatment of anal cancer patients.
  • It is also valuable for the differential diagnosis among benign, premalignant and malignant anal lesions.
  • [MeSH-major] Anus Diseases / diagnosis. Anus Neoplasms / diagnosis. Biopsy, Needle
  • [MeSH-minor] Adult. Carcinoma, Squamous Cell / diagnosis. Cytodiagnosis. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139883.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


11. Jin Z, Yin L, Xue L, Lin M, Zheng Q: Anorectal functional results after transanal endoscopic microsurgery in benign and early malignant tumors. World J Surg; 2010 May;34(5):1128-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anorectal functional results after transanal endoscopic microsurgery in benign and early malignant tumors.
  • Anorectal manometric values showed the mean anal resting pressure (ARP) decrease from 45 +/- 6 mmHg to 29 +/- 4 mmHg (p < 0.05) and the maximum tolerable volume (MTV) decrease from 175 +/- 21 ml to 90 +/- 15 ml (p < 0.05) at the third month after TEM.
  • Endosonography demonstrated internal anal sphincter (IAS) rupture in five patients, and full integrity of the external anal sphincter (EAS) in all patients.
  • Most patients had more times of stools per day and relative higher Wexner scores in a short period after TEM.
  • Thus TEM is safe, in terms of anorectal function, for the cure of benign and early malignant tumors of the rectum.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma, Villous / surgery. Anal Canal / physiopathology. Anus Neoplasms / surgery. Rectal Neoplasms / surgery. Rectum / physiopathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20225126.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Karakitsos P, Pouliakis A, Kordalis G, Georgoulakis J, Kittas C, Kyroudes A: Potential of radial basis function neural networks in discriminating benign from malignant lesions of the lower urinary tract. Anal Quant Cytol Histol; 2005 Feb;27(1):35-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential of radial basis function neural networks in discriminating benign from malignant lesions of the lower urinary tract.
  • OBJECTIVE: To investigate the potential value of morphometry and neural network tools for discriminating benign from malignant nuclei and lesions of the lower urinary tract.
  • STUDY DESIGN: The study group consisted of 33 cases of lithiasis, 41 cases of inflammation, 66 cases of benign hyperplasia of the prostate, 4 cases of carcinoma in situ, 48 cases of grade 1 transitional cell carcinoma of the bladder (TCCB) and 123 cases of grade 2 and 3 TCCB.
  • A radial basis function (RBF)-type neural network was employed to discriminate benign from malignant nuclei, based on the extracted morphometric and textural features.
  • Subsequently a second RBF classifier was employed to discriminate benign from malignant cases.
  • RESULTS: Application of the RBF classifier permitted the correct classification of 93.64% of benign nuclei and 85.61% of malignant, giving an overall accuracy of 84.45%.
  • CONCLUSION: The role of nuclear morphologic features in the cytologic diagnosis of lower urinary tract alterations was confirmed by the results of this study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794450.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Lambrinoudaki I, Augoulea A, Creatsa M, Vlachos N, Christodoulakos G, Papadias C: Endometriosis and other benign and malignant müllerian lesions in pelvic and extrapelvic organs. Anal Quant Cytol Histol; 2009 Jun;31(3):170-6
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometriosis and other benign and malignant müllerian lesions in pelvic and extrapelvic organs.
  • OBJECTIVE: To conduct a retrospective study on case reports found in literature across the world on benign müllerian lesions of the urogenital tract and on cases of malignant transformation from müllerian duct remnants in order to better understand these rare anatomopathologic entities and to avoid overdiagnosis and overtreatment.
  • STUDY DESIGN: We reviewed a number of case reports on benign and malignant müllerian lesions and compared the developments associated with endometriosis, endosalpingiosis and endocervicosis.
  • RESULTS: Our sampling of case reports confirm the suggestion that both malignant neoplasms and benign müllerian lesions can arise in foci of endometriosis in both pelvic and extrapelvic sites.
  • CONCLUSION: The development of malignant tumors is a well-known complication of endometriosis and endosalpingiosis, but data about endocervicosis are unclear.

  • Genetic Alliance. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19634787.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Garbar C, Mascaux C, Wespes E: Expression of MUC1 and sialyl-Tn in benign prostatic glands, high-grade prostate intraepithelial neoplasia and malignant prostatic glands: a preliminary study. Anal Quant Cytol Histol; 2008 Apr;30(2):71-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MUC1 and sialyl-Tn in benign prostatic glands, high-grade prostate intraepithelial neoplasia and malignant prostatic glands: a preliminary study.
  • STUDY DESIGN: One sample histologic paraffin block of 24 radical prostatectomies was selected for presence of both benign and malignant glands; 17 samples also included PIN.
  • RESULTS: MUC1 immunostaining was more often positive for neoplastic cells, progressively from benign (4.7+/-5.3%) to PIN (27.1+/-19.7%) and malignant glands (34.5+/-28.4%).
  • Both antibodies showed a statistical difference between benign glands and PIN or malignant glands but not between PIN and malignant.
  • CONCLUSION: MUC1 and sTn were expressed more intensely in PIN and malignant prostate glands than in benign glands. sTn seemed more specific in favor of cell malignancy.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18561742.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Sialomucins
  •  go-up   go-down


15. Jakab C, Rusvai M, Szabó Z, Szabára A, Kulka J: Expression of the claudin-4 molecule in benign and malignant canine hepatoid gland tumours. Acta Vet Hung; 2009 Dec;57(4):463-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the claudin-4 molecule in benign and malignant canine hepatoid gland tumours.
  • These results suggest that low claudin-4 expression in epitheliomas is a molecular characteristic indicative of increasing cellular disorientation, detachment motility and invasion by tumour cells, and claudin-4 seems to be helpful in distinguishing undifferentiated carcinomas from differentiated carcinomas and epitheliomas of the hepatoid gland.
  • [MeSH-major] Anal Gland Neoplasms / metabolism. Dog Diseases / metabolism. Gene Expression Regulation, Neoplastic / physiology. Membrane Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19897451.001).
  • [ISSN] 0236-6290
  • [Journal-full-title] Acta veterinaria Hungarica
  • [ISO-abbreviation] Acta Vet. Hung.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Claudin-4; 0 / Membrane Proteins
  •  go-up   go-down


16. Jansen SA, Fan X, Karczmar GS, Abe H, Schmidt RA, Newstead GM: Differentiation between benign and malignant breast lesions detected by bilateral dynamic contrast-enhanced MRI: a sensitivity and specificity study. Magn Reson Med; 2008 Apr;59(4):747-54
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between benign and malignant breast lesions detected by bilateral dynamic contrast-enhanced MRI: a sensitivity and specificity study.
  • 3D DCE-MRI data from 100 patients with 34 benign and 79 malignant lesions were selected for review under an Institutional Review Board (IRB)-approved protocol.
  • There was a statistically significant difference between benign and malignant lesions for several model parameters: the uptake rate, initial slope, signal enhancement ratio, and curvature at the peak enhancement (at most P=0.04).

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1996 Sep;200(3):639-49 [8756909.001]
  • [Cites] Radiology. 2007 Dec;245(3):684-91 [18024450.001]
  • [Cites] J Magn Reson Imaging. 1996 Sep-Oct;6(5):743-52 [8890012.001]
  • [Cites] Stat Med. 1998 May 15;17(9):1033-53 [9612889.001]
  • [Cites] Radiology. 1999 Apr;211(1):101-10 [10189459.001]
  • [Cites] Phys Med Biol. 1999 May;44(5):1147-54 [10368008.001]
  • [Cites] Radiol Clin North Am. 2000 Jul;38(4):899-913 [10943285.001]
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):965-74 [11105038.001]
  • [Cites] Eur Radiol. 2001;11(4):531-46 [11354744.001]
  • [Cites] J Comput Assist Tomogr. 2002 May-Jun;26(3):376-86 [12016367.001]
  • [Cites] Acta Radiol. 2003 Jul;44(4):379-86 [12846687.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Sep;82(3):319-26 [14499978.001]
  • [Cites] Radiology. 2003 Oct;229(1):225-32 [14519877.001]
  • [Cites] Magn Reson Med. 2004 Mar;51(3):487-94 [15004789.001]
  • [Cites] Magn Reson Imaging. 2004 May;22(4):467-73 [15120165.001]
  • [Cites] Magn Reson Med. 2004 May;51(5):1066-70 [15122692.001]
  • [Cites] Magn Reson Med. 1995 Apr;33(4):564-8 [7776889.001]
  • [Cites] Radiology. 1995 Oct;197(1):33-8 [7568850.001]
  • [Cites] Radiology. 1995 Dec;197(3):743-7 [7480749.001]
  • [Cites] Cancer. 1996 Jul 1;78(1):91-100 [8646731.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):254-9 [10508284.001]
  • [Cites] Med Image Anal. 2005 Aug;9(4):315-29 [15950895.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):708-18 [15971199.001]
  • [Cites] Radiology. 2005 Sep;236(3):779-88 [16118160.001]
  • [Cites] Radiology. 2005 Sep;236(3):789-800 [16118161.001]
  • [Cites] Ann Intern Med. 2005 Sep 20;143(6):446-57 [16172443.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jun;186(6):1723-32 [16714666.001]
  • [Cites] Am J Surg. 2006 Oct;192(4):520-4 [16978965.001]
  • [Cites] J Magn Reson Imaging. 2007 Jan;25(1):104-12 [17152054.001]
  • [Cites] Magn Reson Imaging. 2007 Jun;25(5):593-603 [17540270.001]
  • [Cites] Magn Reson Imaging. 1996;14(4):337-48 [8782170.001]
  • (PMID = 18383287.001).
  • [ISSN] 0740-3194
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104774-01A2; United States / NCI NIH HHS / CA / R21 CA104774; United States / NCI NIH HHS / CA / R01 CA133490; United States / NCI NIH HHS / CA / R21 CA104774-01A2; United States / NCI NIH HHS / CA / R01 CA078803; United States / NCI NIH HHS / CA / 2 R01 CA078803-05A2; United States / NCI NIH HHS / CA / CA078803-07; United States / NCI NIH HHS / CA / R01 CA078803-07
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 84F6U3J2R6 / gadodiamide; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ NIHMS279369; NLM/ PMC3121098
  •  go-up   go-down


17. Yu N, Kozlowski JM, Park II, Chen L, Zhang Q, Xu D, Doll JA, Crawford SE, Brendler CB, Lee C: Overexpression of transforming growth factor β1 in malignant prostate cells is partly caused by a runaway of TGF-β1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-β type I receptor. Urology; 2010 Dec;76(6):1519.e8-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of transforming growth factor β1 in malignant prostate cells is partly caused by a runaway of TGF-β1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-β type I receptor.
  • METHODS: Malignant (PC3, DU145) and benign (RWPE1, BPH1) prostate epithelial cells were used.
  • RESULTS: Basal levels of TGF-β1 in malignant cells were significantly higher than those in benign cells.
  • Blockade of TGF-β signaling resulted in a significant decrease in TGF-β1 expression in malignant cells, but not in benign cells.
  • Upon TGF-β1 treatment (10 ng/mL), TGF-β1 expression was increased in malignant cells, but not in benign cells.
  • This differential TGF-β1 auto-induction between benign and malignant cells correlated with differential activation of extracellular signal-regulated kinase (ERK).
  • Following TGF-β1 treatment, the activity of serine/threonine phosphatase and recruitment of PP2A-Bα by TβRI increased in benign cells, but not in malignant cells.
  • Inhibition of PP2A in benign cells resulted in an increase in ERK activation and in TGF-β1 auto-induction after TGF-β1 (10 ng/mL) treatment.
  • CONCLUSIONS: These results suggest that TGF-β1 overexpression in malignant cells is caused, at least in part, by a runaway of TGF-β1 auto-induction through ERK activation because of a defective recruitment of PP2A-Bα by TβRI.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] EMBO J. 2007 Sep 5;26(17):3957-67 [17673906.001]
  • [Cites] EMBO Rep. 2008 Oct;9(10):990-7 [18704116.001]
  • [Cites] Int J Oncol. 2007 Feb;30(2):499-507 [17203233.001]
  • [Cites] Am J Pathol. 2006 Oct;169(4):1282-93 [17003485.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Apr;290(4):C1100-8 [16371439.001]
  • [Cites] Respir Res. 2006;7:2 [16390551.001]
  • [Cites] Cell Tissue Res. 2005 Oct;322(1):43-52 [15909166.001]
  • [Cites] Oncogene. 2000 Sep 14;19(39):4531-41 [11002426.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):111-6 [11237527.001]
  • [Cites] J Immunol. 2002 Oct 1;169(7):3485-91 [12244137.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Anal Biochem. 2004 Apr 1;327(1):45-54 [15033509.001]
  • [Cites] Mol Cell. 2004 Jul 23;15(2):170-1 [15260968.001]
  • [Cites] J Biol Chem. 1988 Jun 5;263(16):7741-6 [3259578.001]
  • [Cites] Mol Cell Biol. 1990 Apr;10(4):1492-7 [2108318.001]
  • [Cites] FEBS Lett. 1990 May 21;264(2):187-92 [2162782.001]
  • [Cites] Am J Respir Cell Mol Biol. 1993 Apr;8(4):417-24 [8476635.001]
  • [Cites] Science. 1995 Jun 30;268(5219):1902-6 [7604263.001]
  • [Cites] Ann Surg. 1995 Aug;222(2):146-54 [7639582.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1996 Dec;37(13):2778-82 [8977496.001]
  • [Cites] Br J Urol. 1998 Mar;81(3):403-5 [9523660.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6595-604 [9774674.001]
  • [Cites] Hepatology. 1999 May;29(5):1418-24 [10216124.001]
  • [Cites] Prostate. 1999 Jun 1;39(4):285-90 [10344218.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):2757-61 [18292494.001]
  • [Cites] FASEB J. 2008 Apr;22(4):954-65 [18039929.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Kidney Int. 2005 Sep;68(3):972-84 [16105028.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3557-67 [19447876.001]
  • [Cites] Exp Cell Res. 2007 Sep 10;313(15):3167-74 [17643425.001]
  • (PMID = 21030067.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090386-06A2; United States / NCI NIH HHS / CA / P50 CA090386; United States / NCI NIH HHS / CA / P50 CA090386-06A2; United States / NCI NIH HHS / CA / P50CA90386
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / PPP2R2A protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.1.3.16 / Protein Phosphatase 2
  • [Other-IDs] NLM/ NIHMS194313; NLM/ PMC2997920
  •  go-up   go-down


18. Versa-Ostojić D, Stanković T, Stemberger-Papić S, Vrdoljak-Mozetic D, Manestar M, Krasević M: Nuclear morphometry and AgNOR quantification: computerized image analysis on ovarian mucinous tumor imprints. Anal Quant Cytol Histol; 2008 Jun;30(3):160-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear morphometry and AgNOR quantification: computerized image analysis on ovarian mucinous tumor imprints.
  • OBJECTIVE: To determine the morphometric characteristics of nuclei and silver-stained nucleolar organizer regions (AgNORs) on cytologic imprints and their value in differential cytodiagnosis of benign, atypical proliferative (borderline) and malignant ovarian mucinous tumors.
  • STUDY DESIGN: Forty-six mucinous ovarian tumor imprints (16 benign, 15 borderline, 15 malignant), were analyzed.
  • AgNOR quantification included 7 variables related to the number and area of single, cluster, total and relative AgNOR content per nucleus and the size distribution of AgNORs.
  • RESULTS: Nuclear area and shape factor allowed distinguishing borderline and malignant tumors.
  • The nuclear area in benign tumors was larger than that in borderline tumors; malignant tumors had the highest values.
  • Single and cluster AgNORs were statistically significantly different in borderline tumors compared with malignant tumors, except for the cluster AgNOR area.
  • The total AgNOR area, number and relative area increased from benign through malignant tumors, with statistically significant differences among all groups.
  • By AgNOR size distribution, small AgNORs discriminate malignant from borderline and benign tumors.
  • CONCLUSION: Combining nuclear morphometry and AgNOR analysis on cytologic imprints could be a diagnostically useful method in the assessment of mucinous ovarian tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630841.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / nucleolar organizer region associated proteins
  •  go-up   go-down


19. Rehnberg J, Zendehrokh N, Dejmek A: Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions. Anal Quant Cytol Histol; 2007 Aug;29(4):217-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions.
  • OBJECTIVE: To determine the proliferation rates of mesothelial cells in metastatic and benign effusions.
  • STUDY DESIGN: Immunohistochemistry was performed on formalin-fixed pellets from 16 malignant and 9 benign clinical effusions.
  • Dual staining with antibodies against Ki-67 (MIB-1) and desmin was applied to all effusions to differentiate between benign mesothelial cells and malignant cells, and the proportions of desmin+/Ki-67+ and desmin+/Ki-67- cells were calculated.
  • RESULTS: In 7 malignant effusions no proliferating mesothelial cells were found, whereas some rate of proliferation could always be demonstrated in mesothelial cells in the benign effusions.
  • Further, the median proportions of proliferating cells, malignant 2% vs. benign 11%, differed significantly.
  • CONCLUSIONS: To our knowledge this finding has not been previously described, and it may have implications for both cytologic diagnosis and the understanding of tumor biology and the interaction between tumor cells and mesothelial cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879629.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Desmin; 0 / Ki-67 Antigen
  •  go-up   go-down


20. Kirillov VA, Stebenyaeva EE, Paplevka AA, Demidchik EP: Quantitative changes in thyroid lymphoid cells as a marker of malignancy. Anal Quant Cytol Histol; 2005 Apr;27(2):101-10
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the possibility of using morphometric changes in lymphoid cells in thyroid tissue as a marker of malignant tumors.
  • These features formed the criteria for differentiation between malignant and benign disease.
  • The values for the diagnostic index for the groups with malignant and benign pathology differed significantly.
  • CONCLUSION: One can determine the presence of a malignant tumor in the thyroid gland from the diagnostic index value.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913203.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


21. Ozcan A, Deveci MS, Oztas E, Dede M, Yenen MC, Korgun ET, Gunhan O: Prognostic value of GLUT-1 expression in ovarian surface epithelial tumors: a morphometric study. Anal Quant Cytol Histol; 2005 Aug;27(4):181-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of GLUT-1 expression in ovarian surface epithelial tumors: a morphometric study.
  • OBJECTIVE: To investigate the reported increase in the expression of the glucose transporter GLUT-1 in borderline and malignant ovarian epithelial tumors and its relationship to prognosis.
  • STUDY DESIGN: In this study, areas in which immunohistochemical membranous staining with GLUT-1 were most evident were selected, and the proportions of GLUT-1 expression in 46 benign, 11 borderline and 42 malignant cases of ovarian epithelial tumors were determined quantitatively with a computer and Zeiss Vision KS 400 3.0 (Göttingen, Germany) for Windows (Microsoft, Redmond, Washington, U.S.A.) image analysis.
  • RESULTS: GLUT-1 expression was determined in all borderline tumors (11 of 11) and in 97.6% of malignant tumors (41 of 42).
  • No GLUT-1 expression was observed in benign tumors.
  • The intensity of GLUT-1 staining was lower in borderline tumors than in malignant cases.
  • As differentiation in malignant tumors increased, proportions of GLUT-1 expression showed a relative increase, but this difference was not statistically significant (p = 0.68).
  • CONCLUSION: When GLUT-1 expression in borderline and malignant ovarian epithelial tumors was analyzed against prognosis, no statistically significant difference was identified.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16220828.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Monosaccharide Transport Proteins; 0 / SLC2A1 protein, human
  •  go-up   go-down


22. Nair BC, Kumar S, Rani S, Paliwal OP: Analysis of karyometric variables in spontaneously occurring canine mammary tumors. Anal Quant Cytol Histol; 2006 Oct;28(5):292-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of karyometric variables in spontaneously occurring canine mammary tumors.
  • OBJECTIVE: To study alteration in karyometric variables to distinguish benign from malignant canine mammary tumors.
  • STUDY DESIGN: Formalin-fixed, paraffin-embedded tissue sections from 16 cases of canine mammary tumors were stained with hematoxylin-eosin and analyzed for mean nuclear area, mean nuclear perimeter and shape factor.
  • The morphometric descriptors were then correlated with conventional histologic diagnosis.
  • RESULTS: On Mann-Whitney U-test, nuclear variables, that is, mean nuclear area and mean nuclear perimeter, revealed significant difference between malignant and benign groups (p < 0.01), while shape factor showed significant difference at p < 0.05.
  • All morphometric descriptors showed significant correlation with each other and with histopathologic diagnosis.
  • Contrary to expectations, shape factor was lower in benign compared to malignant tumors.
  • In benign mammary tumors, the highest mean nuclear area and perimeter were 39.59 +/- 10.34 microm2 and 25.39 +/- 4.14 microm, respectively, for fibroadenoma; and in malignant tumors the highest mean nuclear area and perimeter were 48.44 +/- 12.89 microm2 and 27.36 +/- 4.31 microm, respectively, for papillary adenocarcinoma.
  • CONCLUSION: This study provides insight into the alterations in karyometric variables in canine mammary tumors.
  • Mean nuclear area and perimeter appear to have potential to differentiate benign and malignant canine mammary tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17067011.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Gammon RR, Kharazi M, Brandt JT, Keyhani-Rofagha S: Correlation between the papanicolaou stain and the Wright-Giemsa stain in body fluids: a quality assurance study. Anal Quant Cytol Histol; 2006 Jun;28(3):171-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To compare the use of Papanicolaou and Wright-Giemsa stains for the evaluation of body fluids in cytology and hematology laboratories and determine whether other factors account for discrepancies in diagnosis.
  • Cases were divided into 3 categories-benign, atypical, and malignant--and slides of discrepant diagnoses were reviewed.
  • RESULTS: During this period, 198 of 3212 (0.61%) cases received by the hematology laboratory and 252 of 4402 (0.57%) cases received by the cytology laboratory were diagnosed as malignant or atypical.
  • Of 3212 cases simultaneously received by the cytology and hematology laboratories, 17 diagnosed as malignant by hematology were diagnosed benign by cytology (sensitivity 96%).
  • Sixteen cases diagnosed as malignant by cytology were diagnosed as benign by hematology (sensitivity 97%).
  • No benign cases were diagnosed as malignant (specificity 100%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786726.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Dey P: Basic principles and applications of fractal geometry in pathology: a review. Anal Quant Cytol Histol; 2005 Oct;27(5):284-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fractal geometry has been applied to measure the irregularities of nuclear and glandular margins to distinguish malignant lesions from benign ones, to measure the infiltrative margin of a malignant tumor, to assess tumor angiogenesis and to measure the distribution of collagen in tissue.
  • Fractal geometry has also been applied to assess the irregular distribution of chromatin in malignant cells.
  • In the future, fractal geometry may help with the diagnosis, understanding of pathogenesis and management of lesions.
  • It may also provide new insights into disease processes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447821.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-34-5 / Collagen
  •  go-up   go-down


25. Collinson RJ, McC Mortensen NJ: 'How I do it': TEM for tumors of the rectum. J Gastrointest Surg; 2009 Feb;13(2):359-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'How I do it': TEM for tumors of the rectum.
  • INTRODUCTION: Transanal endoscopic microsurgery (TEM) has an established role in the management of benign rectal tumors.
  • It also has an expanding role in the management of malignant tumors, which is more demanding for the clinician.
  • This paper discusses our institutional approach to TEM for benign and malignant tumors and covers some of the current management controversies.
  • [MeSH-major] Microsurgery / methods. Proctoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Anal Canal / surgery. Humans. Postoperative Care. Preoperative Care. Proctoscopes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18461419.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Peng Y, Jiang Y, Chuang ST, Yang XJ: Computer-aided detection of prostate cancer on tissue sections. Appl Immunohistochem Mol Morphol; 2009 Oct;17(5):442-50
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first set of images consisted of 20 training images (10 malignant) used for developing the computer technique and 15 test images (7 malignant) used for testing and optimizing the technique.
  • The second set of images consisted of 299 images (114 malignant) used for evaluation of the performance of the computer technique.
  • The computer technique identified image segments of alpha-methylacyl-CoA racemase-labeled malignant epithelial cells (red), p63, and high-molecular-weight cytokeratin-labeled benign basal cells (brown), and secretory and stromal cells (blue) for identifying prostate cancer automatically.
  • If high-grade prostatic intraepithelial neoplasia, which is a precursor of cancer, and atypical cases were included, the sensitivity and specificity were 85% (97/114) and 89% (165/185), respectively.

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Sep;220(3):781-6 [11526282.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1151-60 [12218571.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):365-71 [12604893.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1121-31 [15343515.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):517-23 [15487448.001]
  • [Cites] Am J Surg Pathol. 1995 Mar;19(3):251-60 [7532918.001]
  • [Cites] Anal Quant Cytol Histol. 1995 Oct;17(5):314-22 [8534334.001]
  • [Cites] Pathol Res Pract. 1995 Sep;191(9):935-44 [8606876.001]
  • [Cites] Radiology. 1996 Jun;199(3):843-8 [8638015.001]
  • [Cites] Acad Radiol. 1999 Jan;6(1):22-33 [9891149.001]
  • [Cites] Abdom Imaging. 2005 Jan-Feb;30(1):26-41 [15647868.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):231-6 [15842047.001]
  • [Cites] Anal Quant Cytol Histol. 2006 Feb;28(1):1-13 [16566275.001]
  • [Cites] Histopathology. 2006 May;48(6):668-73 [16681682.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):248-53 [17210521.001]
  • [Cites] Nat Clin Pract Urol. 2007 Jan;4(1):39-45 [17211424.001]
  • [Cites] N Engl J Med. 2007 Apr 5;356(14):1399-409 [17409321.001]
  • [Cites] N Engl J Med. 2007 Jul 5;357(1):84; author reply 85 [17615628.001]
  • [Cites] N Engl J Med. 2007 Jul 5;357(1):84; author reply 85 [17615630.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Am J Surg Pathol. 2008 Mar;32(3):461-7 [18300803.001]
  • [Cites] AJR Am J Roentgenol. 2008 Apr;190(4):854-9 [18356428.001]
  • (PMID = 19417626.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R21 EB006466; United States / NCI NIH HHS / CA / R21 CA97308; United States / NCI NIH HHS / CA / R21 CA097308-01; United States / NCI NIH HHS / CA / CA097308-02; United States / NCI NIH HHS / CA / R01 CA092361; United States / NCI NIH HHS / CA / CA097308-01; United States / NIBIB NIH HHS / EB / EB006466-02; United States / NIBIB NIH HHS / EB / EB006466-01A1; United States / NIBIB NIH HHS / EB / R21 EB006466-01A1; United States / NIBIB NIH HHS / EB / R21 EB006466-02; United States / NCI NIH HHS / CA / R21 CA097308; United States / NCI NIH HHS / CA / R21 CA097308-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS100571; NLM/ PMC2836393
  •  go-up   go-down


27. Jansen SA, Fan X, Karczmar GS, Abe H, Schmidt RA, Giger M, Newstead GM: DCEMRI of breast lesions: is kinetic analysis equally effective for both mass and nonmass-like enhancement? Med Phys; 2008 Jul;35(7):3102-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The contrast media uptake and washout kinetics in benign and malignant breast lesions were analyzed using an empirical mathematical model (EMM), and model parameters were compared in lesions with mass-like and nonmass-like enhancement characteristics.
  • 34 benign and 78 malignant breast lesions were selected for review.
  • For mass lesions, the contrast uptake rate (alpha), contrast washout rate (beta), iAUC30, SER, Slope(ini), T(peak) and kappa(peak) differed substantially between benign and malignant lesions, and after correcting for multiple tests of significance SER and T(peak) demonstrated significance (p < 0.007).
  • For nonmass lesions, we did not find statistically significant differences in any of the parameters for benign vs. malignant lesions (p > 0.5).
  • Kinetic parameters could distinguish benign and malignant mass lesions effectively, but were not quite as useful in discriminating benign from malignant nonmass lesions.
  • [MeSH-major] Breast Neoplasms / pathology. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2005 Aug 15;104(4):708-18 [15971199.001]
  • [Cites] Invest Radiol. 2005 Jul;40(7):436-41 [15973135.001]
  • [Cites] Breast J. 2005 Nov-Dec;11(6):379-81 [16297079.001]
  • [Cites] Breast J. 2005 Nov-Dec;11(6):382-90 [16297080.001]
  • [Cites] JBR-BTR. 2005 Sep-Oct;88(5):225-32 [16302331.001]
  • [Cites] AJR Am J Roentgenol. 2006 Mar;186(3):865-70 [16498122.001]
  • [Cites] Int J Clin Oncol. 2006 Apr;11(2):108-19 [16622745.001]
  • [Cites] Am J Surg. 2006 Aug;192(2):172-8 [16860625.001]
  • [Cites] Med Phys. 2006 Aug;33(8):2878-87 [16964864.001]
  • [Cites] Radiographics. 2006 Nov-Dec;26(6):1719-34; quiz 1719 [17102046.001]
  • [Cites] CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89 [17392385.001]
  • [Cites] Magn Reson Imaging. 2007 Jun;25(5):593-603 [17540270.001]
  • [Cites] Radiology. 2007 Aug;244(2):356-78 [17641361.001]
  • [Cites] AJR Am J Roentgenol. 2007 Aug;189(2):468-74 [17646475.001]
  • [Cites] Lancet. 2007 Aug 11;370(9586):485-92 [17693177.001]
  • [Cites] Radiology. 2007 Oct;245(1):80-7 [17885182.001]
  • [Cites] Radiology. 2007 Dec;245(3):684-91 [18024450.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2867-76 [10537355.001]
  • [Cites] Radiol Clin North Am. 2000 Jul;38(4):899-913 [10943285.001]
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):965-74 [11105038.001]
  • [Cites] MAGMA. 2000 Dec;11(3):129-37 [11154954.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jul;179(1):171-8 [12076929.001]
  • [Cites] J Clin Pathol. 2002 Aug;55(8):569-74 [12147647.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Sep;21(3 Suppl):47-54 [12585654.001]
  • [Cites] Br J Radiol. 2003 Jan;76(901):3-12 [12595319.001]
  • [Cites] Acta Radiol. 2003 Jul;44(4):379-86 [12846687.001]
  • [Cites] AJR Am J Roentgenol. 2003 Aug;181(2):519-25 [12876038.001]
  • [Cites] Magn Reson Med. 2004 Mar;51(3):487-94 [15004789.001]
  • [Cites] Magn Reson Imaging. 2004 May;22(4):467-73 [15120165.001]
  • [Cites] Magn Reson Med. 2004 May;51(5):1066-70 [15122692.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 20;86(8):614-9 [7511693.001]
  • [Cites] Magn Reson Med. 1995 Apr;33(4):564-8 [7776889.001]
  • [Cites] Radiology. 1995 Aug;196(2):415-9 [7617854.001]
  • [Cites] Radiology. 1995 Dec;197(3):743-7 [7480749.001]
  • [Cites] Cancer. 1996 Jul 1;78(1):91-100 [8646731.001]
  • [Cites] Radiology. 1996 Sep;200(3):639-49 [8756909.001]
  • [Cites] Magn Reson Imaging. 1996;14(4):337-48 [8782170.001]
  • [Cites] Clin Cancer Res. 1996 Nov;2(11):1873-8 [9816143.001]
  • [Cites] Med Image Anal. 1997 Apr;1(3):207-24 [9873907.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1664-9 [9893649.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):254-9 [10508284.001]
  • [Cites] Med Image Anal. 2005 Aug;9(4):315-29 [15950895.001]
  • [Cites] Magn Reson Med Sci. 2003 Dec 31;2(4):159-63 [16222109.001]
  • (PMID = 18697535.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078803; United States / NCI NIH HHS / CA / R21 CA104774; United States / NCI NIH HHS / CA / 2 R01 CA078803-05A2; United States / NCI NIH HHS / CA / R21 CA104774-01 A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ PMC2673559
  •  go-up   go-down


28. Yili Z, Xiaoyan H, Hongwen D, Yun Z, Xin C, Peng W, Youmin G: The value of diffusion-weighted imaging in assessing the ADC changes of tissues adjacent to breast carcinoma. BMC Cancer; 2009;9:18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To define a threshold value of apparent diffusion coefficient (ADC) with which malignant breast lesions can be distinguished from benign lesions, and to evaluate the ADC change of peri-tumor tissue in breast carcinoma by echo planar-diffusion weighted imaging (EPI-DWI).
  • The ADC values were compared between malignant and benign lesions.
  • The ADC values of malignant lesion and layered peri-tumor tissues (from innermost layer 1 to outermost layer 4 with 5 mm every layer) in different directions were compared and the ADC values among different layers were compared.
  • RESULTS: The ADC value of 35 malignant lesions was statistically lower than that of 22 benign lesions (P < 0.05).
  • The ADC value of malignant lesions was statistically lower than that of peri-tumor tissues in different directions (P < 0.05).
  • For peri-tumor tissues, the ADC values increased gradually from layer 1 to layer 4 and there was a significant difference between the ADC values of layer 1 and layer 2 (P < 0.05); while from layer 2 outwards, there was no statistical difference among different layers.
  • CONCLUSION: ADC value was a sensitive and specific parameter that could help to differentiate benign and malignant breast lesions.
  • [MeSH-major] Breast Diseases / diagnosis. Breast Neoplasms / diagnosis. Echo-Planar Imaging / methods
  • [MeSH-minor] Adult. Aged. Breast / pathology. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Fibroadenoma / diagnosis. Fibroadenoma / pathology. Humans. Hyperplasia. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 23;338(3):1353-8 [16269133.001]
  • [Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):644-9 [16163035.001]
  • [Cites] Breast J. 2006 Jan-Feb;12(1):28-36 [16409584.001]
  • [Cites] Cir Esp. 2006 Jan;79(1):3-9 [16426527.001]
  • [Cites] World J Gastroenterol. 2006 Mar 14;12(10):1626-9 [16570359.001]
  • [Cites] Anal Biochem. 2006 Aug 1;355(1):117-24 [16756932.001]
  • [Cites] Magn Reson Imaging. 2006 Sep;24(7):843-7 [16916701.001]
  • [Cites] J Magn Reson Imaging. 2006 Aug;24(2):319-24 [16786565.001]
  • [Cites] Breast J. 2006 Sep-Oct;12(5 Suppl 2):S174-80 [16958998.001]
  • [Cites] Gut. 2006 Nov;55(11):1598-605 [16682430.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2006 Aug;14(3):305-28, v [17098173.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6626-36 [17121881.001]
  • [Cites] Radiol Med. 2006 Dec;111(8):1124-33 [17171522.001]
  • [Cites] Histopathology. 2007 Jan;50(2):232-42 [17222252.001]
  • [Cites] Ai Zheng. 2007 Feb;26(2):168-71 [17298747.001]
  • [Cites] J Magn Reson Imaging. 2007 Jun;25(6):1101-12 [17520731.001]
  • [Cites] J Comput Assist Tomogr. 2007 May-Jun;31(3):449-54 [17538295.001]
  • [Cites] J Magn Reson Imaging. 2001 Mar;13(3):335-43 [11241804.001]
  • [Cites] Radiologe. 2002 Jan;42(1):1-5 [11930535.001]
  • [Cites] J Magn Reson Imaging. 2002 Aug;16(2):172-8 [12203765.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):926-33 [12569592.001]
  • [Cites] Br J Plast Surg. 2003 Jul;56(5):462-70 [12890459.001]
  • [Cites] Oncology (Williston Park). 2003 Nov;17(11):1511-33; discussion 1533-4, 1539, 1542 passim [14682107.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jan;130(1):39-44 [14732766.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2269-80 [15160329.001]
  • [Cites] Annu Rev Med. 1996;47:285-301 [8712782.001]
  • [Cites] Radiology. 2004 Dec;233(3):830-49 [15486214.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):1022-5 [15515012.001]
  • [Cites] Rofo. 2005 Jan;177(1):114-8 [15657829.001]
  • [Cites] Clin Breast Cancer. 2005 Feb;5(6):425-38 [15748463.001]
  • [Cites] Am Surg. 2005 Jan;71(1):22-7; discussion 27-8 [15757052.001]
  • [Cites] Magn Reson Med Sci. 2002 Jul 1;1(2):73-80 [16082129.001]
  • [Cites] Magn Reson Med Sci. 2004 Jul 15;3(2):79-85 [16093623.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Aug;5(4):737-45 [16111473.001]
  • [Cites] Magn Reson Med Sci. 2005;4(1):35-42 [16127252.001]
  • [Cites] Breast Cancer Res Treat. 2005 Dec;94(3):195-8 [16258704.001]
  • (PMID = 19144163.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2633008
  •  go-up   go-down


29. Fan X, Medved M, Karczmar GS, Yang C, Foxley S, Arkani S, Recant W, Zamora MA, Abe H, Newstead GM: Diagnosis of suspicious breast lesions using an empirical mathematical model for dynamic contrast-enhanced MRI. Magn Reson Imaging; 2007 Jun;25(5):593-603
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of suspicious breast lesions using an empirical mathematical model for dynamic contrast-enhanced MRI.
  • The purpose of this study was to test whether an empirical mathematical model (EMM) of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can distinguish between benign and malignant breast lesions.
  • Results demonstrate that benign lesions had uptake (P<2.0 x 10(-5)) and washout (P<.01) rates of contrast agent significantly slower than those of malignant lesions.
  • These diagnostic parameters also effectively differentiated benign from malignant lesions (P<.03).
  • Conventional analysis of contrast medium dynamics, using a subjective classification of contrast medium kinetics in lesions as "washout," "plateau" or "persistent" (sensitivity=83%, specificity=50% and diagnostic accuracy=72%), was less effective than the EMM (sensitivity=100%, specificity=83% and diagnostic accuracy=94%) for the separation of benign and malignant lesions.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):233-41 [10508282.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):223-32 [10508281.001]
  • [Cites] Magn Reson Med. 2004 Nov;52(5):1110-7 [15508148.001]
  • [Cites] Magn Reson Med. 2005 Mar;53(3):724-9 [15723402.001]
  • [Cites] Radiat Med. 2005 Feb;23(1):43-50 [15786751.001]
  • [Cites] Magn Reson Imaging. 2005 May;23(4):519-29 [15919597.001]
  • [Cites] Med Image Anal. 2005 Aug;9(4):315-29 [15950895.001]
  • [Cites] MAGMA. 2006 Feb;19(1):15-21 [16416323.001]
  • [Cites] Am J Surg. 2006 Oct;192(4):520-4 [16978965.001]
  • [Cites] Acta Radiol. 1999 Nov;40(6):585-92 [10598844.001]
  • [Cites] Radiol Clin North Am. 2000 Jul;38(4):899-913 [10943285.001]
  • [Cites] Br J Radiol. 2000 Aug;73(872):806-18 [11026854.001]
  • [Cites] Eur Radiol. 2001;11(4):531-46 [11354744.001]
  • [Cites] Radiology. 2001 Jul;220(1):13-30 [11425968.001]
  • [Cites] Cancer Control. 2001 Sep-Oct;8(5):399-406 [11579335.001]
  • [Cites] Acta Radiol. 2003 Jul;44(4):379-86 [12846687.001]
  • [Cites] AJR Am J Roentgenol. 2003 Aug;181(2):519-25 [12876038.001]
  • [Cites] Magn Reson Med. 2003 Dec;50(6):1151-69 [14648563.001]
  • [Cites] Magn Reson Med. 2004 Mar;51(3):487-94 [15004789.001]
  • [Cites] Magn Reson Imaging. 2004 May;22(4):467-73 [15120165.001]
  • [Cites] J Magn Reson Imaging. 2004 Jul;20(1):122-8 [15221817.001]
  • [Cites] Magn Reson Med. 2004 Aug;52(2):420-9 [15282828.001]
  • [Cites] Radiology. 1989 Mar;170(3 Pt 1):681-6 [2916021.001]
  • [Cites] J Comput Assist Tomogr. 1991 Jul-Aug;15(4):621-8 [2061479.001]
  • [Cites] Magn Reson Med. 1991 Feb;17(2):357-67 [2062210.001]
  • [Cites] Magn Reson Med. 1994 Nov;32(5):646-51 [7808266.001]
  • [Cites] Radiology. 1996 Sep;200(3):639-49 [8756909.001]
  • [Cites] J Magn Reson Imaging. 1997 Jan-Feb;7(1):91-101 [9039598.001]
  • [Cites] Magn Reson Imaging. 1997;15(3):307-17 [9201678.001]
  • [Cites] Radiology. 1998 Aug;208(2):477-83 [9680579.001]
  • [Cites] Acta Radiol. 1998 Sep;39(5):494-500 [9755697.001]
  • [Cites] J Magn Reson Imaging. 1998 Sep-Oct;8(5):1126-34 [9786152.001]
  • [Cites] Med Image Anal. 1997 Apr;1(3):207-24 [9873907.001]
  • [Cites] Radiology. 1999 Apr;211(1):5-7 [10189447.001]
  • [Cites] Radiology. 1999 Apr;211(1):101-10 [10189459.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):254-9 [10508284.001]
  • (PMID = 17540270.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB 003108-01; United States / NCI NIH HHS / CA / R01 CA133490; United States / NIBIB NIH HHS / EB / EB003108-01; United States / NCI NIH HHS / CA / R01 CA078803; United States / NIBIB NIH HHS / EB / R01 EB003108-01; United States / NCI NIH HHS / CA / R01 CA 78803; United States / NIBIB NIH HHS / EB / R01 EB003108; United States / NCI NIH HHS / CA / CA078803-07; United States / NCI NIH HHS / CA / R01 CA078803-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ NIHMS226250; NLM/ PMC2925253
  •  go-up   go-down


30. Mittal R, Perakath B, Chase S, Jesudason MR, Nayak S: Transanal excision of anorectal lesions--a single centre experience. Trop Gastroenterol; 2010 Jan-Mar;31(1):65-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: The aim of this study was to look at the spectrum of disease treated by transanal excision, and their outcomes, in a tertiary care institute.
  • Patients were divided into three groups. (1) Resection for benign disease (2) Curative and (3) Palliative resection for malignant disease.
  • RESULTS: Forty six patients underwent transanal excision, 21 for benign and 25 for malignant disease, 20 with curative and 5 with palliative intent.
  • Tubulovillous adenomas and hyperplastic polyps were the commonest benign lesions.
  • Four patients with malignant melanoma and one with adenocarcinoma underwent palliative resection.
  • CONCLUSION: Transanal excision, when technically feasible, remains the treatment of choice for benign disease of the rectum.
  • It offers good palliation of local symptoms in advanced malignant disease.
  • [MeSH-major] Rectal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Palliative Care. Postoperative Complications. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20860237.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


31. Zhu C, Palmer GM, Breslin TM, Harter J, Ramanujam N: Diagnosis of breast cancer using fluorescence and diffuse reflectance spectroscopy: a Monte-Carlo-model-based approach. J Biomed Opt; 2008 May-Jun;13(3):034015
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of breast cancer using fluorescence and diffuse reflectance spectroscopy: a Monte-Carlo-model-based approach.
  • These models are used to extract the absorption, scattering, and fluorescence properties of malignant and nonmalignant tissues and to diagnose breast cancer based on these intrinsic tissue properties.
  • The relative fluorescence contributions of individual fluorescing components, as well as beta-carotene concentration, hemoglobin saturation, and the mean reduced scattering coefficient display statistically significant differences between malignant and adipose breast tissues.
  • The hemoglobin saturation and the reduced scattering coefficient display statistically significant differences between malignant and fibrous/benign breast tissues.
  • A linear support vector machine classification using (1) fluorescence properties alone, (2) absorption and scattering properties alone, and (3) the combination of all tissue properties achieves comparable classification accuracies of 81 to 84% in sensitivity and 75 to 89% in specificity for discriminating malignant from nonmalignant breast tissues, suggesting each set of tissue properties are diagnostically useful for the discrimination of breast malignancy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024017 [18465980.001]
  • [Cites] J Biomed Opt. 2007 Jan-Feb;12(1):014021 [17343496.001]
  • [Cites] J Biomed Opt. 2000 Apr;5(2):221-8 [10938787.001]
  • [Cites] Acad Radiol. 2001 Mar;8(3):211-8 [11249084.001]
  • [Cites] J Clin Laser Med Surg. 2001 Feb;19(1):35-9 [11547817.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):682-7 [11830520.001]
  • [Cites] Anal Biochem. 2002 May 1;304(1):100-9 [11969193.001]
  • [Cites] Phys Med Biol. 2002 Aug 21;47(16):2847-61 [12222850.001]
  • [Cites] Biotechnol Appl Biochem. 2003 Feb;37(Pt 1):45-50 [12578551.001]
  • [Cites] Appl Opt. 2003 Jun 1;42(16):3170-86 [12790468.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12349-54 [14514888.001]
  • [Cites] IEEE Trans Biomed Eng. 2003 Nov;50(11):1233-42 [14619993.001]
  • [Cites] Phys Med Biol. 1990 Sep;35(9):1317-34 [2236211.001]
  • [Cites] Radiother Oncol. 1991;20 Suppl 1:21-8 [2020765.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3316-22 [2040005.001]
  • [Cites] Bull N Y Acad Med. 1991 Mar-Apr;67(2):143-50 [2049567.001]
  • [Cites] J Photochem Photobiol B. 1992 Oct 30;16(2):187-209 [1474426.001]
  • [Cites] Phys Med Biol. 1997 May;42(5):803-14 [9172260.001]
  • [Cites] Photochem Photobiol. 1997 Oct;66(4):518-22 [9337625.001]
  • [Cites] Lasers Surg Med. 1997;21(5):417-22 [9365951.001]
  • [Cites] Ann N Y Acad Sci. 1998 Feb 9;838:171-93 [9511805.001]
  • [Cites] J Biomed Opt. 2005 Mar-Apr;10(2):024032 [15910105.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12371-6 [16116095.001]
  • [Cites] Appl Opt. 2006 Feb 10;45(5):1062-71 [16512550.001]
  • [Cites] Appl Opt. 2006 Feb 10;45(5):1072-8 [16512551.001]
  • [Cites] Lasers Surg Med. 2006 Aug;38(7):714-24 [16799981.001]
  • [Cites] Neoplasia. 2000 Jan-Apr;2(1-2):26-40 [10933066.001]
  • (PMID = 18601560.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100559-01A1; United States / NCI NIH HHS / CA / R01 CA100559; United States / NCI NIH HHS / CA / 1R01CA100559-01; United States / NCI NIH HHS / CA / R01 CA100559-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS161126; NLM/ PMC2791791
  •  go-up   go-down


32. Chatelain D, Mokrani N, Fléjou JF: [Anal and anal margin tumors]. Ann Pathol; 2007 Dec;27(6):459-75
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal and anal margin tumors].
  • [Transliterated title] Pathologie tumorale anale et péri-anale.
  • Tumors of the anal canal and anal margin are rare.
  • Benign tumors mainly consist of condylomas, cloacogenic polyps and fibro-epithelial polyps.
  • The other malignant tumors are very rare.
  • [MeSH-major] Anus Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Endocrine Gland Neoplasms / epidemiology. Endocrine Gland Neoplasms / pathology. France / epidemiology. Humans. Incidence. Leiomyosarcoma / pathology. Lymphoma / pathology. Melanoma / epidemiology. Melanoma / pathology. Papilloma / pathology. Sarcoma, Kaposi / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18554556.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 110
  •  go-up   go-down


33. Tan YS, Ng LG, Yip SK, Tay MH, Lim AS, Tien SL, Cheng L, Tan PH: Synovial sarcoma of the kidney: a report of 4 cases with pathologic appraisal and differential diagnostic review. Anal Quant Cytol Histol; 2010 Aug;32(4):239-45
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically it needs to be differentiated from other spindle cell lesions occurring within the kidney, including a spectrum of benign to malignant tumors.
  • Among malignant spindle cell tumors of the kidney, mimics of synovial sarcoma are sarcomatoid renal cell carcinoma, sarcomatoid urothelial carcinoma and other primary sarcomas, such as leiomyosarcoma and malignant fibrous histiocytoma.
  • CONCLUSION: The correct diagnosis of synovial sarcoma requires support by an immunohistochemical panel as well as adjunctive investigations like polymerase chain reaction and fluorescence in situ hybridization to determine the presence of the SYT-SSX fusion gene and translocation (X,18), respectively.

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21434526.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / SYT-SSX fusion protein
  •  go-up   go-down


34. Nattkemper TW, Wismüller A: Tumor feature visualization with unsupervised learning. Med Image Anal; 2005 Aug;9(4):344-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor feature visualization with unsupervised learning.
  • Dynamic contrast enhanced magnetic resonance imaging (DCE MRI) is applied for diagnosis and therapy control of breast cancer.
  • The technique is reported to characterize malignant tumors with high sensitivity and highly variable specificity.
  • Computer-based diagnosis (CAD) systems have been proposed to analyze and classify signal time curve data, extracted from hand selected ROI in the DCE MRI data.
  • In this paper, we apply the self-organizing map (SOM) to a set of time curve feature vectors of single voxels from seven benign lesions and seven malignant tumors.
  • Using the trained SOM, we are able to identify voxels with benign or malignant signal characteristics and to visualize lesion cross-sections with pseudo-colors.
  • [MeSH-major] Breast Neoplasms / pathology. Image Processing, Computer-Assisted / methods. Magnetic Resonance Imaging. Neural Networks (Computer)
  • [MeSH-minor] Contrast Media. Diagnosis, Computer-Assisted. Female. Gadolinium DTPA. Humans


35. Levman J, Leung T, Causer P, Plewes D, Martel AL: Classification of dynamic contrast-enhanced magnetic resonance breast lesions by support vector machines. IEEE Trans Med Imaging; 2008 May;27(5):688-96
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early detection of breast cancer is one of the most important factors in determining prognosis for women with malignant tumors.
  • Computer-aided diagnosis (CAD) systems have the potential to assist radiologists in the early detection of cancer.
  • A key component of the development of such a CAD system will be the selection of an appropriate classification function responsible for separating malignant and benign lesions.
  • The purpose of this study is to evaluate the effects of variations in temporal feature vectors and kernel functions on the separation of malignant and benign DCE-MRI breast lesions by support vector machines (SVMs).

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IEEE Trans Med Imaging. 2002 Dec;21(12):1552-63 [12588039.001]
  • [Cites] Acad Radiol. 2003 Feb;10(2):189-97 [12583571.001]
  • [Cites] Radiology. 2003 Oct;229(1):225-32 [14519877.001]
  • [Cites] Med Phys. 2003 Sep;30(9):2350-9 [14528957.001]
  • [Cites] Med Phys. 2004 May;31(5):1076-82 [15191295.001]
  • [Cites] JAMA. 2004 Sep 15;292(11):1317-25 [15367553.001]
  • [Cites] Magn Reson Med. 1998 Jan;39(1):108-15 [9438444.001]
  • [Cites] Am J Hum Genet. 1998 Mar;62(3):676-89 [9497246.001]
  • [Cites] Med Phys. 1998 Sep;25(9):1647-54 [9775369.001]
  • [Cites] Acad Radiol. 2004 Dec;11(12):1344-54 [15596372.001]
  • [Cites] Bioinformatics. 2005 Feb 15;21(4):439-44 [15608050.001]
  • [Cites] Artif Intell Med. 2005 Jun;34(2):129-39 [15894177.001]
  • [Cites] Med Image Anal. 2005 Aug;9(4):344-51 [15907392.001]
  • [Cites] Med Image Comput Comput Assist Interv. 2006;9(Pt 2):686-93 [17354832.001]
  • [Cites] Magn Reson Med. 1999 Jan;41(1):124-31 [10025619.001]
  • [Cites] Magn Reson Imaging. 2001 Jan;19(1):51-7 [11295347.001]
  • [Cites] Semin Roentgenol. 2001 Jul;36(3):238-49 [11475070.001]
  • [Cites] Magn Reson Imaging. 2002 Feb;20(2):147-54 [12034335.001]
  • [Cites] AJR Am J Roentgenol. 2002 Nov;179(5):1193-9 [12388497.001]
  • [Cites] Physiol Meas. 2002 Nov;23(4):727-39 [12450272.001]
  • [Cites] J Magn Reson Imaging. 2003 Mar;17(3):337-42 [12594724.001]
  • (PMID = 18450541.001).
  • [ISSN] 1558-254X
  • [Journal-full-title] IEEE transactions on medical imaging
  • [ISO-abbreviation] IEEE Trans Med Imaging
  • [Language] ENG
  • [Grant] None / None / / 67225; Canada / Canadian Institutes of Health Research / / 67225
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ CAMS1120; NLM/ PMC2891012
  •  go-up   go-down


36. Camargo RS, Shirata NK, di Loreto C, Garcia EA, Castelo A, Longatto Filho A: Significance of AgNOR measurement in thyroid lesions. Anal Quant Cytol Histol; 2006 Aug;28(4):188-92
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the discriminating potential of AgNOR area measurement and count in thyroid tumors using static cytometry equipment.
  • For statistical purposes, lesions were classified as benign and malignant, and both the number and the area of counted NORs showed very similar values.
  • The NORs median among 19 benign tumors was 1.484 (SD +/- 0.265) and of 14 malignant tumors was 1.436 (SD +/- 0.414); the NORs areas were 2.6584 (SD +/- 1.0653) and 2.3643 (SD +/- 0.6320), respectively.
  • CONCLUSION: Our results showed that AgNOR evaluation was not a significant parameter to discriminate between malignant and benign thyroid lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16927638.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Venkatesh SK, Yin M, Glockner JF, Takahashi N, Araoz PA, Talwalkar JA, Ehman RL: MR elastography of liver tumors: preliminary results. AJR Am J Roentgenol; 2008 Jun;190(6):1534-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR elastography of liver tumors: preliminary results.
  • OBJECTIVE: The purpose of this study was to evaluate the potential value of MR elastography (MRE) in the characterization of solid liver tumors.
  • MATERIALS AND METHODS: Forty-four liver tumors (14 metastatic lesions, 12 hepatocellular carcinomas, nine hemangiomas, five cholangiocarcinomas, three cases of focal nodular hyperplasia, and one hepatic adenoma) were evaluated with MRE.
  • The tumors were identified on T2- and T1-weighted and gadolinium-enhanced T1-weighted images, and the MRE images were obtained through the tumor.
  • The mean shear stiffness of the tumor was calculated with a manually specified region of interest over the tumor in the stiffness map.
  • The stiffness value of tumor-free hepatic parenchyma was calculated.
  • Statistical analysis was performed on the stiffness values for differentiation of normal liver, fibrotic liver, benign tumors, and malignant tumors.
  • RESULTS: Malignant liver tumors had significantly greater mean shear stiffness than benign tumors (10.1 kPa vs 2.7 kPa, p < 0.001), fibrotic liver (10.1 kPa vs 5.9 kPa, p < 0.001), and normal liver (10.1 kPa vs 2.3 kPa, p < 0.001).
  • Fibrotic livers had stiffness values overlapping both the benign and the malignant tumors.
  • A cutoff value of 5 kPa accurately differentiated malignant tumors from benign tumors and normal liver parenchyma in this preliminary investigation.
  • CONCLUSION: MR elastography is a promising noninvasive technique for assessing solid liver tumors.
  • Use of MRE may lead to new quantitative tissue characterization parameters for differentiating benign and malignant liver tumors.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2001 Jul;14(1):63-71 [11436216.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Oct;5(10):1207-1213.e2 [17916548.001]
  • [Cites] Med Image Anal. 2001 Dec;5(4):237-54 [11731304.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jun;178(6):1411-7 [12034608.001]
  • [Cites] Clin Radiol. 2002 Nov;57(11):1014-20 [12409113.001]
  • [Cites] Nat Cell Biol. 2003 Sep;5(9):803-11 [12942086.001]
  • [Cites] Med Image Anal. 2003 Dec;7(4):465-73 [14561551.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):695 [14973470.001]
  • [Cites] Ultrason Imaging. 1991 Apr;13(2):111-34 [1858217.001]
  • [Cites] Science. 1995 Sep 29;269(5232):1854-7 [7569924.001]
  • [Cites] Radiology. 1996 Mar;198(3):920-6 [8628896.001]
  • [Cites] Nat Med. 1996 May;2(5):601-3 [8616724.001]
  • [Cites] Radiology. 1997 Jan;202(1):79-86 [8988195.001]
  • [Cites] Magn Reson Imaging. 2005 Feb;23(2):159-65 [15833607.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Oct;9(4):325-42 [15838603.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):241-54 [16169468.001]
  • [Cites] Radiology. 2005 Oct;237(1):202-11 [16118150.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] NMR Biomed. 2006 Apr;19(2):173-9 [16521091.001]
  • [Cites] Radiology. 2006 Aug;240(2):440-8 [16864671.001]
  • [Cites] Radiology. 2007 Apr;243(1):258-67 [17293571.001]
  • [Cites] Acta Radiol. 2007 Apr;48(3):327-30 [17453505.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S49-60 [17486052.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • (PMID = 18492904.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB001981-07; United States / NIBIB NIH HHS / EB / R01 EB001981-08; United States / NIBIB NIH HHS / EB / R01 EB001981; United States / NIBIB NIH HHS / EB / EB001981; United States / NIBIB NIH HHS / EB / R01 EB001981-07; United States / NIBIB NIH HHS / EB / EB001981-08
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS196000; NLM/ PMC2894569
  •  go-up   go-down


38. Bukhari MH, Niazi S, Khan SA, Hashmi I, Perveen S, Qureshi SS, Chaudhry NA, Qureshi GR, Hasan M: Modified method of AgNOR staining for tissue and interpretation in histopathology. Int J Exp Pathol; 2007 Feb;88(1):47-53
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis of malignancy was made on H & E staining.
  • AgNOR counts, variation in size and dispersion of AgNOR dots in cells were graded and compared in malignant and non-malignant lesions.
  • Modified method of AgNOR staining and interpretation was an easy, reliable and reproducible alternative to traditional AgNOR techniques for evaluating proliferation activity of cells in malignant and benign brain lesions. mAgNOR counts of different grades of astrocytoma (2.97+/-0.96, 3.97+/-0.43, 6.01+/-2.74 and 8.01+/-3.56) were significantly (P<0.01) greater when compared with counts of normal brain (0.40+/-0.01), and reactive gliosis (0.60+/-0.01).
  • AgNOR size and dispersion were of higher grade in a significantly greater proportion of malignancy when compared with benign conditions (P<0.05).
  • [MeSH-major] Antigens, Nuclear / analysis. Astrocytoma / diagnosis. Brain / pathology. Brain Neoplasms / diagnosis. Nuclear Proteins / analysis. Silver Staining / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Braz Dent J. 2000;11(2):105-10 [11210258.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):193-9 [11564895.001]
  • [Cites] Proc Natl Acad Sci U S A. 1969 Jun;63(2):378-83 [4895535.001]
  • [Cites] Histochem J. 1986 Jan;18(1):5-14 [2423479.001]
  • [Cites] Lab Invest. 1990 Jul;63(1):137-40 [1695695.001]
  • [Cites] Int Rev Exp Pathol. 1991;32:149-92 [1713900.001]
  • [Cites] Virchows Arch. 1994;424(2):143-8 [7910097.001]
  • [Cites] Hum Pathol. 1993 Feb;24(2):206-10 [8432516.001]
  • [Cites] Virchows Arch. 1994;425(3):265-9 [7812512.001]
  • [Cites] Cancer Detect Prev. 1995;19(3):282-91 [7750118.001]
  • [Cites] Anal Cell Pathol. 1998;17(4):231-42 [10391375.001]
  • [Cites] J Coll Physicians Surg Pak. 2006 Jun;16(6):412-5 [16787619.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(2):143-7 [1514245.001]
  • (PMID = 17244338.001).
  • [ISSN] 0959-9673
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Biomarkers; 0 / Nuclear Proteins; 0 / nucleolar organizer region associated proteins
  • [Other-IDs] NLM/ PMC2517289
  •  go-up   go-down


39. Røkke O, Faerden AE, Øvrebø K: [Transanal endoscopic microsurgery for tumours in rectum]. Tidsskr Nor Laegeforen; 2007 Nov 15;127(22):2954-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Transanal endoskopisk mikrokirurgi ved svulster i rectum.
  • BACKGROUND: Rectal tumors up to 25 cm from the anal verge may be resected by transanal endoscopic microsurgery (TEM).
  • TEM is suitable for resection of benign adenomas, but can also be used for selected malignant tumours.
  • Selected malignant tumours (like small carcinoid tumours and early stage [Tis, T1] adencarcinomas) with higer moderate differentiation may be resected by TEM with the same oncological result as open surgery.
  • TEM is especially suitable to resect benign adenomas, and may also have a place as primary treatment of selected malignant tumours in Norway.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Microsurgery / methods. Proctoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Humans. Neoplasm Recurrence, Local. Postoperative Complications / diagnosis. Proctoscopes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18026244.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 50
  •  go-up   go-down


40. Mudrikova T, Jaspers C, Ellerbroek P, Hoepelman A: HPV-related anogenital disease and HIV infection: not always 'ordinary' condylomata acuminata. Neth J Med; 2008 Mar;66(3):98-102
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HPV-related anogenital disease and HIV infection: not always 'ordinary' condylomata acuminata.
  • Human papillomavirus (HPV) is responsible for various diseases in the anogenital region which range from benign condylomata acuminata to anal carcinoma.
  • Buschke-Loewenstein tumour is a clinically 'intermediate' condition which is histologically benign but due to extensive destruction of the local tissues can show malignant behaviour.
  • Immunocompromised persons, such as those with HIV infection, have a higher incidence of HPV-related anogenital disease.
  • Different aspects of the HPV-related anogenital disease in HIV-positive individuals are discussed.
  • [MeSH-major] Alphapapillomavirus. Anus Neoplasms / virology. Genital Neoplasms, Female / virology. Genital Neoplasms, Male / virology. HIV Infections / complications. Papillomavirus Infections / complications. Precancerous Conditions / virology. Skin Neoplasms / virology. Tumor Virus Infections / complications
  • [MeSH-minor] Condylomata Acuminata / diagnosis. Condylomata Acuminata / virology. Female. Humans. Male. Prognosis. Risk Factors


41. Tsai BM, Finne CO, Nordenstam JF, Christoforidis D, Madoff RD, Mellgren A: Transanal endoscopic microsurgery resection of rectal tumors: outcomes and recommendations. Dis Colon Rectum; 2010 Jan;53(1):16-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery resection of rectal tumors: outcomes and recommendations.
  • PURPOSE: Transanal endoscopic microsurgery provides a minimally invasive alternative to radical surgery for excision of benign and malignant rectal tumors.
  • We analyzed patient and operative factors, complications, and tumor recurrence.
  • RESULTS: Two hundred sixty-nine patients underwent transanal endoscopic microsurgery for benign (n = 158) and malignant (n = 111) tumors.
  • Local recurrence rates for 121 benign and 83 malignant tumors were 5% for adenomas, 9.8% for T1 adenocarcinoma, 23.5% for T2 adenocarcinoma, 100% for T3 adenocarcinoma, and 0% for carcinoid tumors.
  • CONCLUSIONS: Transanal endoscopic microsurgery is a safe and effective method for excision of benign and malignant rectal tumors.
  • Transanal endoscopic microsurgery can be offered for (1) curative resection of benign tumors, carcinoid tumors, and select T1 adenocarcinomas, (2) histopathologic staging in indeterminate cases, and (3) palliative resection in patients medically unfit or unwilling to undergo radical resection.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Colectomy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Microsurgery. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010345.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Iqbal J, Liu T, Mapow B, Swami VK, Hou JS: Importance of flow cytometric analysis of serous effusions in the diagnosis of hematopoietic neoplasms in patients with prior hematopoietic malignancies. Anal Quant Cytol Histol; 2010 Jun;32(3):161-5
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of flow cytometric analysis of serous effusions in the diagnosis of hematopoietic neoplasms in patients with prior hematopoietic malignancies.
  • OBJECTIVE: To determine the criteria for the use of immunophenotyping by flow cytometry (FCM) in the diagnosis of hematopoietic lesions.
  • The cytopathologic diagnosis was compared with the final diagnosis as modified by subsequent FCM.
  • RESULTS: The cytopathologic diagnosis was benign in 61 cases (69%), atypical in 20 cases (22%) and malignant in 8 cases (9%).
  • In these patients, the working cytopathologic diagnosis was modified from benign/atypical to malignant in 2 (11%) cases and atypical to benign in 11 (33%) cases.
  • CONCLUSION: FCM studies were helpful in the cytopathologic diagnosis in 35% of body fluid specimens, permitting appropriate cancer staging and management.
  • In the absence of a prior clinical history, immunophenotyping by FCM in body fluid specimens should be ordered after adequacy studies when there is cytologic atypia or a strong suspicion of malignancy on the cytopathologic diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701070.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


43. Wiltgen M, Gerger A, Wagner C, Bergthaler P, Smolle J: Evaluation of texture features in spatial and frequency domain for automatic discrimination of histologic tissue. Anal Quant Cytol Histol; 2007 Aug;29(4):251-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the applicability of different texture features in automatic discrimination of microscopic views from benign common nevi and malignant melanoma lesions.
  • Discriminant analysis based on the percentage of "malignant elements" showed correct classification of all nevi cases and 95% of melanoma cases.
  • CONCLUSION: TCA is a potential diagnostic tool in automatic analysis of melanocytic skin tumors.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879634.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Kronenwett U, Huwendiek S, Castro J, Ried T, Auer G: Characterisation of breast fine-needle aspiration biopsies by centrosome aberrations and genomic instability. Br J Cancer; 2005 Jan 31;92(2):389-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have suggested that aneuploidy in malignant tumours could be a consequence of centrosome aberrations.
  • Benign lesions did not show any centrosome aberrations.
  • Our results indicate the percentage of cells with centrosome aberrations as being sufficient to divide the investigated tumours into three significantly different groups: benign lesions with no centrosomal aberrations, and two malignant tumour types with mean values of 2.1 and 9.6% of centrosomal defects, respectively.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Centrosome / pathology. DNA, Neoplasm / analysis. Genomic Instability

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Quant Cytol. 1980 Sep;2(3):161-5 [6252802.001]
  • [Cites] Acta Radiol Ther Phys Biol. 1968 Aug;7(4):241-62 [4179434.001]
  • [Cites] Cancer. 1988 Jul 15;62(2):331-41 [3383134.001]
  • [Cites] Cancer. 1988 Aug 1;62(3):521-30 [3390793.001]
  • [Cites] Hum Pathol. 1989 Jun;20(6):518-27 [2470665.001]
  • [Cites] Cell. 1991 May 31;65(5):825-36 [1840506.001]
  • [Cites] Radiol Clin North Am. 1992 Jan;30(1):167-85 [1732925.001]
  • [Cites] Nature. 1992 Mar 5;356(6364):80-3 [1538786.001]
  • [Cites] Eur J Surg Oncol. 1992 Apr;18(2):108-11 [1582502.001]
  • [Cites] Curr Opin Cell Biol. 1993 Feb;5(1):105-15 [8448021.001]
  • [Cites] Hum Pathol. 1993 Dec;24(12):1348-53 [8276382.001]
  • [Cites] Annu Rev Biochem. 1994;63:639-74 [7979251.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5415-23 [7585611.001]
  • [Cites] Oncology (Williston Park). 1996 Jun;10(6):867-82, 887; discussion 887-90 [8823802.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2765-80 [9205089.001]
  • [Cites] Br J Biomed Sci. 1997 Jun;54(2):140-8 [9231461.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2950-5 [9501196.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):223-4 [9521314.001]
  • [Cites] Diagn Cytopathol. 1998 Jun;18(6):462-7 [9626523.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3974-85 [9731511.001]
  • [Cites] Cell Motil Cytoskeleton. 1998;41(4):281-8 [9858153.001]
  • [Cites] Nat Cell Biol. 1999 Jun;1(2):88-93 [10559879.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1941-51 [10595924.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Feb;27(2):183-90 [10612807.001]
  • [Cites] Curr Opin Cell Biol. 2000 Feb;12(1):113-8 [10679351.001]
  • [Cites] Curr Opin Oncol. 2000 Jan;12(1):82-8 [10687734.001]
  • [Cites] Curr Top Dev Biol. 2000;49:267-89 [11005023.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):279-84 [11301343.001]
  • [Cites] Genes Dev. 2001 May 15;15(10):1167-81 [11358861.001]
  • [Cites] Cell. 2001 May 18;105(4):417-20 [11371338.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1978-83 [11830638.001]
  • [Cites] Int J Oncol. 2002 Jun;20(6):1161-5 [12011993.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1398-404 [12649205.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):904-9 [14871819.001]
  • [Cites] Cancer Res. 1984 Jan;44(1):394-6 [6690053.001]
  • (PMID = 15558069.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2361862
  •  go-up   go-down


45. Mu T, Nandi AK, Rangayyan RM: Classification of breast masses using selected shape, edge-sharpness, and texture features with linear and kernel-based classifiers. J Digit Imaging; 2008 Jun;21(2):153-69
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast masses due to benign disease and malignant tumors related to breast cancer differ in terms of shape, edge-sharpness, and texture characteristics.
  • In this study, we evaluate a set of 22 features including 5 shape factors, 3 edge-sharpness measures, and 14 texture features computed from 111 regions in mammograms, with 46 regions related to malignant tumors and 65 to benign masses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Biol Eng Comput. 2006 Aug;44(8):683-94 [16937210.001]
  • [Cites] Med Biol Eng Comput. 2006 Mar;44(1-2):15-26 [16929917.001]
  • [Cites] Comput Med Imaging Graph. 2007 Jun-Jul;31(4-5):198-211 [17349778.001]
  • [Cites] Med Biol Eng Comput. 2007 Aug;45(8):769-80 [17659369.001]
  • [Cites] J Digit Imaging. 2007 Sep;20(3):223-37 [17021926.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2007;2007:4911-4 [18003107.001]
  • [Cites] Med Phys. 2007 Nov;34(11):4256-69 [18072490.001]
  • [Cites] IEEE Trans Inf Technol Biomed. 2008 Jan;12(1):55-65 [18270037.001]
  • [Cites] IEEE Trans Med Imaging. 1999 Dec;18(12):1170-7 [10695529.001]
  • [Cites] Med Biol Eng Comput. 2000 Sep;38(5):487-96 [11094803.001]
  • [Cites] IEEE Trans Med Imaging. 2000 Oct;19(10):1032-43 [11131493.001]
  • [Cites] Med Phys. 2001 Jul;28(7):1455-65 [11488579.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Dec;20(12):1215-27 [11811822.001]
  • [Cites] IEEE Trans Med Imaging. 2002 Dec;21(12):1552-63 [12588039.001]
  • [Cites] IEEE Trans Med Imaging. 1997 Dec;16(6):799-810 [9533580.001]
  • [Cites] Med Phys. 1998 Apr;25(4):516-26 [9571620.001]
  • [Cites] Stat Med. 1998 May 15;17(9):1033-53 [9612889.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1795-9 [15505630.001]
  • [Cites] Am J Clin Oncol. 2005 Feb;28(1):1-4 [15685026.001]
  • [Cites] JAMA. 2005 Mar 9;293(10):1245-56 [15755947.001]
  • [Cites] IEEE Trans Neural Netw. 2005 Mar;16(2):460-74 [15787152.001]
  • [Cites] IEEE Trans Med Imaging. 2005 Oct;24(10):1278-85 [16229415.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2006 Jan;28(1):69-74 [16402620.001]
  • [Cites] Radiology. 2006 May;239(2):375-83 [16569779.001]
  • [Cites] Phys Med Biol. 2006 Jul 7;51(13):R5-27 [16790920.001]
  • [Cites] Med Phys. 2006 Nov;33(11):4157-68 [17153394.001]
  • (PMID = 18306000.001).
  • [ISSN] 0897-1889
  • [Journal-full-title] Journal of digital imaging
  • [ISO-abbreviation] J Digit Imaging
  • [Language] ENG
  • [Grant] United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3043867
  •  go-up   go-down


46. Zacharakis E, Freilich S, Rekhraj S, Athanasiou T, Paraskeva P, Ziprin P, Darzi A: Transanal endoscopic microsurgery for rectal tumors: the St. Mary's experience. Am J Surg; 2007 Nov;194(5):694-8
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery for rectal tumors: the St. Mary's experience.
  • BACKGROUND: The aim of this study is to describe a single institution's experience in the use of transanal endoscopic microsurgery for rectal tumors.
  • The histologic diagnosis was adenoma in 48 and adenocarcinoma in 28 patients.
  • During the follow-up, benign tumor recurrence was detected in 3 patients (6.3%).
  • The recurrence rates among patients with T1, T2, and T3 malignant tumors were 7.1%, 42.8%, and 66.6%, respectively.
  • COMMENTS: Transanal endoscopic microsurgery is a safe and feasible technique with low incomplete excision rates and may be the preferred method in patients with benign rectal tumors.
  • Its role in the management of malignant tumors should be limited to selected patients with T1 lesions.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Colonoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Female. Humans. Male. Microsurgery. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936438.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Katona TM, Lopez-Beltran A, MacLennan GT, Cheng L, Montironi R, Cheng L: Soft tissue tumors of the penis: a review. Anal Quant Cytol Histol; 2006 Aug;28(4):193-206
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue tumors of the penis: a review.
  • Penile soft tissue tumors comprise 5% of tumors at this site and most have been reported as isolated case reports.
  • The purpose of this review is to aid the practicing surgical pathologist in distinguishing penile soft tissue tumors, such as sarcomatoid squamous cell carcinoma, from other prognostically and therapeutically important entities in the differential diagnosis.
  • The immunohistochemical profiles and salient morphologic clues that may help distinguish penile spindle cell tumors from sarcomatoid carcinomas are evaluated.
  • Soft tissue tumors of the penis may be classified as benign or malignant, as superficial or deep and in terms of age at presentation. All are rare.
  • The most common benign soft tissue tumors that affect the penis are vascular neoplasms, followed by tumors of neural, myoid and fibrous origin.
  • Among reported cases, the most frequent malignant penile soft tissue tumors are Kaposi sarcoma and leiomyosarcoma.
  • Correctly diagnosing penile soft tissue tumors is imperative, because the biologic behavior and the clinical management of these neoplasms vary considerably.
  • Accurate diagnosis is best facilitated by consideration of all available aspects of the case, including clinical information, histopathologic findings and immunohistochemical results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16927639.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 63
  •  go-up   go-down


48. Khaled A, Hammami H, Fazaa B, Kourda N, Kamoun MR, Ben Jilany S, Zoghlami A: Primary amelanotic anorectal melanoma: an uncommon neoplasia with poor prognosis. Pathologica; 2009 Jun;101(3):126-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary amelanotic anorectal melanoma: an uncommon neoplasia with poor prognosis.
  • There is usually a delay in diagnosis because about 30% of these cancers are amelanotic and are often mistaken for benign conditions.
  • Herein, we report a case of amelanotic anorectal malignant melanoma with an unusual metastatic deposit in the vulva and also review the literature.
  • CASE REPORT: A 67-year-old woman presented with a history of prolapse of an anal tumour.
  • Clinical examination showed a pedunculated and ulcerated amelanotic tumour associated with three other nodules, 1 cm in diameter, localized in the vulval mucosa.
  • Histological examination and immunohistochemical staining of all tumours demonstrated malignant melanoma.
  • DISCUSSION: Nine cases of amelanotic malignant melanoma have been reported in the literature.
  • The age at diagnosis ranged from 45 to 77 years.
  • Anorectal melanoma is most common in the rectum, followed by the anal canal.
  • [MeSH-major] Anus Neoplasms / pathology. Melanoma, Amelanotic / secondary. Rectal Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Immunohistochemistry. Vulvar Neoplasms / metabolism. Vulvar Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886548.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


49. Yang JY, Yang MQ, Luo Z, Ma Y, Li J, Deng Y, Huang X: A hybrid machine learning-based method for classifying the Cushing's Syndrome with comorbid adrenocortical lesions. BMC Genomics; 2008;9 Suppl 1:S23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The prognosis for many cancers could be improved dramatically if they could be detected while still at the microscopic disease stage.
  • Because more than one marker must be considered to obtain a classification of cancer or no cancer, and if cancer, to classify it as malignant, borderline, or benign, we must develop an intelligent decision system that can fullfill such an unmet medical need.
  • We have also used immunohistochemistry techniques to measure the gene expression profiles from a number of antigens such as cyclin E, P27KIP1, FHIT, Ki-67, PCNA, Bax, Bcl-2, P53, Fas, FasL and hTERT in several particular types of neuroendocrine tumors such as pheochromocytomas, paragangliomas, and the adrenocortical carcinomas (ACC), adenomas (ACA), and hyperplasia (ACH) involved with Cushing's syndrome.
  • We provided statistical evidence that higher expression levels of hTERT, PCNA and Ki-67 etc. are associated with a higher risk that the tumors are malignant or borderline as opposed to benign.
  • We also investigated whether higher expression levels of P27KIP1 and FHIT, etc., are associated with a decreased risk of adrenomedullary tumors.
  • While no significant difference was found between cell-arrest antigens such as P27KIP1 for malignant, borderline, and benign tumors, there was a significant difference between expression levels of such antigens in normal adrenal medulla samples and in adrenomedullary tumors.
  • This research has many potential applications; it might provide an alternative diagnostic tool and a better understanding of the mechanisms involved in malignant transformation as well as information that is useful for treatment planning and cancer prevention.
  • [MeSH-major] Adrenal Cortex Neoplasms / classification. Algorithms. Artificial Intelligence. Biomarkers, Tumor / metabolism. Cushing Syndrome / classification

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):376-81 [11875703.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):2995-9 [12926152.001]
  • [Cites] Int J Mol Med. 2003 Oct;12(4):437-42 [12964015.001]
  • [Cites] Cancer Lett. 2003 Sep 25;199(2):131-8 [12969785.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5299-306 [14602765.001]
  • [Cites] Ultrastruct Pathol. 2003 Nov-Dec;27(6):417-22 [14660280.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2000-6 [15026336.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1472-7 [15042681.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2363-70 [15197197.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2004 Aug;261(7):376-80 [14605812.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5745-52 [15313915.001]
  • [Cites] Eur J Cancer. 2004 Sep;40(14):2175-83 [15341994.001]
  • [Cites] Cell Oncol. 2004;26(1-2):13-20 [15371653.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1571-4 [15467769.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] J Pathol. 1992 Oct;168(2):161-2 [1460534.001]
  • [Cites] Br J Cancer. 1995 Feb;71(2):278-81 [7530983.001]
  • [Cites] Cell. 1996 Feb 23;84(4):587-97 [8598045.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Sep;32B(5):328-32 [8944836.001]
  • [Cites] Zentralbl Chir. 1997;122(6):430-7 [9334108.001]
  • [Cites] Arch Surg. 1997 Aug;132(8):914-9 [9267279.001]
  • [Cites] J Pediatr Surg. 1998 Apr;33(4):644-6 [9574770.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12):2533-6 [9635574.001]
  • [Cites] Trends Biochem Sci. 1998 Jul;23(7):236-8 [9697409.001]
  • [Cites] Br J Urol. 1998 Aug;82(2):199-205 [9722754.001]
  • [Cites] Anal Cell Pathol. 1998;16(4):185-92 [9762365.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4708-14 [9788626.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3615-20 [11891319.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(5):728-35 [11916557.001]
  • [Cites] Gynecol Oncol. 2002 Jun;85(3):404-14 [12051866.001]
  • [Cites] J Neurooncol. 2002 Apr;57(2):115-21 [12125971.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):455-7 [12543802.001]
  • [Cites] Oncogene. 2003 Jan 23;22(3):461-6 [12545168.001]
  • [Cites] Int J Mol Med. 2003 Apr;11(4):441-7 [12632095.001]
  • [Cites] Vet Pathol. 2003 Mar;40(2):136-42 [12637752.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):187-91 [12640096.001]
  • [Cites] Head Neck. 2003 Apr;25(4):280-8 [12658732.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Feb;129(2):84-8 [12669232.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1213-6 [12698186.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 May;15(5):515-23 [12702909.001]
  • [Cites] APMIS. 2003 Apr;111(4):451-7 [12780518.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3724-8 [12839965.001]
  • [Cites] Laryngorhinootologie. 2003 Jun;82(6):436-7 [12851852.001]
  • [Cites] Mol Pathol. 2003 Aug;56(4):226-31 [12890744.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):331-7 [12893195.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):2837-43 [12926121.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5032-7 [9823304.001]
  • [Cites] Int J Antimicrob Agents. 1998 Aug;10(3):245-8 [9832286.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5478-83 [9850082.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):12-20 [9858527.001]
  • [Cites] Ann Intern Med. 1999 May 4;130(9):759-71 [10357696.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1618-24 [10334551.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8489-92 [10411902.001]
  • [Cites] Methods. 1999 Jul;18(3):401-6 [10455000.001]
  • [Cites] Carcinogenesis. 2004 Nov;25(11):2165-71 [15231689.001]
  • [Cites] J Cell Physiol. 2005 Feb;202(2):518-23 [15389587.001]
  • [Cites] Mol Cancer. 2004 Dec 1;3:33 [15574200.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R28-32 [15642167.001]
  • [Cites] Biol Cell. 2005 Mar;97(3):221-9 [15584900.001]
  • [Cites] Oncogene. 2005 Mar 3;24(10):1774-87 [15674352.001]
  • [Cites] Biochemistry (Mosc). 2005 Mar;70(3):275-91 [15823082.001]
  • [Cites] Arkh Patol. 2005 Mar-Apr;67(2):13-7 [15938112.001]
  • [Cites] Int J Gynecol Pathol. 2005 Jul;24(3):228-34 [15968197.001]
  • [Cites] Br J Surg. 2005 Aug;92(8):1002-7 [15931661.001]
  • [Cites] J Mol Recognit. 2005 Sep-Oct;18(5):343-84 [16094605.001]
  • [Cites] Gynecol Oncol. 2002 Aug;86(2):144-9 [12144820.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3898-905 [12228211.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2890-3 [12231533.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • [Cites] Hum Pathol. 2005 Sep;36(9):994-1002 [16153463.001]
  • [Cites] World J Gastroenterol. 2005 Sep 28;11(36):5735-8 [16237777.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 30;265(3):658-63 [10600477.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):18-21 [10646844.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):570-6 [10747315.001]
  • [Cites] BJU Int. 2000 Apr;85(6):759-66 [10759680.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2341-8 [10873085.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):966-78 [10888772.001]
  • [Cites] Scand J Gastroenterol. 2000 Jun;35(6):637-41 [10912665.001]
  • [Cites] Eur J Gynaecol Oncol. 2000;21(3):267-72 [10949392.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Dec;123(6):779-83 [11112979.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):270-5 [11161387.001]
  • [Cites] J Cutan Pathol. 2001 Mar;28(3):120-6 [11168762.001]
  • [Cites] Bioinformatics. 2000 Dec;16(12):1062-72 [11159325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3346-51 [11248081.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3581-5 [11325823.001]
  • [Cites] Br J Cancer. 2001 Jul 20;85(2):247-54 [11461085.001]
  • [Cites] Eur J Endocrinol. 2001 Sep;145(3):335-41 [11517015.001]
  • [Cites] Mol Cell. 2001 Aug;8(2):407-15 [11545742.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8659-63 [11751381.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):514-9 [11839671.001]
  • (PMID = 18366613.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proliferating Cell Nuclear Antigen
  • [Other-IDs] NLM/ PMC2386065
  •  go-up   go-down


50. Freudenberg S, Palma P, Grobholz R, Ngendahayo L, Post S: HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case. Dis Colon Rectum; 2005 Aug;48(8):1656-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case.
  • PURPOSE: This article describes and discusses primary Burkitt's lymphoma of the anus which is an extremely rare site of origin.
  • METHODS AND RESULTS: A 38-year-old HIV+ Rwandan farmer had an 8-cm x 13-cm anal tumor.
  • CONCLUSIONS: Because of the AIDS epidemic and the increase of anal malignant pathologies, anal Burkitt's lymphoma may appear more frequently.
  • [MeSH-major] Anus Neoplasms / diagnosis. Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis
  • [MeSH-minor] Adult. Colostomy. Fatal Outcome. HIV Seropositivity / diagnosis. Herpesvirus 4, Human / isolation & purification. Humans. Male. Rectum / surgery

  • Genetic Alliance. consumer health - HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034658.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova OE, Starikov AV, Kuznetsova NP, Vlassov VV, Laktionov PP: Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer; 2006 May 22;94(10):1492-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation.
  • Tumour development is characterised by the increased circulating DNA (cirDNA) concentration and by tumour-related changes in blood plasma DNA.
  • Tumour development was shown to lead to significant changes in the distribution of cirDNA between cell-free and cell-surface-bound fractions.
  • Analysis of RARbeta2 and RASSF1A methylation in the total cirDNA provides 95% diagnostic coverage in breast cancer patients, 60% in patients with benign lesions, and is without false-positive results in healthy women.
  • Results of the study indicate that methylation-specific PCR of RARbeta2 and RASSF1A genes based on the total cirDNA combined with the quantitative analysis of cirDNA distribution between cell-bound and cell-free fractions in blood provide the sensitive and accurate detection and discrimination of malignant and benign breast tumours.
  • [MeSH-major] Breast Neoplasms / blood. DNA Methylation. DNA, Neoplasm / blood. DNA-Binding Proteins / genetics. Fibroadenoma / blood. Receptors, Retinoic Acid / genetics. Transcription Factors / genetics. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2000 Apr;906:5-7 [10818586.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1075:191-6 [17108211.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):71-6 [11829433.001]
  • [Cites] Anticancer Drugs. 2002 Apr;13(4):353-7 [11984080.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5462-82 [12154408.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):149-52 [12455027.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:217-20 [15251963.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:221-7 [15251964.001]
  • [Cites] Anal Biochem. 1980 Mar 1;102(2):344-52 [6158890.001]
  • [Cites] J Clin Invest. 1985 Dec;76(6):2182-90 [3001145.001]
  • [Cites] Mol Biol (Mosk). 1988 Nov-Dec;22(6):1667-72 [3252155.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Nucleic Acids Res. 1999 Jun 1;27(11):2315-24 [10325420.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3956-63 [10339505.001]
  • [Cites] Histol Histopathol. 1999 Oct;14(4):1159-64 [10506932.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(6-7):873-7 [15560075.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):389-94 [10956415.001]
  • (PMID = 16641902.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / HIC1 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta
  • [Other-IDs] NLM/ PMC2361269
  •  go-up   go-down


52. Laughney AM, Krishnaswamy V, Garcia-Allende PB, Conde OM, Wells WA, Paulsen KD, Pogue BW: Automated classification of breast pathology using local measures of broadband reflectance. J Biomed Opt; 2010 Nov-Dec;15(6):066019
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We demonstrate that morphological features pertinent to a tissue's pathology may be ascertained from localized measures of broadband reflectance, with a mesoscopic resolution (100-μm lateral spot size) that permits scanning of an entire margin for residual disease.
  • The technical aspects and optimization of a k-nearest neighbor classifier for automated diagnosis of pathologies are presented, and its efficacy is validated in 29 breast tissue specimens.
  • When discriminating between benign and malignant pathologies, a sensitivity and specificity of 91 and 77% was achieved.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Jul 6;406(6791):35-6 [10894529.001]
  • [Cites] J Biomed Opt. 2010 Jul-Aug;15(4):047001 [20799832.001]
  • [Cites] J Biomed Opt. 2000 Apr;5(2):221-8 [10938787.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):656-64 [11034242.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1620-9 [11375944.001]
  • [Cites] Am J Obstet Gynecol. 2002 Mar;186(3):374-82 [11904594.001]
  • [Cites] Semin Diagn Pathol. 2002 Nov;19(4):207-18 [12469788.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1681-92 [12655525.001]
  • [Cites] IEEE Trans Biomed Eng. 2003 Nov;50(11):1233-42 [14619993.001]
  • [Cites] Ann Surg Oncol. 2004 Jan;11(1):65-70 [14699036.001]
  • [Cites] Appl Opt. 2004 May 20;43(15):3048-54 [15176191.001]
  • [Cites] Opt Lett. 2004 May 15;29(10):1087-9 [15181994.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jun;111(6):514-7 [3555403.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):747-53 [2777664.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):356-63 [1445509.001]
  • [Cites] Arch Surg. 1994 Sep;129(9):952-6; discussion 956-7 [8080378.001]
  • [Cites] Anal Chem. 1995 Mar 1;67(5):777-83 [7762814.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):259-67 [8625101.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2189-92 [8635082.001]
  • [Cites] Phys Med Biol. 1997 May;42(5):803-14 [9172260.001]
  • [Cites] Photochem Photobiol. 1998 Jul;68(1):123-32 [9679458.001]
  • [Cites] JAMA. 2005 Feb 23;293(8):964-9 [15728167.001]
  • [Cites] Am Surg. 2005 Jan;71(1):22-7; discussion 27-8 [15757052.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2573-81 [15901955.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):051704 [16292956.001]
  • [Cites] Arch Pathol Lab Med. 2005 Dec;129(12):1565-74 [16329729.001]
  • [Cites] Breast J. 2006 Mar-Apr;12(2):150-3 [16509840.001]
  • [Cites] J Biomed Opt. 2006 Jul-Aug;11(4):041106 [16965134.001]
  • [Cites] J Biomed Opt. 2006 Nov-Dec;11(6):064007 [17212530.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1458-71 [17260108.001]
  • [Cites] J Biomed Opt. 2008 May-Jun;13(3):034015 [18601560.001]
  • [Cites] Eur J Surg Oncol. 2009 Jan;35(1):32-7 [18539425.001]
  • [Cites] J Biomed Opt. 2009 Jan-Feb;14(1):014004 [19256692.001]
  • [Cites] Langenbecks Arch Surg. 2009 Jul;394(4):591-609 [18781322.001]
  • [Cites] J Biomed Opt. 2009 May-Jun;14(3):034034 [19566327.001]
  • [Cites] Ann Surg Oncol. 2009 Oct;16(10):2717-30 [19609829.001]
  • [Cites] Am J Surg. 2009 Oct;198(4):566-74 [19800470.001]
  • [Cites] Lasers Surg Med. 2010 Jan;42(1):15-23 [20077490.001]
  • [Cites] Am J Surg Pathol. 2000 Aug;24(8):1058-67 [10935646.001]
  • (PMID = 21198193.001).
  • [ISSN] 1560-2281
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA080139; United States / NCI NIH HHS / CA / P01 CA80139
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3032233
  •  go-up   go-down


53. Gormley RH, Kovarik CL: Dermatologic manifestations of HPV in HIV-infected individuals. Curr HIV/AIDS Rep; 2009 Aug;6(3):130-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatologic human papillomavirus (HPV) infection in HIV patients manifests as both anogenital and nongenital skin disease.
  • Anogenital HPV-related disease includes benign condyloma acuminata, the most common cutaneous manifestation of genital HPV infection; intermediate malignancy or premalignant conditions including giant condyloma acuminata (also called Buschke-Loewenstein tumor), anal intraepithelial neoplasia, penile intraepithelial neoplasia, and vaginal or vulvar intraepithelial neoplasia; and frankly malignant disease including Bowen's disease and invasive anal, penile, or vulvar carcinoma.
  • Cutaneous HPV-related disease in nongenital skin is also increased in HIV-positive patients, in the form of benign common warts, epidermodysplasia verruciformis-like skin lesions, and nonmelanoma skin cancers.
  • This review and update addresses the above listed dermatologic manifestations of HPV disease in HIV-infected individuals, with an emphasis on new findings and published data from 2006 to 2008.
  • [MeSH-minor] Antiretroviral Therapy, Highly Active. Carcinoma in Situ / etiology. Carcinoma in Situ / physiopathology. Humans. Papillomavirus Vaccines / therapeutic use. Skin Neoplasms / etiology. Skin Neoplasms / physiopathology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19589298.001).
  • [ISSN] 1548-3576
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 69
  •  go-up   go-down


54. Duensing A, Chin A, Wang L, Kuan SF, Duensing S: Analysis of centrosome overduplication in correlation to cell division errors in high-risk human papillomavirus (HPV)-associated anal neoplasms. Virology; 2008 Mar 1;372(1):157-64
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of centrosome overduplication in correlation to cell division errors in high-risk human papillomavirus (HPV)-associated anal neoplasms.
  • High-risk HPV-associated anal neoplasms are difficult to treat and biomarkers of malignant progression are needed.
  • However, a detailed analysis of centrosome overduplication in primary HPV-associated neoplasms has not been performed so far.
  • Here, we determined the frequency of centrosome overduplication in HPV-associated anal lesions using a recently identified marker for mature maternal centrioles, Cep170.
  • Remarkably, centrosome overduplication, but not aberrant centrosome numbers per se or centrosome accumulation, correlated significantly with the presence of cell division errors.
  • In addition, our experiments revealed that in particular pseudo-bipolar mitoses may play a role in the propagation of chromosomal instability in high-risk HPV-associated tumors.
  • These results provide new insights into the role of centrosome aberrations in cell division errors and encourage further studies on centrosome overduplication as a predictive biomarker of malignant progression in HPV-associated anal lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol Res Commun. 1999 Sep-Dec;2(3):190-6 [10662596.001]
  • [Cites] Adv Dent Res. 2006;19(1):99-105 [16672559.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2356-60 [11289095.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):279-84 [11301343.001]
  • [Cites] Biochim Biophys Acta. 2001;1471(2):M81-8 [11342187.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] Inflamm Res. 2002 Aug;51(8):416-22 [12234059.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):815-25 [12415252.001]
  • [Cites] Virus Res. 2002 Nov;89(2):213-28 [12445661.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7075-82 [12460929.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):355-73 [15137962.001]
  • [Cites] Microbiol Mol Biol Rev. 2004 Jun;68(2):362-72 [15187189.001]
  • [Cites] Mol Cancer. 2003 Sep 8;2:30 [14498992.001]
  • [Cites] N Engl J Med. 1984 Apr 5;310(14):880-3 [6321986.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]
  • [Cites] Curr Opin Oncol. 1995 Sep;7(5):437-41 [8541389.001]
  • [Cites] Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78 [8876633.001]
  • [Cites] Acta Oncol. 1997;36(1):3-12 [9090961.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Jun;104(6):723-7 [9197877.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Aug;19(4):233-40 [9258658.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4210-3 [9331077.001]
  • [Cites] Cancer Lett. 1998 Jan 16;123(1):47-52 [9461017.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2950-5 [9501196.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):15-20 [9709296.001]
  • [Cites] Mol Biol Cell. 2005 Mar;16(3):1095-107 [15616186.001]
  • [Cites] Br J Surg. 2005 Mar;92(3):277-90 [15736144.001]
  • [Cites] Cell Biol Int. 2005 May;29(5):352-9 [15890539.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):182-9 [16186736.001]
  • [Cites] Nature. 2005 Oct 13;437(7061):1043-7 [16222300.001]
  • [Cites] Curr Opin Cell Biol. 2006 Feb;18(1):74-8 [16361091.001]
  • [Cites] Cell Cycle. 2006 Dec;5(24):2899-902 [17172866.001]
  • [Cites] Int J STD AIDS. 2007 Feb;18(2):77-80 [17331275.001]
  • [Cites] Trends Cell Biol. 2007 May;17(5):215-21 [17383880.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jun;8(6):451-63 [17505520.001]
  • [Cites] Oncogene. 2007 Sep 20;26(43):6280-8 [17438528.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10002-7 [10944189.001]
  • (PMID = 18036631.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112598-03; United States / NCI NIH HHS / CA / R01 CA112598; United States / NCI NIH HHS / CA / R01 CA 112598; United States / NCI NIH HHS / CA / R01 CA112598-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cep170 protein, human; 0 / Phosphoproteins; 0 / Tubulin
  • [Other-IDs] NLM/ NIHMS38243; NLM/ PMC2267749
  •  go-up   go-down


55. Yegingil H, Shih WY, Shih WH: Probing model tumor interfacial properties using piezoelectric cantilevers. Rev Sci Instrum; 2010 Sep;81(9):095104
Hazardous Substances Data Bank. ZIRCONIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probing model tumor interfacial properties using piezoelectric cantilevers.
  • Invasive malignant breast cancers are typically branchy and benign breast tumors are typically smooth.
  • It is of interest to characterize tumor branchiness (roughness) to differentiate invasive malignant breast cancer from noninvasive ones.
  • In this study, we examined the shear modulus (G) to elastic modulus (E) ratio, G/E, as a quantity to describe model tumor interfacial roughness using a piezoelectric cantilever capable of measuring both tissue elastic modulus and tissue shear modulus.
  • We constructed model tissues with tumors by embedding one-dimensional (1D) corrugated inclusions and three-dimensional (3D) spiky-ball inclusions made of modeling clay in gelatin.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Lead, elemental .
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ultrasonics. 2000 Mar;38(1-8):400-4 [10829696.001]
  • [Cites] Arch Surg. 2001 Feb;136(2):204-8 [11177142.001]
  • [Cites] J Digit Imaging. 2002;15 Suppl 1:224-7 [12105735.001]
  • [Cites] Ultrasound Med Biol. 2003 Jun;29(6):813-23 [12837497.001]
  • [Cites] Annu Rev Biomed Eng. 2003;5:57-78 [12704084.001]
  • [Cites] IEEE Trans Med Imaging. 2004 Jan;23(1):111-21 [14719692.001]
  • [Cites] Radiology. 1999 Jun;211(3):845-50 [10352614.001]
  • [Cites] Phys Med Biol. 2006 Jan 21;51(2):425-41 [16394348.001]
  • [Cites] Physiol Meas. 2005 Jun;26(3):215-28 [15798297.001]
  • [Cites] Phys Med Biol. 2007 Mar 21;52(6):1565-76 [17327649.001]
  • [Cites] Med Eng Phys. 2008 Oct;30(8):1013-9 [18495518.001]
  • [Cites] Rev Sci Instrum. 2007 Nov;78(11):115101 [18052498.001]
  • [Cites] Med Image Anal. 2007 Aug;11(4):361-73 [17509927.001]
  • (PMID = 20887005.001).
  • [ISSN] 1089-7623
  • [Journal-full-title] The Review of scientific instruments
  • [ISO-abbreviation] Rev Sci Instrum
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB000720; United States / NIBIB NIH HHS / EB / 1 R01 EB000720
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aluminum Silicates; 12626-81-2 / lead titanate zirconate; 1302-87-0 / clay; 2P299V784P / Lead; C6V6S92N3C / Zirconium; D1JT611TNE / Titanium
  • [Other-IDs] NLM/ PMC2955722
  •  go-up   go-down


56. Speake D, Lees N, McMahon RF, Hill J: Who should be followed up after transanal endoscopic resection of rectal tumours? Colorectal Dis; 2008 May;10(4):330-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 117 procedures performed, 80 were for benign disease and 37 for malignancy.
  • Within the benign group 39 (49%) resections were intact with clear surgical resection margins and yielded zero recurrences; 22 (27%) resections were macroscopically intact with microscopically involved surgical resection margin and yielded two recurrences; and 19 (24%) resections were piecemeal and yielded eight recurrences.
  • Within the malignant group all 37 patients had resection specimens which were intact with clear surgical resection margins.
  • Of the 35 who went on to long-term follow-up post-TEM (0.6-8.1 years, median 4) four developed recurrent cancer (two local with submucosal disease and two liver metastases).
  • CONCLUSION: For benign rectal neoplasms, resection of an intact specimen with histologically clear surgical resection margins was associated with no observed mucosal recurrence.
  • Local recurrence for malignant cases was submucosal and detected by palpation.
  • [MeSH-major] Adenoma. Carcinoma. Endoscopy, Gastrointestinal / methods. Microsurgery / methods. Neoplasm Recurrence, Local / prevention & control. Rectal Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Case-Control Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190616.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Messadi M, Bessaid A, Taleb-Ahmed A: Extraction of specific parameters for skin tumour classification. J Med Eng Technol; 2009;33(4):288-95
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraction of specific parameters for skin tumour classification.
  • In this paper, a methodological approach to the classification of tumour skin lesions in dermoscopy images is presented.
  • Melanomas are the most malignant skin tumours.
  • This type of cancer is increasing rapidly; its related mortality rate is increasing more modestly, and inversely proportional to the thickness of the tumour.
  • Using skin tumour features such as colour, symmetry and border regularity, an attempt is made to determine if the skin tumour is a melanoma or a benign tumour.
  • In this work, we are interested in extracting specific attributes which can be used for computer-aided diagnosis of melanoma, especially among general practitioners.
  • In the second step, an automatic segmentation is applied to the image of the skin tumour.
  • This step is essential to characterize the shape of the lesion and also to locate the tumour for analysis.
  • Then, a sequences of transformations is applied to the image to measure a set of attributes (A: asymmetry, B: border, C: colour and D: diameter) which contain sufficient information to differentiate a melanoma from benign lesions.
  • Finally, the various signs of specific lesion (ABCD) are provided to an artificial neural network to differentiate between malignant tumours and benign lesions.
  • [MeSH-major] Image Interpretation, Computer-Assisted / methods. Melanoma / diagnosis. Pattern Recognition, Automated / methods. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1999 Dec;135(12):1459-65 [10606050.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Mar;20(3):233-9 [11341712.001]
  • [Cites] Comput Med Imaging Graph. 1992 May-Jun;16(3):191-7 [1623494.001]
  • [Cites] Anal Quant Cytol Histol. 1993 Feb;15(1):1-11 [8471104.001]
  • [Cites] Comput Biol Med. 1997 Nov;27(6):533-43 [9437554.001]
  • [Cites] Med Biol Eng Comput. 2005 Jul;43(4):436-42 [16255424.001]
  • [Cites] Comput Med Imaging Graph. 2007 Sep;31(6):362-73 [17387001.001]
  • (PMID = 19384704.001).
  • [ISSN] 1464-522X
  • [Journal-full-title] Journal of medical engineering & technology
  • [ISO-abbreviation] J Med Eng Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2683694
  •  go-up   go-down


58. Riddick AC, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, Hogan A, Sethia KK, Ellis V, Collins AT, Maitland NJ, Ball RY, Edwards DR: Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer; 2005 Jun 20;92(12):2171-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracellular proteases of the matrix metalloproteinase (MMP) and serine protease families participate in many aspects of tumour growth and metastasis.
  • Using quantitative real-time RT-PCR analysis, we have undertaken a comprehensive survey of the expression of these enzymes and of their natural inhibitors in 44 cases of human prostate cancer and 23 benign prostate specimens.
  • We found increased expression of MMP10, 15, 24, 25 and 26, urokinase plasminogen activator-receptor (uPAR) and plasminogen activator inhibitor-1 (PAI1), and the newly characterised serine proteases hepsin and matriptase-1 (MTSP1) in malignant tissue compared to benign prostate tissue.
  • The cellular localisation of the expression of the deregulated genes was evaluated using primary malignant epithelial and stromal cell cultures derived from radical prostatectomy specimens.
  • [MeSH-major] Matrix Metalloproteinases / genetics. Prostatic Neoplasms / genetics. Serine Endopeptidases / genetics. Tissue Inhibitor of Metalloproteinases / genetics
  • [MeSH-minor] Aged. Disease Progression. GPI-Linked Proteins. Gene Expression Profiling. Humans. Male. Membrane Glycoproteins / biosynthesis. Membrane Glycoproteins / genetics. Middle Aged. Prognosis. Prostate / metabolism. Prostate / pathology. Prostatectomy. RNA, Messenger. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2002 Oct;42(4):398-406 [12361907.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):46845-8 [12384513.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6812-6 [12460890.001]
  • [Cites] Cancer Detect Prev. 2002;26(6):435-43 [12507228.001]
  • [Cites] J Urol. 2003 Mar;169(3):1157-61 [12576872.001]
  • [Cites] BJU Int. 2003 Mar;91(4):315-23; discussion 323-4 [12603403.001]
  • [Cites] J Urol. 2003 Apr;169(4):1316-9 [12629351.001]
  • [Cites] Mol Cancer Res. 2003 Mar;1(5):333-45 [12651907.001]
  • [Cites] Nat Med. 2003 Apr;9(4):407-15 [12652295.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):198-206 [15386409.001]
  • [Cites] Exp Biol Med (Maywood). 2004 Dec;229(11):1090-6 [15564434.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55540-4 [15501821.001]
  • [Cites] Urol Res. 2005 Feb;33(1):44-50 [15517230.001]
  • [Cites] Prostate. 2000 Jan;42(1):18-25 [10579795.001]
  • [Cites] Ann Oncol. 2000 Mar;11(3):327-32 [10811500.001]
  • [Cites] Oncol Rep. 2000 Jul-Aug;7(4):879-82 [10854562.001]
  • [Cites] Cell Mol Life Sci. 2000 Jan 20;57(1):25-40 [10949579.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36720-5 [10962009.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6927-34 [11156392.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2365-70 [11289097.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1301-11 [11290548.001]
  • [Cites] Expert Rev Mol Med. 2003 Sep;5(23):1-39 [14585170.001]
  • [Cites] Nat Genet. 2003 Nov;35(3):252-7 [14517555.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 26;312(4):1196-201 [14652000.001]
  • [Cites] J Urol. 2004 Jan;171(1):187-91 [14665873.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3937-44 [14666700.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8511-5 [14679018.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):463-70 [14735194.001]
  • [Cites] Oncogene. 2004 Jan 22;23(3):845-51 [14647437.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):590-8 [14744773.001]
  • [Cites] Oncogene. 2003 Apr 10;22(14):2121-34 [12687014.001]
  • [Cites] Curr Top Dev Biol. 2003;54:263-312 [12696753.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):15056-64 [12586837.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2292-9 [12727852.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):422-33 [12778132.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):453-9 [12798711.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7847-52 [12788977.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):382-7 [12845678.001]
  • [Cites] J Histochem Cytochem. 2003 Aug;51(8):1017-25 [12871983.001]
  • [Cites] Eur J Haematol. 2003 Aug;71(2):91-9 [12890147.001]
  • [Cites] Adv Exp Med Biol. 2003;532:91-107 [12908552.001]
  • [Cites] Exp Cell Res. 2003 Aug 15;288(2):246-56 [12915116.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(3):217-22 [12970724.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):40364-72 [12904305.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6758-62 [14583471.001]
  • [Cites] J Biol Chem. 1997 Apr 4;272(14):9147-52 [9083044.001]
  • [Cites] Clin Exp Metastasis. 1997 May;15(3):246-58 [9174126.001]
  • [Cites] Oncogene. 1997 Jun 12;14(23):2767-74 [9190892.001]
  • [Cites] J Urol. 1998 Nov;160(5):1872-6 [9783977.001]
  • [Cites] J Clin Invest. 1998 Dec 1;102(11):2002-10 [9835626.001]
  • [Cites] Prostate. 1999 May;39(2):123-9 [10221568.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2570-6 [10363975.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2094-102 [10473092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11054-61 [10500122.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):952-61 [14871825.001]
  • [Cites] Prostate. 2004 May 1;59(2):167-76 [15042617.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):155-69 [15069676.001]
  • [Cites] Chest. 2004 May;125(5):1843-52 [15136399.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):185-95 [15324701.001]
  • [Cites] J Immunol. 2004 Sep 15;173(6):3605-11 [15356104.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):228-35 [15368474.001]
  • [Cites] J Urol. 1974 Jan;111(1):58-64 [4813554.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] J Cancer Res Clin Oncol. 1991;117(2):144-50 [1848860.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4493-8 [7691397.001]
  • [Cites] Am J Pathol. 1994 Mar;144(3):585-91 [8129044.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):497-502 [11304683.001]
  • [Cites] Leuk Lymphoma. 2000 Nov;39(5-6):485-93 [11342332.001]
  • [Cites] Biochem J. 2001 Jun 15;356(Pt 3):705-18 [11389678.001]
  • [Cites] Br J Cancer. 2001 Jul 6;85(1):55-63 [11437402.001]
  • [Cites] Oncogene. 2001 Jul 19;20(32):4337-43 [11466614.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:463-516 [11687497.001]
  • [Cites] J Urol. 2001 Dec;166(6):2171-7 [11696729.001]
  • [Cites] J Cell Sci. 2001 Nov;114(Pt 21):3865-72 [11719553.001]
  • [Cites] Cell. 2001 Dec 14;107(6):789-800 [11747814.001]
  • [Cites] Blood. 2002 Jan 1;99(1):258-67 [11756180.001]
  • [Cites] Anal Biochem. 2002 Jan 15;300(2):269-73 [11779121.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1101-7 [11948120.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2245-52 [11948407.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2169-80 [12057920.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jul;3(7):509-19 [12094217.001]
  • [Cites] J Cell Sci. 2002 Oct 1;115(Pt 19):3719-27 [12235282.001]
  • [Cites] Cancer Detect Prev. 2002;26(3):222-8 [12269770.001]
  • (PMID = 15928670.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / RECK protein, human; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC2361819
  •  go-up   go-down


59. Jasiński A, Szyca R, Tomaszewski S, Leksowski K: [Long-term results of rectal tumors treatment by transanal endoscopic microsurgery (TEM)]. Pol Merkur Lekarski; 2007 May;22(131):379-80
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of rectal tumors treatment by transanal endoscopic microsurgery (TEM)].
  • Transanal endoscopic microsurgery (TEM) is a minimally invasive technique for excision of selected benign and malignant rectal neoplasmas.
  • The aim of this study was to assess the long-term results after benign and malignant rectal lesions excision using TEM.
  • CONCLUSION: TEM is a safe, effective treatment for selected cases of benign lesions and some cases of early stage rectal cancer.
  • [MeSH-major] Adenoma / surgery. Anal Canal / surgery. Endoscopy, Gastrointestinal. Liver Neoplasms / secondary. Microsurgery. Rectal Neoplasms / surgery. Rectum / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anastomosis, Surgical. Digestive System Surgical Procedures. Female. Follow-Up Studies. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local. Recovery of Function. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679373.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


60. Bullitt E, Zeng D, Gerig G, Aylward S, Joshi S, Smith JK, Lin W, Ewend MG: Vessel tortuosity and brain tumor malignancy: a blinded study. Acad Radiol; 2005 Oct;12(10):1232-40
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vessel tortuosity and brain tumor malignancy: a blinded study.
  • Characteristic vessel tortuosity abnormalities appear early during tumor development, affect initially healthy vessels, spread beyond the confines of tumor margins, and do not simply mirror tissue perfusion.
  • The ability to detect and quantify tortuosity abnormalities on high-resolution magnetic resonance angiography (MRA) images offers a new approach to the noninvasive diagnosis of malignancy.
  • MATERIALS AND METHODS: The regional vasculature of 34 healthy subjects was compared with the tumor-associated vasculature of 30 brain tumors before surgical resection.
  • The operator performing the analysis was blinded to the diagnosis.
  • Vessels were segmented from an MRA of each subject, a region of interest was defined in each tumor patient and was mapped to all healthy controls, and a statistical analysis of vessel shape measures was then performed over the region of interest.
  • Many difficult cases were included, such as pinpoint, hemorrhagic, and irradiated tumors, as were hypervascular benign tumors.
  • Tumors were identified as benign or malignant on the basis of histological evaluation.
  • RESULTS: A discriminant analysis performed at the study's conclusion successfully classified all but one of the 30 tumors as benign or malignant on the basis of vessel tortuosity.
  • CONCLUSIONS: Quantitative, statistical measures of vessel shape offer a new approach to the diagnosis and staging of disease.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acad Radiol. 2003 Dec;10(12):1341-8 [14697002.001]
  • [Cites] Int J Mol Med. 2002 Mar;9(3):299-310 [11836637.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] Neuroradiology. 2001 May;43(5):345-52 [11396737.001]
  • [Cites] Brain Tumor Pathol. 2000;17(3):111-20 [11310918.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3683-8 [10919633.001]
  • [Cites] Cancer Biother Radiopharm. 1999 Feb;14(1):31-6 [10850285.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):143-7 [10639516.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):94-5 [10639502.001]
  • [Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Sep;22(9):1163-71 [12956271.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1284-91 [11948144.001]
  • [Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]
  • [Cites] Med Image Anal. 2005 Feb;9(1):39-49 [15581811.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):585-90 [15560716.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):577-84 [15560715.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1969 Apr;105(4):795-805 [4308528.001]
  • [Cites] IEEE Trans Med Imaging. 2002 Feb;21(2):61-75 [11929106.001]
  • (PMID = 16179200.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB000219-08A1; United States / NIBIB NIH HHS / EB / R01 EB000219-07; United States / NIBIB NIH HHS / EB / R01 EB000219-08A1; United States / NIBIB NIH HHS / EB / R01 EB000219; United States / NIBIB NIH HHS / EB / EB000219-07
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS53777; NLM/ PMC2517122
  •  go-up   go-down


61. Wagner DG, Yao JL, di Sant'Agnese PA, Cheng L, Lopez-Beltran A, Montironi R, Huang J: Soft tissue tumors of the prostate: a review. Anal Quant Cytol Histol; 2007 Dec;29(6):341-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue tumors of the prostate: a review.
  • Some prostates that are suspected to be involved by prostatic adenocarcinoma or nodular prostatic hyperplasia through clinical examination and imaging studies proves on histologic examination to be a soft tissue tumor.
  • This paper outlines the most common soft tissue tumors of the prostate and categorizes them into benign, malignant or miscellaneous.
  • Pathologists must be aware that most, if not all, soft tissue tumors of the body may also be found in the prostate.
  • Diagnostic immunohistochemistry is an important adjunct to histopathology for proper diagnosis and tumor subclassification.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18225389.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 90
  •  go-up   go-down


62. Rangayyan RM, Nguyen TM: Fractal analysis of contours of breast masses in mammograms. J Digit Imaging; 2007 Sep;20(3):223-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast masses present shape and gray-scale characteristics that vary between benign masses and malignant tumors in mammograms.
  • Receiver operating characteristics (ROC) analysis was performed to assess and compare the performance of fractal dimension and four previously developed shape factors in the classification of breast masses as benign or malignant.
  • [MeSH-major] Breast Neoplasms / radiography. Fractals. Mammography. Radiographic Image Interpretation, Computer-Assisted
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. ROC Curve

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Biol Eng Comput. 2000 Sep;38(5):487-96 [11094803.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):78-83 [10502430.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Jul;20(7):559-67 [11465463.001]
  • [Cites] Med Phys. 2001 Jul;28(7):1455-65 [11488579.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Dec;20(12):1215-27 [11811822.001]
  • [Cites] IEEE Trans Inf Technol Biomed. 2002 Mar;6(1):54-8 [11936597.001]
  • [Cites] Gynecol Oncol. 2002 Dec;87(3):295-302 [12468328.001]
  • [Cites] Med Image Anal. 2003 Mar;7(1):47-64 [12467721.001]
  • [Cites] Diagn Cytopathol. 2003 Aug;29(2):85-6 [12889046.001]
  • [Cites] Semin Nucl Med. 1978 Oct;8(4):283-98 [112681.001]
  • [Cites] Sci Am. 1990 Feb;262(2):42-9 [2296715.001]
  • [Cites] Phys Med Biol. 1990 Feb;35(2):235-47 [2315379.001]
  • [Cites] J Bone Miner Res. 1994 Nov;9(11):1797-802 [7863830.001]
  • [Cites] Phys Med Biol. 1996 May;41(5):909-23 [8735257.001]
  • [Cites] Med Phys. 1996 Aug;23(8):1337-45 [8873030.001]
  • [Cites] Microcirculation. 1997 Dec;4(4):395-402 [9431507.001]
  • [Cites] IEEE Trans Med Imaging. 1997 Dec;16(6):799-810 [9533580.001]
  • [Cites] IEEE Trans Med Imaging. 2000 Oct;19(10):1032-43 [11131493.001]
  • (PMID = 17021926.001).
  • [ISSN] 0897-1889
  • [Journal-full-title] Journal of digital imaging
  • [ISO-abbreviation] J Digit Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3043900
  •  go-up   go-down


63. McNeill RE, Miller N, Kerin MJ: Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer. BMC Mol Biol; 2007;8:107
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The expression and validity of candidate ECs (GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0, B2M, GUSB, MRPL19, PUM1 and PSMC4) was determined in 6 benign and 21 malignant primary breast cancer tissues.
  • ESR1 expression was appreciably higher in malignant compared to benign tissues and there was a significant effect of EC on the magnitude of the error associated with the relative quantity of ESR1.
  • [MeSH-major] Breast Neoplasms / genetics. Gene Expression Profiling. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Biomarkers, Tumor / genetics. Estrogen Receptor alpha / genetics. Female. Gene Expression Regulation, Neoplastic. Humans. Reproducibility of Results

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 May 5;275(18):13967-73 [10788523.001]
  • [Cites] Cancer Lett. 2006 Jun 8;237(1):123-9 [16019133.001]
  • [Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]
  • [Cites] Anal Biochem. 2001 Aug 1;295(1):17-21 [11476540.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 19;1574(2):152-6 [11955624.001]
  • [Cites] Science. 2002 Apr 19;296(5567):557-9 [11964485.001]
  • [Cites] Nucleic Acids Res. 2002 May 1;30(9):e36 [11972351.001]
  • [Cites] Exp Hematol. 2002 Jun;30(6):503-12 [12063017.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2474-86 [14562124.001]
  • [Cites] Biotechniques. 2004 Jan;36(1):84-6, 88, 90-1 [14740490.001]
  • [Cites] J Pathol. 2004 Apr;202(4):395-402 [15095266.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5245-50 [15289330.001]
  • [Cites] Genome Biol. 2004;5(8):R59 [15287981.001]
  • [Cites] J Biomol Tech. 2004 Sep;15(3):155-66 [15331581.001]
  • [Cites] In Vitro Cell Dev Biol. 1987 Aug;23(8):585-90 [3114226.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5616-9 [3664468.001]
  • [Cites] Biotechnology (N Y). 1992 Apr;10(4):413-7 [1368485.001]
  • [Cites] Epithelial Cell Biol. 1992 Jul;1(3):99-104 [1307945.001]
  • [Cites] Biotechnology (N Y). 1993 Sep;11(9):1026-30 [7764001.001]
  • [Cites] BMC Cancer. 2006;6:49 [16515701.001]
  • [Cites] Breast Cancer Res. 2006;8(2):R23 [16626501.001]
  • [Cites] J Clin Oncol. 2006 Aug 10;24(23):3726-34 [16720680.001]
  • [Cites] Biotechnol Lett. 2006 Oct;28(19):1601-13 [16900335.001]
  • [Cites] BMC Cancer. 2006;6:216 [16945123.001]
  • [Cites] Nat Protoc. 2006;1(3):1559-82 [17406449.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jun 15;211(2):491-6 [7794260.001]
  • [Cites] Oncol Rep. 1998 Mar-Apr;5(2):469-71 [9468581.001]
  • [Cites] Nucleic Acids Res. 2004;32(21):6212-7 [15576347.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):154-9 [15543203.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jan;6(1):69-78 [15688068.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3315-9 [15867229.001]
  • [Cites] Genes Immun. 2005 Jun;6(4):279-84 [15815687.001]
  • [Cites] Anal Biochem. 2005 Jul 1;342(1):69-77 [15958182.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Jul;5(4):493-8 [16013967.001]
  • [Cites] Adv Physiol Educ. 2005 Sep;29(3):151-9 [16109794.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7376-83 [16243810.001]
  • [Cites] Eur Respir J. 2005 Dec;26(6):1002-8 [16319328.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8348-57 [16322295.001]
  • [Cites] BMC Bioinformatics. 2006;7:85 [16504059.001]
  • [Cites] Mol Aspects Med. 2006 Apr-Jun;27(2-3):95-125 [16460794.001]
  • [Cites] Mol Aspects Med. 2006 Apr-Jun;27(2-3):126-39 [16469371.001]
  • [Cites] J Urol. 2006 May;175(5):1915-20 [16600798.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • (PMID = 18042273.001).
  • [ISSN] 1471-2199
  • [Journal-full-title] BMC molecular biology
  • [ISO-abbreviation] BMC Mol. Biol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / estrogen receptor alpha, human
  • [Other-IDs] NLM/ PMC2211316
  •  go-up   go-down


64. Monaco JP, Tomaszewski JE, Feldman MD, Hagemann I, Moradi M, Mousavi P, Boag A, Davidson C, Abolmaesumi P, Madabhushi A: High-throughput detection of prostate cancer in histological sections using probabilistic pairwise Markov models. Med Image Anal; 2010 Aug;14(4):617-29
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We obtain this high-throughput by tailoring the system to analyze the HSs at low resolution (8microm per pixel).
  • This motivates the following algorithm: (Step 1) glands are segmented, (Step 2) the segmented glands are classified as malignant or benign, and (Step 3) the malignant glands are consolidated into continuous regions.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • [Cites] IEEE Trans Med Imaging. 2001 Jan;20(1):45-57 [11293691.001]
  • [Cites] Med Phys. 2009 Sep;36(9):3927-39 [19810465.001]
  • [Cites] J Urol. 2004 Sep;172(3):910-4 [15310996.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1121-31 [15343515.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2004 Mar;26(3):408-13 [15376887.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):125-8 [5948714.001]
  • [Cites] Comput Biomed Res. 1999 Feb;32(1):1-12 [10066352.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1499-507 [10334537.001]
  • [Cites] BJU Int. 2005 Jun;95(8):1146-52 [15877724.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7005-12 [16192588.001]
  • [Cites] IEEE Trans Med Imaging. 2005 Dec;24(12):1611-25 [16350920.001]
  • [Cites] Adv Anat Pathol. 2006 Jan;13(1):57-9 [16462155.001]
  • [Cites] J Urol. 2006 Apr;175(4):1337-40 [16515993.001]
  • [Cites] IEEE Trans Image Process. 2006 Apr;15(4):952-68 [16579381.001]
  • [Cites] Cytometry B Clin Cytom. 2007 Jul;72(4):227-40 [17285628.001]
  • [Cites] J Clin Invest. 2007 Jul;117(7):1876-83 [17557117.001]
  • [Cites] IEEE Trans Med Imaging. 2007 Oct;26(10):1366-78 [17948727.001]
  • [Cites] Eur Urol. 2008 Jan;53(1):68-80 [17920184.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2008 Jun;30(6):1068-80 [18421111.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3923-9 [18711180.001]
  • [Cites] IEEE Trans Med Imaging. 2009 Jun;28(6):906-15 [19164079.001]
  • [Cites] IEEE Trans Med Imaging. 2009 Jul;28(7):1037-50 [19164082.001]
  • [Cites] IEEE Trans Biomed Eng. 2003 Jun;50(6):697-704 [12814236.001]
  • (PMID = 20493759.001).
  • [ISSN] 1361-8423
  • [Journal-full-title] Medical image analysis
  • [ISO-abbreviation] Med Image Anal
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21CA1271-86-01; United States / NCI NIH HHS / CA / CA127186-02S1; United States / NCI NIH HHS / CA / R21 CA127186-02S1; United States / NCI NIH HHS / CA / R03CA128081-01; United States / NCI NIH HHS / CA / R01 CA136535; United States / NCI NIH HHS / CA / R03 CA128081-01; United States / NCI NIH HHS / CA / R21 CA127186; United States / NCI NIH HHS / CA / R01CA136535-01; United States / NCI NIH HHS / CA / CA128081-01; United States / NCI NIH HHS / CA / R21 CA127186-01; United States / NCI NIH HHS / CA / 3 R21 CA127186-02S1; United States / NCI NIH HHS / CA / R03 CA128081; United States / NCI NIH HHS / CA / CA127186-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS207594; NLM/ PMC2916937
  •  go-up   go-down


65. Chen W, Giger ML, Newstead GM, Bick U, Jansen SA, Li H, Lan L: Computerized assessment of breast lesion malignancy using DCE-MRI robustness study on two independent clinical datasets from two manufacturers. Acad Radiol; 2010 Jul;17(7):822-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Area under the receiver operating characteristic curve (AUC) was used as a performance figure of merit in the task of distinguishing between malignant and benign lesions.
  • CONCLUSION: These results demonstrate the robustness of our computerized classification system in the task of distinguishing between malignant and benign breast lesions on dynamic contrast-enhanced (DCE) MRI images from two manufacturers.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 AUR. All rights reserved.
  • [Cites] Med Phys. 2006 Aug;33(8):2878-87 [16964864.001]
  • [Cites] Med Phys. 2004 May;31(5):1076-82 [15191295.001]
  • [Cites] IEEE Trans Med Imaging. 2006 Dec;25(12):1627-36 [17167997.001]
  • [Cites] J Magn Reson Imaging. 2007 Jan;25(1):89-95 [17154399.001]
  • [Cites] Circulation. 2007 Feb 20;115(7):928-35 [17309939.001]
  • [Cites] J Magn Reson Imaging. 2007 Mar;25(3):495-501 [17279534.001]
  • [Cites] CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89 [17392385.001]
  • [Cites] N Engl J Med. 2007 Mar 29;356(13):1295-303 [17392300.001]
  • [Cites] Radiology. 2007 Jul;244(1):94-103 [17507720.001]
  • [Cites] Radiology. 2007 Aug;244(2):356-78 [17641361.001]
  • [Cites] Radiology. 2007 Sep;244(3):672-91 [17709824.001]
  • [Cites] Magn Reson Med. 2007 Sep;58(3):562-71 [17763361.001]
  • [Cites] Acad Radiol. 2008 Apr;15(4):408-16 [18342764.001]
  • [Cites] IEEE Trans Med Imaging. 2008 May;27(5):688-96 [18450541.001]
  • [Cites] Acad Radiol. 2008 Nov;15(11):1446-57 [18995195.001]
  • [Cites] Acad Radiol. 2008 Dec;15(12):1513-25 [19000868.001]
  • [Cites] NMR Biomed. 2009 Jan;22(1):40-53 [18022997.001]
  • [Cites] Acad Radiol. 2009 Jul;16(7):842-51 [19409817.001]
  • [Cites] Acad Radiol. 2006 Jan;13(1):63-72 [16399033.001]
  • [Cites] Radiology. 2006 Jan;238(1):42-53 [16373758.001]
  • [Cites] IEEE Trans Med Imaging. 2005 Oct;24(10):1256-66 [16229413.001]
  • [Cites] Radiology. 2005 Mar;234(3):693-701 [15650040.001]
  • [Cites] Radiology. 1999 Sep;212(3):817-27 [10478252.001]
  • [Cites] Acad Radiol. 1999 Jan;6(1):22-33 [9891149.001]
  • [Cites] Med Image Anal. 1997 Apr;1(3):207-24 [9873907.001]
  • [Cites] Med Phys. 1998 Sep;25(9):1647-54 [9775369.001]
  • [Cites] Stat Med. 1998 May 15;17(9):1033-53 [9612889.001]
  • [Cites] Invest Radiol. 1993 Jan;28(1):59-63 [8425854.001]
  • [Cites] Radiology. 1989 Mar;170(3 Pt 1):681-6 [2916021.001]
  • [Cites] Eur Radiol. 2004 Jul;14(7):1217-25 [15034745.001]
  • [Cites] AJR Am J Roentgenol. 2009 Sep;193(3):832-9 [19696299.001]
  • [Cites] Magn Reson Med. 2003 Jul;50(1):92-8 [12815683.001]
  • [Cites] Radiology. 2002 Aug;224(2):560-8 [12147857.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Sep;20(9):886-99 [11585206.001]
  • [Cites] Radiology. 2001 Sep;220(3):787-94 [11526283.001]
  • [Cites] J Magn Reson Imaging. 2001 Jun;13(6):889-95 [11382949.001]
  • [Cites] Magn Reson Imaging. 2001 Jan;19(1):51-7 [11295347.001]
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):965-74 [11105038.001]
  • [Cites] Acad Radiol. 1999 Mar;6(3):156-63 [10898034.001]
  • [Cites] Med Phys. 1999 Oct;26(10):2176-82 [10535635.001]
  • [Cites] Acad Radiol. 2006 Nov;13(11):1344-54 [17070452.001]
  • (PMID = 20540907.001).
  • [ISSN] 1878-4046
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R33 CA113800-03; United States / NCI NIH HHS / CA / P50 CA125183; United States / NCI NIH HHS / CA / P50 CA125183-010001; United States / NCI NIH HHS / CA / P50-CA125183; United States / NCI NIH HHS / CA / R33 CA113800; United States / NCI NIH HHS / CA / CA113800-03; United States / NCI NIH HHS / CA / CA125183-010001; United States / PHS HHS / / R33-113800
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS206462; NLM/ PMC2907891
  •  go-up   go-down


66. Atallah S, Albert M, Larach S: Transanal minimally invasive surgery: a giant leap forward. Surg Endosc; 2010 Sep;24(9):2200-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the clinical application of this technique and present preliminary data that show TAMIS to be an effective tool for resection of both malignant and benign lesions of the rectum.
  • Patients with biopsy-proven malignant lesions were required to undergo endorectal ultrasound preoperatively to determine tumor stage.
  • To perform TAMIS, a single-incision laparoscopic surgery port (SILS Port, Covidien) is introduced into the anal canal by applying steady manual pressure.
  • The average distance from the anal verge was 9.3 cm and the mean tumor diameter confirmed by pathology measured 2.93 cm.
  • [MeSH-major] Laparoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Biopsy. Endosonography. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures. Neoplasm Staging. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20174935.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


67. Christensen AF, Nyhuus B, Nielsen MB: Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer. Dis Colon Rectum; 2009 Mar;52(3):484-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer.
  • PURPOSE: This study was designed to evaluate the interobserver and intraobserver agreement of two-dimensional (2-D) and three-dimensional (3-D) anal endosonography for the detection of local recurrence anal carcinoma.
  • METHODS: Thirty-six patients were treated for anal carcinoma, and seven had recurrent disease.
  • The observers scored each examination according to the following scale regarding presence of local recurrence: 1 = no finding/benign findings; 2 = properly benign findings; 3 = suspicious findings/malignant findings.
  • CONCLUSIONS: Three-dimensional endosonography proved to have significantly better interobserver and intraobserver agreement than 2-D endosonography concerning detection of recurrent anal cancer.
  • [MeSH-major] Anus Neoplasms / ultrasonography. Endosonography. Neoplasm Recurrence, Local / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / ultrasonography. Female. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Observer Variation. Retrospective Studies

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333050.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Anand BS, Verstovsek G, Cole G: Tubulovillous adenoma of anal canal: a case report. World J Gastroenterol; 2006 Mar 21;12(11):1780-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulovillous adenoma of anal canal: a case report.
  • Tumors arising from the anal canal are usually of epithelial origin and are mostly squamous cell carcinoma or basal cell carcinoma.
  • We present a case of benign anal adenomas arising from the anus, an extremely rare diagnosis.
  • Examination revealed a 4 cm friable mass attached to the anus by a stalk.
  • Microscopic examination revealed a tubulovillus adenoma with no areas of high grade dysplasia or malignant transformation.
  • The squamocolumnar junction was visible at the edges of the lesion confirming the anal origin of the tumor.
  • We believe the tubulovillus adenoma arose from either an anal gland or its duct that opens into the anus.
  • Although seen rarely, it is important to recognize and treat these tumors at an early stage because of their potential to transform into adenocarcinoma.
  • [MeSH-major] Adenoma, Villous / diagnosis. Anus Neoplasms / diagnosis
  • [MeSH-minor] Aged. Anal Canal / pathology. Cell Transformation, Neoplastic. Humans. Male

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):217-9 [15677547.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1634 [8548224.001]
  • (PMID = 16586552.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4124358
  •  go-up   go-down


69. Nakao A, Takeda S, Nomoto S, Kanazumi N, Kasuya H, Sugimoto H, Fujii T, Yamada S: Pancreatic head resection with segmental duodenectomy for pancreatic neoplasms. J Hepatobiliary Pancreat Sci; 2010 Nov;17(6):788-91
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic head resection with segmental duodenectomy for pancreatic neoplasms.
  • BACKGROUND/PURPOSE: We have experienced 67 cases of pancreatic head resection with segmental duodenectomy (PHRSD) for benign or low-grade malignant tumor of the pancreatic head region.
  • In addition, by conserving the anterior inferior pancreatoduodenal artery, the third portion and anal side or the second portion of the duodenum are preserved with good arterial circulation.
  • RESULTS: In 67 cases with diseases of the pancreatic head region, chiefly intraductal papillary mucinous neoplasms, this procedure was successfully performed without operative or hospital death.
  • [MeSH-major] Pancreatectomy / methods. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / surgery. Choledochostomy / methods. Follow-Up Studies. Humans. Neoplasm Staging. Quality of Life. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19882374.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


70. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS: Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn; 2005 Aug;7(3):413-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both benign and malignant tumors represent heterogenous tissue containing tumor cells and non-neoplastic mesenchymal and inflammatory cells.
  • It is particularly useful for tumors containing abundant non-neoplastic cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Biol. 2001 Mar;8(3):243-52 [11306349.001]
  • [Cites] Clin Chem. 2002 Mar;48(3):428-35 [11861435.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):227-34 [11895870.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5261-6 [11959976.001]
  • [Cites] Hum Mutat. 2002 May;19(5):479-85 [11968080.001]
  • [Cites] J Mol Diagn. 2002 Nov;4(4):185-90 [12411585.001]
  • [Cites] Clin Chem. 2002 Dec;48(12):2164-70 [12446472.001]
  • [Cites] Electrophoresis. 2002 Dec;23(24):4072-9 [12481262.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):146-50 [12866414.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):152-6 [12866415.001]
  • [Cites] J Mol Diagn. 2003 Nov;5(4):243-9 [14573784.001]
  • [Cites] Mol Biotechnol. 2004 Feb;26(2):147-64 [14764940.001]
  • [Cites] Nucleic Acids Res. 2004;32(5):e53 [15037663.001]
  • [Cites] Hum Mutat. 2004 May;23(5):406-12 [15108270.001]
  • [Cites] Hum Mutat. 2004 May;23(5):437-41 [15108274.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:250-6 [15251969.001]
  • [Cites] J Mol Diagn. 2004 Aug;6(3):236-42 [15269301.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5847-51 [1631067.001]
  • [Cites] Biotechniques. 1994 May;16(5):938-43 [8068351.001]
  • [Cites] J Clin Pathol. 1994 Dec;47(12):1082-4 [7876379.001]
  • [Cites] J Pathol. 1996 Jul;179(3):254-9 [8774479.001]
  • [Cites] Clin Chem. 1996 Sep;42(9):1382-90 [8787693.001]
  • [Cites] Diagn Mol Pathol. 1996 Dec;5(4):260-4 [8955617.001]
  • [Cites] Anal Biochem. 1997 May 1;247(2):394-403 [9177704.001]
  • [Cites] J Immunol Methods. 1997 Aug 7;206(1-2):11-9 [9328563.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):373-9 [9708798.001]
  • [Cites] Curr Opin Biotechnol. 1998 Dec;9(6):602-8 [9889145.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):83-95 [9916922.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41 [10430926.001]
  • [Cites] Biotechniques. 2000 Jan;28(1):140-4, 146-7 [10649785.001]
  • [Cites] Gene. 2000 Aug 8;253(2):249-57 [10940563.001]
  • [Cites] Clin Chem. 2000 Dec;46(12):1929-38 [11106325.001]
  • [Cites] Genome Res. 2001 Jan;11(1):3-11 [11156611.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):105-10 [15681481.001]
  • (PMID = 16049314.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / PHS HHS / / P01-9467802; United States / PHS HHS / / P01-9483703; United States / PHS HHS / / R01-9485602
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC1867544
  •  go-up   go-down


71. Michel A, Kopp-Schneider A, Zentgraf H, Gruber AD, de Villiers EM: E6/E7 expression of human papillomavirus type 20 (HPV-20) and HPV-27 influences proliferation and differentiation of the skin in UV-irradiated SKH-hr1 transgenic mice. J Virol; 2006 Nov;80(22):11153-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The functional role of UV irradiation, in combination with the E6 and E7 proteins of the cutaneous human papillomavirus (HPV) types in the malignant conversion of benign papillomatous lesions, has not been elucidated.
  • [MeSH-minor] Animals. Bromodeoxyuridine / metabolism. Epidermis / metabolism. Epidermis / radiation effects. Epidermis / virology. Female. Histocytochemistry. Immunohistochemistry. Keratin-6 / biosynthesis. Male. Membrane Proteins / biosynthesis. Mice. Mice, Transgenic. Papilloma / pathology. Papilloma / virology. Papillomavirus Infections / virology. Phosphoproteins / biosynthesis. Protein Precursors / biosynthesis. Skin Neoplasms / pathology. Skin Neoplasms / virology. Trans-Activators / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Feb 10;19(6):821-6 [10698500.001]
  • [Cites] Mol Carcinog. 2005 Jan;42(1):40-52 [15547921.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1975-81 [11106570.001]
  • [Cites] Genes Dev. 2000 Dec 1;14(23):3065-73 [11114894.001]
  • [Cites] J Invest Dermatol. 2001 Feb;116(2):330-8 [11180011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3156-61 [11248048.001]
  • [Cites] Arch Dermatol. 2001 Mar;137(3):384 [11255361.001]
  • [Cites] Int J Cancer. 2001 Mar 15;91(6):828-34 [11275987.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1247-53 [11583952.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Mol Biol Cell. 2002 Jun;13(6):1857-70 [12058054.001]
  • [Cites] Virology. 2002 Jul 5;298(2):240-7 [12127787.001]
  • [Cites] J Biol Chem. 2002 Nov 1;277(44):42268-79 [12200429.001]
  • [Cites] Br J Dermatol. 2003 Jul;149(1):64-73 [12890196.001]
  • [Cites] J Virol. 2003 Oct;77(19):10186-201 [12970404.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):23-35 [14681688.001]
  • [Cites] Genes Dev. 2004 Jan 15;18(2):126-31 [14729569.001]
  • [Cites] Br J Dermatol. 2004 May;150(5):949-57 [15149508.001]
  • [Cites] J Invest Dermatol. 2004 Jul;123(1):13-22 [15191537.001]
  • [Cites] Cell Cycle. 2004 Apr;3(4):411-3 [14976425.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1771-8 [15105299.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Cell Biol. 1989 Jul;109(1):295-307 [2473080.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2490-5 [15699322.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1394-400 [15735026.001]
  • [Cites] Mutat Res. 2005 Apr 1;571(1-2):91-106 [15748641.001]
  • [Cites] Cell Cycle. 2005 May;4(5):689-96 [15846070.001]
  • [Cites] J Virol. 2005 Dec;79(23):14899-908 [16282489.001]
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1099-105 [10594758.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):201-7 [10623668.001]
  • [Cites] Cell. 1990 Aug 24;62(4):697-708 [1696852.001]
  • [Cites] Cell. 1990 Dec 21;63(6):1129-36 [2175676.001]
  • [Cites] J Virol. 1991 Jun;65(6):3335-9 [1851881.001]
  • [Cites] Arch Virol. 1992;125(1-4):355-60 [1642560.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 1;90(9):4216-20 [8483937.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5583-7 [8390671.001]
  • [Cites] Curr Top Microbiol Immunol. 1994;186:157-75 [8205840.001]
  • [Cites] J Virol. 1994 Jul;68(7):4358-68 [7515971.001]
  • [Cites] Cell Growth Differ. 1994 Jun;5(6):667-75 [7522035.001]
  • [Cites] Mol Cell Biol. 1994 Dec;14(12):8250-8 [7969162.001]
  • [Cites] Cancer. 1995 Jan 15;75(2 Suppl):607-12 [7804986.001]
  • [Cites] Arch Dermatol. 1995 Nov;131(11):1312-8 [7503577.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):274-8 [8552621.001]
  • [Cites] J Natl Cancer Inst. 1996 Jun 19;88(12):802-11 [8637046.001]
  • [Cites] Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78 [8876633.001]
  • [Cites] J Biol Chem. 1997 Jan 17;272(3):2021-30 [8999895.001]
  • [Cites] Arch Dermatol Res. 1996 Dec;289(1):28-34 [9017132.001]
  • [Cites] Carcinogenesis. 1997 May;18(5):897-904 [9163673.001]
  • [Cites] J Invest Dermatol. 1997 Sep;109(3):340-7 [9284102.001]
  • [Cites] Clin Exp Dermatol. 1997 Jan;22(1):11-6 [9330045.001]
  • [Cites] Int J Cancer. 1997 Nov 4;73(3):356-61 [9359482.001]
  • [Cites] Virology. 1997 Dec 8;239(1):132-49 [9426453.001]
  • [Cites] Virology. 1997 Dec 22;239(2):296-302 [9434721.001]
  • [Cites] J Virol. 1998 Jun;72(6):5016-24 [9573271.001]
  • [Cites] Mol Carcinog. 1998 Jul;22(3):167-74 [9688142.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Mol Carcinog. 1999 Aug;25(4):231-40 [10449029.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4591-602 [10493513.001]
  • [Cites] Semin Cancer Biol. 1999 Dec;9(6):413-22 [10712888.001]
  • (PMID = 16971438.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-6; 0 / Membrane Proteins; 0 / Oncogene Proteins, Viral; 0 / Phosphoproteins; 0 / Protein Precursors; 0 / Trans-Activators; 0 / Trp63 protein, mouse; 0 / Tumor Suppressor Protein p53; 0 / loricrin; 60108-77-2 / involucrin; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ PMC1642157
  •  go-up   go-down


72. Huang YL, Jiang YR, Chen DR, Moon WK: Level set contouring for breast tumor in sonography. J Digit Imaging; 2007 Sep;20(3):238-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Level set contouring for breast tumor in sonography.
  • The echogenicity, echotexture, shape, and contour of a lesion are revealed to be effective sonographic features for physicians to identify a tumor as either benign or malignant.
  • Automatic contouring for breast tumors in sonography may assist physicians without relevant experience, in making correct diagnoses.
  • This study develops an efficient method for automatically detecting contours of breast tumors in sonography.
  • First, a sophisticated preprocessing filter reduces the noise, but preserves the shape and contrast of the breast tumor.
  • An adaptive initial contouring method is then performed to obtain an approximate circular contour of the tumor.
  • Finally, the deformation-based level set segmentation automatically extracts the precise contours of breast tumors from ultrasound (US) images.
  • The proposed contouring method evaluates US images from 118 patients with breast tumors.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Image Processing, Computer-Assisted. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Image Enhancement / methods. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biomed Tech (Berl). 2002;47 Suppl 1 Pt 2:633-5 [12465259.001]
  • [Cites] Radiology. 2003 Feb;226(2):504-14 [12563146.001]
  • [Cites] Neuroimage. 2004 Mar;21(3):1037-44 [15006671.001]
  • [Cites] Ultrasound Med Biol. 2004 May;30(5):625-32 [15183228.001]
  • [Cites] Med Image Anal. 2004 Sep;8(3):217-31 [15450217.001]
  • [Cites] Annu Rev Biomed Eng. 1999;1:559-88 [11701500.001]
  • [Cites] Med Phys. 2001 Aug;28(8):1652-9 [11548934.001]
  • [Cites] Ultrason Imaging. 2000 Oct;22(4):214-36 [11370905.001]
  • [Cites] Semin Ultrasound CT MR. 2000 Aug;21(4):308-16 [11014253.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jan;170(1):109-14 [9423610.001]
  • [Cites] IEEE Trans Med Imaging. 2004 Apr;23(4):447-58 [15084070.001]
  • [Cites] Radiology. 1999 Nov;213(2):407-12 [10551220.001]
  • [Cites] Radiology. 1999 Dec;213(3):889-94 [10580971.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):696-9 [10843366.001]
  • [Cites] Med Phys. 2000 Aug;27(8):1777-88 [10984224.001]
  • [Cites] Ultrasound Obstet Gynecol. 2005 Oct;26(5):558-66 [16086435.001]
  • [Cites] IEEE Trans Image Process. 2005 Jan;14(1):49-62 [15646872.001]
  • (PMID = 17252171.001).
  • [ISSN] 0897-1889
  • [Journal-full-title] Journal of digital imaging
  • [ISO-abbreviation] J Digit Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3043893
  •  go-up   go-down


73. Woenckhaus M, Grepmeier U, Werner B, Schulz C, Rockmann F, Wild PJ, Röckelein G, Blaszyk H, Schuierer M, Hofstaedter F, Hartmann A, Dietmaier W: Microsatellite analysis of pleural supernatants could increase sensitivity of pleural fluid cytology. J Mol Diagn; 2005 Oct;7(4):517-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A common diagnostic problem lies in distinguishing malignant from benign pleural effusions using routine cytological evaluation.
  • We studied pleural fluid samples obtained from 14 patients with histologically confirmed malignancy and from 6 patients with benign pleural effusions using 12 microsatellite markers from 8 different chromosomal regions.
  • Microsatellite analyses of pleural fluid supernatants showed genetic alterations in tumor patients only.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Genetic Markers / genetics. Humans. Loss of Heterozygosity / genetics. Male. Middle Aged. Neoplasms / diagnosis. Neoplasms / genetics. Neoplasms / pathology. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Health Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Jan 21;18(3):643-50 [9989814.001]
  • [Cites] Eur Respir J. 1997 Feb;10(2):476-81 [9042652.001]
  • [Cites] Pathol Res Pract. 1996 Dec;192(12):1206-10 [9182290.001]
  • [Cites] J Oral Pathol Med. 1997 Aug;26(7):322-6 [9250932.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1366-73 [9308707.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4749-56 [9354436.001]
  • [Cites] Ann Thorac Surg. 1997 Oct;64(4):941-4 [9354505.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2028-32 [10580028.001]
  • [Cites] Anal Cell Pathol. 1999;19(1):7-20 [10661621.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):341-7 [10023701.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 17;91(4):332-9 [10050866.001]
  • [Cites] Diagn Cytopathol. 1999 Jun;20(6):350-7 [10352907.001]
  • [Cites] Surg Oncol Clin N Am. 1999 Oct;8(4):641-56, vi [10452932.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2297-303 [10499596.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(1):65-73 [10505546.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7335-46 [15534110.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2502-9 [15814626.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Internist (Berl). 1996 Sep;37(9):959-68; quiz 968 [8964697.001]
  • [Cites] Anal Cell Pathol. 1996 Nov;12(2):85-98 [8986293.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1508-14 [10667431.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):707-11 [10676657.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2488-91 [10811129.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):448-55 [10821492.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3155-9 [10866304.001]
  • [Cites] Cancer. 2000 Aug 25;90(4):258-63 [10966568.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5954-8 [11085511.001]
  • [Cites] Int J Cancer. 2001 Jan 15;91(2):200-4 [11146445.001]
  • [Cites] Cancer. 2001 Feb 25;93(1):68-72 [11241268.001]
  • [Cites] Cancer Lett. 2001 Apr 10;165(1):63-9 [11248420.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4675-8 [11406535.001]
  • [Cites] Chest. 2001 Jul;120(1):50-4 [11451815.001]
  • [Cites] Diagn Cytopathol. 2001 Oct;25(4):225-30 [11599105.001]
  • [Cites] Cancer. 2001 Oct 25;93(5):293-308 [11668464.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Oct 1;164(7):1312-8 [11673227.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):35-40 [11801538.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2370-7 [11956099.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):210-9 [11990857.001]
  • [Cites] Eur Urol. 2002 Jun;41(6):668-76 [12074786.001]
  • [Cites] Anal Cell Pathol. 2002;24(1):5-15 [12122279.001]
  • [Cites] Int J Cancer. 2002 Aug 10;100(5):534-41 [12124802.001]
  • [Cites] Lab Invest. 2002 Sep;82(9):1147-53 [12218075.001]
  • [Cites] Diagn Cytopathol. 2002 Oct;27(4):210-3 [12357497.001]
  • [Cites] Ann Pathol. 2002 Sep;22(4):277-88 [12410150.001]
  • [Cites] J Gastroenterol. 2002;37(10):831-9 [12424567.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):172-7 [12800191.001]
  • [Cites] Pathol Res Pract. 2003;199(6):355-62 [12924435.001]
  • [Cites] Eur J Haematol. 2003 Sep;71(3):174-8 [12930317.001]
  • [Cites] Histol Histopathol. 2003 Oct;18(4):1053-7 [12973674.001]
  • [Cites] Biogerontology. 2003;4(4):233-50 [14501188.001]
  • [Cites] Int J Oncol. 2003 Nov;23(5):1357-63 [14532977.001]
  • [Cites] Clin Lab Med. 2003 Sep;23(3):729-54, viii [14560537.001]
  • [Cites] Pancreas. 2004 Jan;28(1):13-9 [14707724.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jan;83(2):119-28 [14997042.001]
  • [Cites] Lung Cancer. 2004 Apr;44(1):33-42 [15013581.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2716-26 [15048096.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):96-100 [15185349.001]
  • [Cites] Clin Med. 2004 May-Jun;4(3):207-10 [15244350.001]
  • [Cites] Breast Cancer Res Treat. 2004 Sep;87(1):23-31 [15377848.001]
  • [Cites] Int J Cancer. 2004 Nov 20;112(4):643-6 [15382045.001]
  • [Cites] Diagn Cytopathol. 2004 Oct;31(4):246-54 [15452897.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Jan 15;19(3-4):271-9 [3943048.001]
  • [Cites] Eur J Respir Dis. 1985 Nov;67(5):326-34 [4085584.001]
  • [Cites] Cancer Res. 1990 Nov 15;50(22):7166-73 [1977514.001]
  • [Cites] Mod Pathol. 1991 May;4(3):320-4 [2068057.001]
  • [Cites] Int J Cancer. 1992 Oct 21;52(4):534-7 [1399132.001]
  • [Cites] Mol Cell Endocrinol. 1993 Apr;92(2):153-60 [8319825.001]
  • [Cites] Nat Med. 1996 Sep;2(9):1035-7 [8782464.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Nov;20(3):268-74 [9365834.001]
  • [Cites] Electrophoresis. 1997 Sep;18(10):1742-9 [9372265.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):113-6 [9541693.001]
  • [Cites] Gynecol Oncol. 1999 Jan;72(1):3-9 [9889022.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):83-95 [9916922.001]
  • (PMID = 16237222.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC1888495
  •  go-up   go-down


74. Haka AS, Shafer-Peltier KE, Fitzmaurice M, Crowe J, Dasari RR, Feld MS: Diagnosing breast cancer by using Raman spectroscopy. Proc Natl Acad Sci U S A; 2005 Aug 30;102(35):12371-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We employ Raman spectroscopy to diagnose benign and malignant lesions in human breast tissue based on chemical composition.
  • The fit coefficients for fat and collagen are the key parameters in the resulting diagnostic algorithm, which classifies samples according to their specific pathological diagnoses, attaining 94% sensitivity and 96% specificity for distinguishing cancerous tissues from normal and benign tissues.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Clin Oncol. 1999 Sep;29(9):413-20 [10563193.001]
  • [Cites] Arch Surg. 1999 Jul;134(7):712-5; discussion 715-6 [10401820.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2767-72 [10706610.001]
  • [Cites] J Biomed Opt. 2000 Apr;5(2):221-8 [10938787.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1769-72 [10974624.001]
  • [Cites] Med J Aust. 2001 Feb 19;174(4):185-8 [11270760.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4420-5 [11287650.001]
  • [Cites] Cardiovasc Pathol. 2001 Mar-Apr;10(2):69-82 [11425600.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):101-8 [12109843.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5375-80 [12235010.001]
  • [Cites] Appl Opt. 2004 Jan 20;43(3):542-54 [14765912.001]
  • [Cites] Radiology. 2004 Apr;231(1):215-24 [14990810.001]
  • [Cites] Cancer. 1990 Sep 15;66(6 Suppl):1326-35 [2205361.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Anal Chem. 1994 Feb 1;66(3):319-26 [8135372.001]
  • [Cites] Radiology. 1994 Sep;192(3):793-5 [8058949.001]
  • [Cites] Anal Chem. 1995 Mar 1;67(5):777-83 [7762814.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1997 Jun 29;352(1354):661-8 [9232853.001]
  • [Cites] Photochem Photobiol. 1997 Oct;66(4):518-22 [9337625.001]
  • [Cites] Lasers Surg Med. 1997;21(5):417-22 [9365951.001]
  • [Cites] Photochem Photobiol. 1998 Jan;67(1):4-14 [9477760.001]
  • [Cites] Photochem Photobiol. 1998 Jan;67(1):15-22 [9477761.001]
  • [Cites] Phys Med Biol. 2000 Feb;45(2):R1-59 [10701500.001]
  • (PMID = 16116095.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR002594; United States / NHLBI NIH HHS / HL / HL51265; United States / NCRR NIH HHS / RR / RR02594
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-34-5 / Collagen
  • [Other-IDs] NLM/ PMC1194905
  •  go-up   go-down


75. Gross G: Impact of prophylactic human papillomavirus vaccines on dermatology and venereology. G Ital Dermatol Venereol; 2008 Aug;143(4):259-65
HIV InSite. treatment guidelines - HIV InSite .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The quadrivalent HPV6, 11, 16, 18 vaccine also prevents anogenital warts (condylomata acuminata) which are the most common benign tumors of this body region.
  • Men would profit from a vaccine that protects against HPV infections, especially anogenital warts, as well as penile and anal carcinomas.
  • HPV disease can be widespread, chronic and often may rapidly progress to malignant tumors.
  • [MeSH-minor] Adolescent. Adult. Anus Neoplasms / prevention & control. Anus Neoplasms / virology. Condylomata Acuminata / prevention & control. Condylomata Acuminata / virology. Female. Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18. Humans. Male. Papilloma / prevention & control. Papilloma / virology. Penile Neoplasms / prevention & control. Penile Neoplasms / virology. Respiratory Tract Neoplasms / prevention & control. Respiratory Tract Neoplasms / virology. Sex Factors. Sexually Transmitted Diseases, Viral / prevention & control. Vulvar Neoplasms / prevention & control. Vulvar Neoplasms / virology. Young Adult

  • MedlinePlus Health Information. consumer health - HPV.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833082.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; 0 / Papillomavirus Vaccines
  • [Number-of-references] 53
  •  go-up   go-down


76. Monk BJ, Tewari KS: The spectrum and clinical sequelae of human papillomavirus infection. Gynecol Oncol; 2007 Nov;107(2 Suppl 1):S6-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection with the human papillomavirus (HPV) is the most common sexually transmitted disease afflicting approximately 80% of the population.
  • In addition to cervical cancer, other malignancies in both men and women such as esophageal, oropharyngeal, and anal cancer have been causally associated with this virus.
  • HPV-16 is the most common HPV type associated with a malignant phenotype regardless of organ of origin.
  • Other non-oncogenic HPV types including HPV types 6 and 11 are associated with over 90% of benign HPV-related lesions such as genital warts and juvenile respiratory papillomatosis.
  • [MeSH-major] Papillomavirus Infections / diagnosis. Papillomavirus Infections / therapy
  • [MeSH-minor] Adult. Anus Neoplasms / virology. Child. Condylomata Acuminata / virology. Esophageal Neoplasms / virology. Female. Genital Neoplasms, Female / virology. Genital Neoplasms, Male / virology. Humans. Laryngeal Neoplasms / virology. Male. Oropharyngeal Neoplasms / virology. Papilloma / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499914.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


77. Tang HW, Luo MN, Li T, Pan L: Quantitative DNA imaging in breast tumor cells by a Hadamard transform fluorescence imaging microscope. Anal Sci; 2006 May;22(5):701-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative DNA imaging in breast tumor cells by a Hadamard transform fluorescence imaging microscope.
  • In this study, the high potential value of the microscope in biomedical analysis has been demonstrated by using it to evaluate the malignancy degree of thirty cases of human breast tumors based on the measurements of cellular DNA contents, with conclusions highly accordant with pathological diagnosis.
  • The microscope was also successfully applied to cellular morphological analysis, and it was demonstrated that a significant linear relationship exists between tumor nuclear DNA contents and the nuclear area, and malignant and benign tumors are significantly different in both DNA contents and nuclear area.
  • [MeSH-major] Breast Neoplasms / pathology. DNA, Neoplasm / analysis
  • [MeSH-minor] Female. Humans. Image Cytometry. Microscopy, Fluorescence. Ploidies. Sensitivity and Specificity. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770048.001).
  • [ISSN] 0910-6340
  • [Journal-full-title] Analytical sciences : the international journal of the Japan Society for Analytical Chemistry
  • [ISO-abbreviation] Anal Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


78. van de Luijtgaarden AC, Veth RP, Slootweg PJ, Wijers-Koster PM, Schultze Kool LJ, Bovee JV, van der Graaf WT: Metastatic potential of an aneurysmal bone cyst. Virchows Arch; 2009 Nov;455(5):455-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aneurysmal bone cysts (ABCs) are benign bone tumors consisting of blood-filled cavities lined by connective tissue septa.
  • Multiple cases of malignant transformation of ABC into (osteo)sarcoma have been described, as well as a number of cases of telangiectatic osteosarcoma which had been misdiagnosed as ABC.
  • Diagnosis was confirmed by the presence of a break in the USP6 gene, which is pathognomonic for ABC, in a pulmonary metastasis of our patient.
  • Sarcomatous transformation as an explanation for this behavior was ruled out by demonstrating diploid DNA content in both the pulmonary lesion and the primary tumor.
  • [MeSH-major] Bone Cysts, Aneurysmal / pathology. Bone Neoplasms / pathology. Neoplasms, Second Primary / pathology. Osteosarcoma / pathology. Proto-Oncogene Proteins / genetics. Ubiquitin Thiolesterase / genetics
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Bevacizumab. Carcinoma / complications. Cell Transformation, Neoplastic / pathology. Diabetes Mellitus, Type 2 / complications. Embolization, Therapeutic. Female. Humans. Hyperplasia. In Situ Hybridization, Fluorescence. Kidney Neoplasms / secondary. Lung Neoplasms / secondary. Middle Aged. Thyroid Gland / pathology. Uterine Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2000 Jun;28(2):233-4 [10825009.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):311-5 [16755186.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):e1; author reply e2 [16382110.001]
  • [Cites] Oncogene. 2005 May 12;24(21):3419-26 [15735689.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):265-6 [10502326.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1206-10 [11106078.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):583-602 [19396867.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Oct 15;178(2):155-9 [17954273.001]
  • [Cites] Pediatr Dev Pathol. 2007 Jan-Feb;10(1):46-9 [17378626.001]
  • [Cites] Pediatr Dev Pathol. 2006 Jan-Feb;9(1):38-43 [16808643.001]
  • [Cites] Pediatr Dev Pathol. 2001 Jul-Aug;4(4):418-9 [11441369.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Sep;129(2):177-80 [11566352.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):636-9 [11764383.001]
  • [Cites] Anal Cell Pathol. 2001;23(2):89-95 [11904464.001]
  • [Cites] Life Sci. 2003 Aug 1;73(11):1427-36 [12850503.001]
  • [Cites] J Formos Med Assoc. 2003 Sep;102(9):631-6 [14625608.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1920-3 [15026324.001]
  • [Cites] Mod Pathol. 2004 May;17(5):518-25 [15044915.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1773-80 [15509545.001]
  • [Cites] Pediatr Radiol. 1986;16(2):140-3 [3456553.001]
  • [Cites] Skeletal Radiol. 1987;16(3):196-200 [3473690.001]
  • [Cites] Cancer. 1988 Jun 15;61(12):2532-40 [3163257.001]
  • [Cites] Ital J Orthop Traumatol. 1987 Dec;13(4):425-36 [3503870.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Jan;58(1):2-13 [1728946.001]
  • [Cites] Cancer. 1992 Jun 15;69(12):2921-31 [1591685.001]
  • [Cites] Surg Today. 1994;24(5):476-80 [8054822.001]
  • [Cites] Cytometry. 1995 Mar 1;19(3):256-62 [7736870.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Oct 1;84(1):27-31 [7497439.001]
  • [Cites] Pathologe. 1996 Jan;17(1):44-9 [8685095.001]
  • [Cites] Clin Orthop Relat Res. 1997 Feb;(335):253-61 [9020226.001]
  • (PMID = 19838726.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins; 2S9ZZM9Q9V / Bevacizumab; EC 3.1.2.15 / USP6 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
  •  go-up   go-down


79. Qian W, Zhukov T, Song D, Tockman MS: Computerized analysis of cellular features and biomarkers for cytologic diagnosis of early lung cancer. Anal Quant Cytol Histol; 2007 Apr;29(2):103-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computerized analysis of cellular features and biomarkers for cytologic diagnosis of early lung cancer.
  • OBJECTIVE: To present a set of novel computerized analysis algorithms to construct a computer-aided cytologic diagnosis (CACD) system to differentiate lung cancer biomarkers and identify cancer cells in the tissue-based specimen images.
  • STUDY DESIGN: Molecular methods, including application of cancer-specific markers, may prove to be complementary to cytology diagnosis, especially when they are combined with CACD system for biomarker assessment.
  • CONCLUSION: The presented algorithms and CACD system for cellular feature enhancement, segmentation and classification are very important in distinguishing benign and malignant lesions.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484274.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


80. Berman DM, Wincovitch S, Garfield S, Romeo MJ: Grading melanocytic dysplasia in paraffin wax embedded tissue by the nucleic acid index. J Clin Pathol; 2005 Nov;58(11):1206-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although nucleic acid derangements are the hallmark of melanocytic dysplasia, the gold standard for its diagnosis remains the microscopic evaluation of haematoxylin and eosin stained slides.
  • RESULTS: When applied to benign naevi, dysplastic naevi, and melanoma, a very strong significant association was seen between lower NAI and malignant potential (p < 0.0001).
  • Interestingly, the NAI for dysplastic naevi is between that of melanoma and most benign naevi, consistent with their intermediate biological behaviour and histological appearance.
  • CONCLUSION: By providing a quantitative measure for melanocytic neoplasia, the NAI may improve the diagnosis of melanocytic lesions and the selection of treatment.
  • [MeSH-major] DNA, Neoplasm / analysis. Dysplastic Nevus Syndrome / diagnosis. Melanoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Image Processing, Computer-Assisted / methods. Melanocytes / pathology. Microscopy, Confocal / methods. Mitotic Index. Nevus, Pigmented / diagnosis. Nevus, Pigmented / genetics. Nevus, Pigmented / pathology. Paraffin Embedding. RNA, Neoplasm / analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 1998 Nov;96(5):487-94 [9829812.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):419-26 [9816186.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):19-20 [12447372.001]
  • [Cites] Am J Dermatopathol. 2003 Jun;25(3):190-7 [12775980.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3081-6 [12789284.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):764-71 [12920220.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Oct;25(5):243-53 [14603721.001]
  • [Cites] Melanoma Res. 2003 Dec;13(6):581-6 [14646621.001]
  • [Cites] Br J Dermatol. 2004 Feb;150(2):179-85 [14996086.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):342-8 [15009715.001]
  • [Cites] J Am Acad Dermatol. 2004 Jul;51(1 Suppl):S65-9 [15243517.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121 Suppl:S3-32 [15298148.001]
  • [Cites] Lancet. 1977 Apr 16;1(8016):864-5 [67377.001]
  • [Cites] Arch Dermatol. 1978 May;114(5):732-8 [646394.001]
  • [Cites] Cancer Res. 1978 Jul;38(7):1893-8 [77721.001]
  • [Cites] Microsc Acta. 1981 Jan;84(1):37-42 [6163065.001]
  • [Cites] Cytometry. 1982 Jan;2(4):212-8 [6173180.001]
  • [Cites] Cytometry. 1982 Jul;3(1):28-35 [6180873.001]
  • [Cites] Am J Clin Pathol. 1985 Jun;83(6):722-5 [2408462.001]
  • [Cites] J Am Acad Dermatol. 1989 Oct;21(4 Pt 1):773-80 [2808793.001]
  • [Cites] J Cutan Pathol. 1993 Apr;20(2):121-5 [8320355.001]
  • [Cites] Kurume Med J. 1994;41(1):1-13 [7933912.001]
  • [Cites] Hum Pathol. 1996 Jun;27(6):528-31 [8666360.001]
  • [Cites] Cytometry. 1997 Feb 1;27(2):99-105 [9012376.001]
  • [Cites] Histochem Cell Biol. 1997 Apr;107(4):267-78 [9151109.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1370-7 [10717619.001]
  • (PMID = 16254113.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC1770753
  •  go-up   go-down


81. Tytherleigh MG, Birtle AJ, Cohen CE, Glynne-Jones R, Livingstone J, Gilbert J: Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour. Surgeon; 2006 Dec;4(6):378-83
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour.
  • BACKGROUND: The Buschke-Löwenstein tumour (BLT) or giant condyloma acuminata is a rare disease which affects the anogenital region.
  • Although histologically benign, it behaves in a malignant fashion, infiltrating the surrounding tissues.
  • The morbidity and mortality from this tumour is high, as is the risk of recurrence following treatment.
  • It lies on the continuum between the benign condylomata acuminata and squamous cell carcinoma.
  • Chemoradiation remains the mainstay of treatment for anal cancers but has not been routinely employed in the management of the BLT without squamous cell carcinoma transformation.
  • RESULTS: The first patient had a good symptomatic response to the chemoradiation but unfortunately died of recurrent disease following surgery.
  • CONCLUSION: Pre-operative chemoradiation has proved to be useful in management for histologically proven benign BLT
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Condylomata Acuminata / therapy. Neoadjuvant Therapy. Perineum / pathology. Perineum / surgery. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Abdominal Neoplasms / secondary. Abdominal Neoplasms / therapy. Adult. Anus Neoplasms / secondary. Anus Neoplasms / therapy. Carcinoma in Situ / pathology. Carcinoma in Situ / therapy. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Rectal Neoplasms / secondary. Rectal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152203.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


82. Haka AS, Volynskaya Z, Gardecki JA, Nazemi J, Shenk R, Wang N, Dasari RR, Fitzmaurice M, Feld MS: Diagnosing breast cancer using Raman spectroscopy: prospective analysis. J Biomed Opt; 2009 Sep-Oct;14(5):054023
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the first prospective test of Raman spectroscopy in diagnosing normal, benign, and malignant human breast tissues.
  • In previous work, we developed an accurate, internally validated algorithm for breast cancer diagnosis based on analysis of Raman spectra acquired from fresh-frozen in vitro tissue samples.
  • Prospective application of the algorithm to the clinical data set resulted in a sensitivity of 83%, a specificity of 93%, a positive predictive value of 36%, and a negative predictive value of 99% for distinguishing cancerous from normal and benign tissues.
  • Sources of bias in the in vitro calibration and ex vivo prospective data sets, including disease prevalence and disease spectrum, are examined and analytical methods for comparison provided.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Phys Med Biol. 2000 Feb;45(2):R1-59 [10701500.001]
  • [Cites] J Biomed Opt. 2000 Apr;5(2):221-8 [10938787.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4420-5 [11287650.001]
  • [Cites] Eur J Radiol. 2002 Apr;42(1):40-51 [12039019.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):101-8 [12109843.001]
  • [Cites] Breast Cancer Res Treat. 2002 Sep;75(2):119-25 [12243504.001]
  • [Cites] Ann Intern Med. 2002 Oct 1;137(7):598-602 [12353947.001]
  • [Cites] J Cell Biochem Suppl. 2002;39:125-37 [12552612.001]
  • [Cites] Appl Opt. 2003 Nov 1;42(31):6412-21 [14649285.001]
  • [Cites] Appl Opt. 2004 Jan 20;43(3):542-54 [14765912.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Anal Chem. 1994 Feb 1;66(3):319-26 [8135372.001]
  • [Cites] Anal Chem. 1995 Mar 1;67(5):777-83 [7762814.001]
  • [Cites] Lasers Surg Med. 1996;19(1):46-62 [8836996.001]
  • [Cites] Lasers Surg Med. 1996;19(1):63-74 [8836997.001]
  • [Cites] Lasers Surg Med. 1997;21(5):417-22 [9365951.001]
  • [Cites] Photochem Photobiol. 1998 Jan;67(1):4-14 [9477760.001]
  • [Cites] Photochem Photobiol. 1998 Jan;67(1):15-22 [9477761.001]
  • [Cites] Phys Med Biol. 2005 Jun 21;50(12):2837-58 [15930606.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12371-6 [16116095.001]
  • [Cites] Phys Med Biol. 2005 Sep 7;50(17):3941-56 [16177522.001]
  • [Cites] J Biomed Opt. 2005 May-Jun;10(3):031113 [16229638.001]
  • [Cites] Lasers Surg Med. 2006 Aug;38(7):714-24 [16799981.001]
  • [Cites] Acta Oncol. 2007;46(2):172-80 [17453365.001]
  • [Cites] J Biomed Opt. 2007 Mar-Apr;12(2):024008 [17477723.001]
  • [Cites] J Biomed Opt. 2007 Nov-Dec;12(6):064012 [18163828.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4424-30 [18519705.001]
  • [Cites] IEEE Trans Biomed Eng. 1999 Nov;46(11):1293-303 [10582414.001]
  • (PMID = 19895125.001).
  • [ISSN] 1560-2281
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR002594; United States / NHLBI NIH HHS / HL / R01 HL064675; United States / NHLBI NIH HHS / HL / HL-64675; United States / NCRR NIH HHS / RR / P41-RR-02594
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2774977
  •  go-up   go-down


83. Levenson VV: DNA methylation as a universal biomarker. Expert Rev Mol Diagn; 2010 May;10(4):481-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell-free circulating DNA carries not only tumor-specific changes in its sequence but also distinctive epigenetic marks, namely DNA methylation, in certain GC-rich fragments.
  • Analysis of DNA methylation using cell-free circulating DNA can facilitate development of very accurate biomarkers for detection, diagnosis, prediction of response to therapy and prognosis of outcomes.
  • Recent data suggest that benign and inflammatory diseases have very specific methylation patterns within cell-free circulating DNA, which are different from the pattern of a malignant tumor of the same organ.
  • In addition, specific methylation patterns have been detected for cancers of different organs, so a differential diagnosis of site-specific cancer appears feasible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2009 Jul 7;101(1):124-31 [19536096.001]
  • [Cites] Trends Genet. 2009 Jul;25(7):288-97 [19540013.001]
  • [Cites] PLoS One. 2009;4(8):e6617 [19672297.001]
  • [Cites] Endocrinology. 2009 Sep;150(9):4003-11 [19574400.001]
  • [Cites] Semin Reprod Med. 2009 Sep;27(5):417-28 [19711252.001]
  • [Cites] Cancer Invest. 2009 Oct;27(8):877-84 [19548140.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:243-50 [12724229.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1881-7 [12932666.001]
  • [Cites] Rocz Akad Med Bialymst. 2003;48:34-41 [14737938.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1871-4 [15041700.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4442-52 [15231653.001]
  • [Cites] Curr Opin Mol Ther. 2004 Jun;6(3):273-8 [15264429.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):4933-8 [15297393.001]
  • [Cites] Am J Gastroenterol. 1990 Apr;85(4):350-5 [2183589.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Biotechniques. 1994 Mar;16(3):416-7 [8185912.001]
  • [Cites] Biochem Soc Trans. 2008 Aug;36(Pt 4):575-83 [18631120.001]
  • [Cites] Mol Cancer. 2008;7:81 [18947422.001]
  • [Cites] Int J Cancer. 2009 Feb 15;124(4):905-10 [19035455.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):40-6 [18851871.001]
  • [Cites] Expert Rev Neurother. 2009 Jan;9(1):87-98 [19102671.001]
  • [Cites] J Mol Diagn. 2009 Jan;11(1):60-5 [19074590.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):315-23 [19118060.001]
  • [Cites] Int J Urol. 2009 Jan;16(1):17-22 [18721202.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):502-10 [19147755.001]
  • [Cites] Brief Funct Genomic Proteomic. 2009 May;8(3):174-83 [19535508.001]
  • [Cites] Methods Mol Biol. 2009;590:165-76 [19763503.001]
  • [Cites] J Cell Biochem. 2009 Sep 1;108(1):3-9 [19507229.001]
  • [Cites] Biol Chem. 2009 Nov;390(11):1145-53 [19747081.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2782-9 [19755648.001]
  • [Cites] Genet Test Mol Biomarkers. 2009 Oct;13(5):623-30 [19814617.001]
  • [Cites] Expert Rev Mol Diagn. 2009 Oct;9(7):651-7 [19817550.001]
  • [Cites] Lancet Neurol. 2009 Nov;8(11):1056-72 [19833297.001]
  • [Cites] Am Fam Physician. 2009 Oct 15;80(8):815-20 [19835343.001]
  • [Cites] Int Rev Neurobiol. 2009;89:67-84 [19900616.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Dec;195(2):112-9 [19963110.001]
  • [Cites] Cancer. 2010 Apr 1;116(7):1674-80 [20143430.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 Jun;136(6):847-54 [19924441.001]
  • [Cites] J Appl Physiol (1985). 2010 Sep;109(3):927-33 [20110548.001]
  • [Cites] Nucleic Acids Res. 2000 Apr 15;28(8):E32 [10734209.001]
  • [Cites] Oncogene. 2001 Jun 7;20(26):3348-53 [11423985.001]
  • [Cites] Nucleic Acids Res. 2001 Jul 1;29(13):E65-5 [11433041.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;945:51-8 [11708494.001]
  • [Cites] Clin Chim Acta. 2002 Jul;321(1-2):77-87 [12031596.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2246-52 [12114427.001]
  • [Cites] Arch Pathol Lab Med. 2009 Mar;133(3):454-64 [19260750.001]
  • [Cites] J Clin Pathol. 2009 Apr;62(4):308-13 [19329710.001]
  • [Cites] FEBS J. 2009 Apr;276(8):2157-64 [19250312.001]
  • [Cites] J Neuropathol Exp Neurol. 2009 Apr;68(4):356-64 [19287316.001]
  • [Cites] Ann Surg Oncol. 2009 May;16(5):1378-83 [19224282.001]
  • [Cites] Free Radic Biol Med. 2009 May 1;46(9):1241-9 [19245828.001]
  • [Cites] Curr Mol Med. 2009 Apr;9(3):315-23 [19355913.001]
  • [Cites] Expert Rev Mol Diagn. 2009 Apr;9(3):243-57 [19379083.001]
  • [Cites] Methods Mol Biol. 2009;520:21-38 [19381945.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):165-71 [19429480.001]
  • [Cites] FEBS Lett. 2009 Jun 5;583(11):1713-20 [19376112.001]
  • [Cites] Clin Cancer Res. 2009 Jun 1;15(11):3881-8 [19470736.001]
  • [Cites] Curr Alzheimer Res. 2009 Jun;6(3):196-204 [19519301.001]
  • [Cites] Nucleic Acids Res. 1997 Nov 1;25(21):4422-6 [9336479.001]
  • [Cites] Nucleic Acids Res. 1998 May 15;26(10):2255-64 [9580672.001]
  • [Cites] Anal Biochem. 1998 Nov 1;264(1):129-32 [9784198.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1141-5 [15734995.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4101-17 [15899800.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2788-94 [16675572.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1492-5 [16641902.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6111-7 [16778184.001]
  • [Cites] Clin Chem. 2006 Sep;52(9):1820-4 [16840584.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4262-9 [16908936.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1859-65 [16983705.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1075:235-43 [17108217.001]
  • [Cites] Cancer Biol Ther. 2006 Oct;5(10):1369-74 [16969071.001]
  • [Cites] FEBS Lett. 2007 Mar 6;581(5):795-9 [17289032.001]
  • [Cites] Life Sci. 2007 Apr 3;80(17):1608-18 [17343877.001]
  • [Cites] Anticancer Res. 2007 Mar-Apr;27(2):1207-12 [17465264.001]
  • [Cites] Nucleic Acids Res. 2007;35(9):2893-903 [17439964.001]
  • [Cites] J Neurosci Res. 2007 Jul;85(9):2006-16 [17469138.001]
  • [Cites] Oncol Rep. 2007 Aug;18(2):329-36 [17611652.001]
  • [Cites] Prostate. 2008 Jan 1;68(1):42-9 [18004747.001]
  • [Cites] J Urol. 2008 Jan;179(1):346-52 [18006010.001]
  • [Cites] Clin Neuropharmacol. 2008 Mar-Apr;31(2):104-19 [18382183.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2327-35 [18467724.001]
  • [Cites] PLoS One. 2008;3(7):e2698 [18628954.001]
  • [Cites] J Urol. 2009 Jul;182(1):324-9 [19447423.001]
  • (PMID = 20465502.001).
  • [ISSN] 1744-8352
  • [Journal-full-title] Expert review of molecular diagnostics
  • [ISO-abbreviation] Expert Rev. Mol. Diagn.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / R21RR024420; United States / NINDS NIH HHS / NS / R21NS060311; United States / NCRR NIH HHS / RR / R21 RR024420; United States / NINDS NIH HHS / NS / R21 NS060311-02; United States / NINDS NIH HHS / NS / R21 NS060311; United States / NCRR NIH HHS / RR / R21 RR024420-02; United States / NINDS NIH HHS / NS / NS060311-02; United States / NCRR NIH HHS / RR / RR024420-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 9007-49-2 / DNA
  • [Number-of-references] 83
  • [Other-IDs] NLM/ NIHMS229603; NLM/ PMC2933138
  •  go-up   go-down


84. Zheng Y, Englander S, Baloch S, Zacharaki EI, Fan Y, Schnall MD, Shen D: STEP: spatiotemporal enhancement pattern for MR-based breast tumor diagnosis. Med Phys; 2009 Jul;36(7):3192-204
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] STEP: spatiotemporal enhancement pattern for MR-based breast tumor diagnosis.
  • The authors propose a spatiotemporal enhancement pattern (STEP) for comprehensive characterization of breast tumors in contrast-enhanced MR images.
  • By viewing serial contrast-enhanced MR images as a single spatiotemporal image, they formulate the STEP as a combination of (1) dynamic enhancement and architectural features of a tumor, and (2) the spatial variations of pixelwise temporal enhancements.
  • Although the latter has been widely used by radiologists for diagnostic purposes, it has rarely been employed for computer-aided diagnosis.
  • Second, for effectively extracting the STEP features from tumors, we develop a graph-cut based segmentation algorithm that aims at refining coarse manual segmentations of tumors.
  • The STEP features are assessed through their diagnostic performance for differentiating between benign and malignant tumors using a linear classifier (along with a simple ranking-based feature selection) in a leave-one-out cross-validation setting.
  • [MeSH-major] Breast Neoplasms / diagnosis. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Radiol. 2003 Jul;44(4):379-86 [12846687.001]
  • [Cites] IEEE Trans Med Imaging. 2008 May;27(5):688-96 [18450541.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2001 May;9(2):295-302, vi [11493420.001]
  • [Cites] J Magn Reson Imaging. 1999 Dec;10(6):982-90 [10581516.001]
  • [Cites] Med Phys. 2004 May;31(5):1076-82 [15191295.001]
  • [Cites] Stat Med. 1998 May 15;17(9):1033-53 [9612889.001]
  • [Cites] Med Phys. 1998 Sep;25(9):1647-54 [9775369.001]
  • [Cites] Med Image Anal. 1997 Apr;1(3):207-24 [9873907.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):223-32 [10508281.001]
  • [Cites] Acad Radiol. 2004 Dec;11(12):1344-54 [15596372.001]
  • [Cites] Med Image Anal. 2005 Aug;9(4):315-29 [15950895.001]
  • [Cites] Radiology. 2006 Jan;238(1):42-53 [16373758.001]
  • [Cites] J Clin Oncol. 2006 Jul 10;24(20):3293-8 [16829653.001]
  • [Cites] Med Phys. 2006 Aug;33(8):2878-87 [16964864.001]
  • [Cites] IEEE Trans Med Imaging. 2006 Dec;25(12):1627-36 [17167997.001]
  • [Cites] Med Image Comput Comput Assist Interv. 2007;10(Pt 2):393-401 [18044593.001]
  • [Cites] NMR Biomed. 2002 Apr;15(2):154-63 [11870911.001]
  • (PMID = 19673218.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA140841; United States / NCI NIH HHS / CA / 1R21CA140841
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2852449
  •  go-up   go-down


85. Wietfeldt ED, Thiele J: Malignancies of the anal margin and perianal skin. Clin Colon Rectal Surg; 2009 May;22(2):127-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies of the anal margin and perianal skin.
  • Malignancies of the anal margin and perianal skin are relatively uncommon lesions, comprising 3 to 4% of all anorectal malignancies.
  • Commonly included in this group of cancers are Bowen's disease (intraepithelial squamous cell cancer), perianal Paget's disease (intraepithelial adenocarcinoma), invasive squamous cell cancer, basal cell cancer, and malignant melanoma.
  • Buschke-Lowenstein tumor, or giant condyloma acuminatum, is not always included because this lesion is technically benign, although it displays aggressive local invasive behavior that makes it difficult to manage.
  • Proper diagnosis requires a high index of suspicion on the part of the surgeon.
  • Innocent local irritations will resolve in a short time with appropriate therapy; those that persist must be biopsied for tissue diagnosis.
  • Wide local excision is the mainstay of treatment for early stage tumors as it preserves continence and obtains adequate local control.
  • All have met with a fair amount of success in controlling local disease; however, the number of patients treated in each instance is small, making it difficult to design an evidence-based treatment strategy.
  • Invasion and metastasis are relatively rare in this group of neoplasms; perianal Paget's disease has the highest risk of associated underlying neoplasm.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2008 Dec;51(12):1842-5 [18584248.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):11-21 [17199561.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):587-90 [11442599.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]
  • [Cites] Br J Dermatol. 1995 Jun;132(6):970-2 [7662577.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • (PMID = 20436838.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780245
  • [Keywords] NOTNLM ; Anal margin cancer / diagnosis / local excision / radiation therapy / treatment options
  •  go-up   go-down


86. Kremer R, Best LA, Savulescu D, Gavish M, Nagler RM: Pleural fluid analysis of lung cancer vs benign inflammatory disease patients. Br J Cancer; 2010 Mar 30;102(7):1180-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleural fluid analysis of lung cancer vs benign inflammatory disease patients.
  • BACKGROUND: Correct diagnosis of pleural effusion (PE) as either benign or malignant is crucial, although conventional cytological evaluation is of limited diagnostic accuracy, with relatively low sensitivity rates.
  • We analysed data from 19 patients diagnosed with lung cancer (nine adeno-Ca, five non-small-cell Ca (not specified), four squamous-cell Ca, one large-cell Ca) and 22 patients with benign inflammatory pathologies: secondary to trauma, pneumonia or TB.
  • RESULTS: Pleural effusion concentrations of seven analysed biological markers were significantly lower in lung cancer patients than in benign inflammatory patients, especially in matrix metalloproteinase (MMP)-9, MMP-3 and CycD1 (lower by 65% (P<0.000003), 40% (P<0.0007) and 34% (P<0.0001), respectively), and in Ki67, ImAnOx, carbonyls and p27.
  • [MeSH-major] Lung Neoplasms / diagnosis. Pleural Effusion / diagnosis
  • [MeSH-minor] Adenocarcinoma / metabolism. Aged. Biomarkers / metabolism. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / metabolism. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Cyclin D1 / metabolism. Female. Humans. Ki-67 Antigen / metabolism. Male. Matrix Metalloproteinase 3 / metabolism. Matrix Metalloproteinase 9 / metabolism. Middle Aged. Pneumonia / diagnosis. Pneumonia / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Lung Res. 2004 Jun;30(4):297-309 [15204835.001]
  • [Cites] Respiration. 2005 Mar-Apr;72(2):166-75 [15824527.001]
  • [Cites] Clin Lung Cancer. 2005 Sep;7 Suppl 1:S39-44 [16159418.001]
  • [Cites] J Mol Diagn. 2005 Oct;7(4):517-24 [16237222.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):1-9 [16893591.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):45-52 [16574204.001]
  • [Cites] Cancer. 2007 Jan 1;109(1):54-9 [17099862.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2007 Apr;62(4):361-6 [17452728.001]
  • [Cites] Oncol Rep. 2007 Aug;18(2):425-31 [17611666.001]
  • [Cites] Thorax. 2008 Jan;63(1):35-41 [17573438.001]
  • [Cites] Carcinogenesis. 2008 Jun;29(6):1249-57 [18477648.001]
  • [Cites] EMBO Rep. 2008 Aug;9(8):766-73 [18566599.001]
  • [Cites] J Med Virol. 2009 Mar;81(3):467-72 [19152410.001]
  • [Cites] Curr Med Chem. 2009;16(10):1214-28 [19355880.001]
  • [Cites] Curr Pharm Des. 2009;15(12):1349-57 [19355973.001]
  • [Cites] Clin Microbiol Rev. 2009 Apr;22(2):224-39, Table of Contents [19366913.001]
  • [Cites] J Invest Dermatol. 2009 May;129(5):1258-70 [19020550.001]
  • [Cites] Circ J. 2009 Jun;73(6):977-85 [19430165.001]
  • [Cites] Autoimmun Rev. 2009 Jul;8(8):697-701 [19393193.001]
  • [Cites] Toxicology. 2009 Jul 10;261(3):143-51 [19464336.001]
  • [Cites] Cell Cycle. 2009 Jul 1;8(13):2005-13 [19550141.001]
  • [Cites] Clin Invest Med. 2009;32(4):E293-300 [19640333.001]
  • [Cites] Infect Disord Drug Targets. 2009 Aug;9(4):376-89 [19689380.001]
  • [Cites] Br J Cancer. 2009 Oct 6;101(7):1194-8 [19789535.001]
  • [Cites] FEBS J. 2009 Oct;276(20):5747-54 [19754872.001]
  • [Cites] Infect Immun. 2003 May;71(5):2859-67 [12704159.001]
  • [Cites] FEBS Lett. 2004 Feb 13;559(1-3):45-50 [14960305.001]
  • [Cites] Oncology. 1970;24(1):26-30 [4984638.001]
  • [Cites] Thorax. 1983 Oct;38(10):747-50 [6417814.001]
  • [Cites] Eur J Respir Dis. 1985 Nov;67(5):326-34 [4085584.001]
  • [Cites] Mod Pathol. 1991 May;4(3):320-4 [2068057.001]
  • [Cites] Chest. 1996 Jan;109(1):158-62 [8549179.001]
  • [Cites] Anal Cell Pathol. 1996 Nov;12(2):85-98 [8986293.001]
  • [Cites] Chest. 1997 Oct;112(4 Suppl):291S-295S [9337306.001]
  • [Cites] Ann Thorac Surg. 1997 Oct;64(4):941-4 [9354505.001]
  • [Cites] Clin Chest Med. 1998 Jun;19(2):351-61 [9646986.001]
  • [Cites] Diagn Cytopathol. 1999 Jun;20(6):350-7 [10352907.001]
  • [Cites] Eur Respir J. 2005 Jan;25(1):104-9 [15640330.001]
  • [Cites] J Mater Sci Mater Med. 2004 Dec;15(12):1355-60 [15747189.001]
  • [Cites] Int J Oncol. 2005 May;26(5):1363-8 [15809729.001]
  • [Cites] EMBO J. 2005 Apr 6;24(7):1311-7 [15775985.001]
  • (PMID = 20216542.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen; 136601-57-5 / Cyclin D1; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2853096
  •  go-up   go-down


87. Assenza M, Ricci G, Antoniozzi A, Martines V, Valesini L, Romeo V, Modini C: Sigmoidorectal intussusception in adults: a case report. Clin Ter; 2010;161(1):65-7
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 75-year-old women was admitted to our hospital due to anal bleeding from 5 days.
  • In children it is usually primary and benign, and pneumatic or hydrostatic reduction of the intussusception is sufficient to treat the condition in 80% of patients.
  • In contrast a demonstrable etiology is found in 70% to 90% of cases in adults, and approximately 40%-50% of them are caused by malignant neoplasms.
  • Due to the low incidence and the rare consideration given to this condition among adults the preoperative diagnosis can be difficult, especially in emergency cases.
  • [MeSH-major] Adenoma / diagnosis. Intussusception / surgery. Rectal Diseases / diagnosis. Sigmoid Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20393683.001).
  • [ISSN] 1972-6007
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


88. Lanteri R, Aliotta I, Racalbuto A, Licata A: Anal GIST in older old patient: a case report. G Chir; 2005 Apr;26(4):135-7
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal GIST in older old patient: a case report.
  • It is generally difficult to determine if they are to be considered as a benign or malignant neoplastic disease.
  • We present the case of a patient with recurrence of anal GIST who was examined 8 years after the first treatment.
  • During rectal exploration we found a mass spreading inside the lumen 3 cm from the anal verge.
  • Colonoscopy showed that the tumour, which was 7 x 5 cm in size, was inside the wall with normal mucosa.
  • The patient was discharged 5 days after surgery and is alive; she only showed a small local recurrence of disease 30 months after treatment.
  • Histological examination confirmed that the tumour was a GIST This case provides the basis for a discussion about characteristics and the evolution of this group of pathologies.
  • [MeSH-major] Anus Neoplasms / surgery. Gastrointestinal Stromal Tumors / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16035248.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


89. Reschner A, Harlin H, Laven B, Eriksson F, Pisa P, Egevad L: Expression of immunomodulating genes in prostate cancer and benign prostatic tissue. Anal Quant Cytol Histol; 2009 Apr;31(2):74-82
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of immunomodulating genes in prostate cancer and benign prostatic tissue.
  • OBJECTIVE: To investigate the expression of immunomodulating genes in prostate cancer and benign prostatic tissue.
  • STUDY DESIGN: We investigated by quantitative real-time polymerase chain reaction the expression of indoleamine 2,3-dioxygenase, arginase 1, arginase 2, inducible form of nitric oxide synthase, cyclooxygenase 2 (COX-2), programmed death ligand 1 and interleukin 10 in 36 matched pairs of samples from prostate cancer and benign prostatic tissue.
  • RESULTS: Among the genes analyzed, arginase 2 and COX-2 showed statistically significant up-regulation and down-regulation, respectively, in malignant compared to benign prostate tissue.
  • In addition, arginase 1 was more often present in cancer than benign samples.
  • We provide a snapshot of immunosuppressive gene expression at the transcriptional level in the prostate tumor microenvironment.

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19402383.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / CD274 protein, human; 0 / IL10 protein, human; 0 / Immunologic Factors; 0 / Indoleamine-Pyrrole 2,3,-Dioxygenase; 130068-27-8 / Interleukin-10; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.5.3.1 / Arginase; EC 3.5.3.1 / arginase II, human
  •  go-up   go-down


90. Emms SG: Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy. Aust Vet J; 2005 Jun;83(6):340-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy.
  • A retrospective study of anal sac tumours without pulmonary metastases, from the author's clinical records for the period July 1989 to July 2002, was conducted to establish the response to treatment with surgery and melphalan chemotherapy.
  • Of 21 dogs with tumours of the anal sacs 19 had apocrine gland adenocarcinomas of anal sac origin, one had a benign papillary cystadenoma and another had a malignant melanoma.
  • Two of the 19 dogs had bilateral anal sac adenocarcinomas.
  • Ten of the 19 dogs with apocrine gland adenocarcinomas of anal sac origin had sublumbar lymphadenopathy.
  • Fourteen dogs with apocrine gland adenocarcinomas of anal sac origin were treated by surgical cytoreduction and chemotherapy with melphalan.
  • Cytoreduction was by local excision of the anal sac in all 14 dogs and concurrent removal of the sublumbar retroperitoneal lymph nodes in the seven dogs with regional lymph node metastases.
  • The median survival time of dogs with sublumbar nodal metastasis was 20 months and for dogs with tumour localised to the anal sac the median survival time was 29.3 months.
  • This study suggests there is a role for melphalan in the treatment of dogs with anal sac adenocarcinoma when combined with cytoreductive surgery, with treatment survival times and the local recurrence rate of the primary tumour comparing favourably with previously published treatment regimes.
  • [MeSH-major] Anal Gland Neoplasms / epidemiology. Anal Sacs. Dog Diseases / epidemiology
  • [MeSH-minor] Adenocarcinoma / veterinary. Animals. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Cystadenoma, Papillary / veterinary. Dogs. Female. Male. Melanoma / veterinary. Neoplasm Metastasis. Records as Topic / veterinary. Retrospective Studies. Survival Analysis. Victoria / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986909.001).
  • [ISSN] 0005-0423
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


91. Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, Al-Ahmadie H, Alves V, Xiao SY, Anders RA, Hart JA: Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol; 2010 Aug;34(8):1147-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms.
  • The distinction of hepatocellular carcinoma (HCC) from metastatic tumor in the liver often presents a diagnostic challenge that carries significant impact on prognostication and therapy.
  • The sensitivities of Arg-1 in well, moderately, and poorly differentiated HCCs are 100%, 96.2%, and 85.7%, respectively, whereas, in comparison, HepPar-1 demonstrated sensitivities of 100%, 83.0%, and 46.4% for well, moderately, and poorly differentiated tumors, respectively.
  • We also examined Arg-1 expression in nonhepatocellular tumors, including many that are potential mimics of HCC (renal cell carcinomas, neuroendocrine tumors, melanomas, gastric adenocarcinomas, and adrenocortical carcinomas) and found that only 2 non-HCC tumors were reactive for Arg-1.
  • Arg-1 represents a sensitive and specific marker of benign and malignant hepatocytes that may ultimately prove to be a useful diagnostic tool in routine surgical pathology practice.
  • [MeSH-major] Arginase / analysis. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / enzymology. Hepatocytes / enzymology. Immunohistochemistry. Liver Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Clin Nutr Metab Care. 1998 Jul;1(4):335-9 [10565370.001]
  • [Cites] J Biomed Biotechnol. 2010;2010:683485 [20029630.001]
  • [Cites] Am J Clin Pathol. 2001 May;115(5):689-94 [11345832.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):978-88 [12170084.001]
  • [Cites] Hum Pathol. 2002 Dec;33(12):1175-81 [12514785.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):137-44 [12591966.001]
  • [Cites] Am J Clin Pathol. 2003 Mar;119(3):361-6 [12645337.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7565-73 [15187136.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):884-92 [15198362.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):514-20 [15221469.001]
  • [Cites] J Nutr. 2004 Oct;134(10 Suppl):2820S-2825S; discussion 2853S [15465793.001]
  • [Cites] Histochemistry. 1987;87(5):465-70 [3323144.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1050-4 [7692729.001]
  • [Cites] Int J Dev Neurosci. 1994 Jun;12(4):337-42 [7976488.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):686-92 [9237179.001]
  • [Cites] J Immunol. 1998 Jun 1;160(11):5347-54 [9605134.001]
  • [Cites] Mod Pathol. 1998 Oct;11(10):934-8 [